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Abstract 
As the global phenomenon of population aging has become very prominent in the 
last few decades, diseases of the aging such as Alzheimer’s and Parkinson’s disease 
have taken the spotlight as the new challenges of modern medicine. In fact, aging is 
the biggest risk factor for neurodegeneration. 
 
Neurodegenerative diseases are particularly difficult to study, as animal models often 
fail to recapitulate human disease phenotypes, together with the challenging aspects 
of monitoring cognitive functions in smaller animals.  
Thanks to stem cell research, we’re now able to derive large quantities of human 
neurons in vitro. This has been incredibly helpful for neuroscientific research, but 
stem cell-derived neurons show cellular and molecular features, such as epigenetic 
characteristics and metabolic activity, that resemble embryonic neurons and thus fail 
to recapitulate the damage and oxidative stress typical of aged neurons.  
 
In 2010 the first report of in vitro fibroblast-derived neurons opened the way for an 
alternative source of neurons, that could easily be derived from individual patients, 
and most importantly maintain the cellular age of the original fibroblasts. This 
presents then as a better tool to study diseases that affect aged neurons in vitro. The 
conversion process is nonetheless quite inefficient and leads to a very heterogeneous 
mix of cell types, in which a limited number of induced neurons would need to be 
isolated from contaminating fibroblasts, myoblasts and cells of uncharacterized 
subtypes.  
 
In this thesis I describe my efforts to identify the drivers of the reprogramming 
process that lead to a successful conversion from a fibroblast to a neuron, and the 
roadblocks that might be hindering it. To achieve this, I decided to take a genetic 
screening approach, taking advantage of the emerging CRISPR/Cas9 technology that 
has made genetic knock-outs relatively easy and quick to achieve. By converting 
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Cas9-expessing mouse embryonic fibroblasts (MEFs) into induced neurons (iN) while 
expressing target gRNAs, I performed a loss-of-function screen to identify genes 
involved in the conversion process.   
 
I first identified a genetic reporter that allows me to isolate the induced neurons from 
the remaining cell types in the heterogeneous culture. I then selected a subset of 
genes within the mouse genome as likely candidates to be involved in the cell identity 
conversion and then proceeded to perform the screen. 
I identified two genes, Stxbp1 and Sf3a1, as required for iN conversion and survival 
in the conversion context. Stxbp1 is known to be required for neuronal survival, as its 
knock-out prevents neurotransmitter release and leads to neuronal death. This thus 
represents confirmation that iN are a reliable platform to study neuron biology. Sf3a1 
is part of the SF3A complex involved in pre-mRNA splicing and has previously been 
reported to be required for cell identity transitions, but, to the best of my knowledge, 
had yet not been associated with cell survival in the context of fibroblast to neuron 
conversion.  
This work presents a solid platform to genetically engineer and characterize in vitro 
induced neurons and highlights their relevance to broader neuronal culture systems 













Neurodegenerative diseases have been emerging as the next big challenge in modern 
medicine, as the increase in average life expectancy has led to global population 
aging. 
These diseases are associated with defects of cognitive and motor functions as the 
brain and nerves decline over time. 
It is crucial to understand what keeps brains and neurons healthy, what goes wrong 
in the cells of patients affected by disease, and how to address these defects to 
restore proper functions. 
 
Neurodegenerative diseases are particularly difficult to study, as very few animal 
models can recapitulate the pattern of disease seen in humans, and culturing 
neurons in a lab is challenging. Advances in research around stem cells – the cells 
with the potential to grow indefinitely and generate any cell type in the body – meant 
we can now derive and characterise large quantities of human neurons in a lab. 
Unfortunately, the neurons derived from stem cells resemble the neurons of 
embryos and young children, and thus are not a good model to study diseases of 
aging, where neurons have accumulated internal damage and stress over the years. 
 
A few years ago, scientists managed to convert human skin cells into neurons in the 
lab. The neurons obtained from skin cells actually maintain the “cellular age” of the 
patient from whom the cells were originally taken. This provides an exciting platform 
to study aged neurons and understand what goes wrong in cells of patients with 
neurodegenerative diseases. Nonetheless, the efficiency of converting skin cells into 
neurons is very low, and many of the cells remain stuck at an intermediate stage or 
die off.  
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In my PhD, I investigated what happens during a successful conversion of a skin cell 
into a neuron, and what genetic mechanisms are responsible instead when the 
conversion fails.  
By eliminating the genetic components that hinder the conversion, and thus 
efficiently producing a pure population of neurons in a dish, this system could one 
day be used in the clinic to study patient-derived cells and potentially tailor drug 
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Chapter 1 Introduction 
1.1 Reprogramming cellular identity in vitro to study specialised cell 
types 
1.1.1 A historical note on cell identity and cell fate changes 
The National Institutes of Health (NIH) claim that our bodies contain circa 200 
different cell types. This has long since been disputed, as the technological advances 
in imaging and single-cell “-omics” gave us a more comprehensive understanding of 
the detailed composition of each cell. Much like the Human Protein Atlas Project 
(Uhlén et al., 2005; Uhlen et al., 2015), several research groups and funding agencies, 
including the Wellcome Trust and the Chan-Zuckerberg Initiative, have set-out to 
define a Human Cell Atlas and compile a map of all the cell types and subtypes that 
make-up the tissues in the body (Yong, 2016).   
Crucially though, even though all these cells can have hugely different functions, they 
all share the same genetic information (DNA). This was a revolutionary discovery 
during the 20th century, as until then, one of the hypotheses around embryology and 
development was that cells progressively lose genetic information as they specialise 
and only retain the genes necessary for their function. 
The first steps in characterising this phenomenon came from the work of 
developmental biologists Robert Briggs and Thomas King. Using Rana pipiens as a 
model organism and a nuclear transfer technology they developed, they transplanted 
nuclei from blastula, gastrula and tail-bud cells into enucleated egg cells. Blastula and 
gastrula cell nuclei were able to generate viable offsprings, although gastrula nuclei 
showed lower efficiencies, whereas tail-bud cells initiated embryonic development 
but induced severe abnormalities (Briggs & King, 1952). 
Building on this work, John Gurdon in 1962 performed a series of experiments on 
Xenopus laevis that would eventually lead him to be awarded the Nobel Prize in 2012. 
Firstly, he showed that, after optimisation of the nuclear transfer technique, he could 
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use nuclei from tadpole gut epithelium as donor nuclei for successful development 
of embryos, initially up to the larva stage (Gurdon, 1962a) and then into fully 
developed and fertile individuals (Gurdon, 1962b). This was proof that fully 
differentiated cells contain all the genetic information to produce a whole organism. 
It was also proof that cell identity is not set in stone: in this case, nuclear identity 
could be reprogrammed by the egg cell environment, to a zygote state. 
 
Only a few years before, in 1957, Conrad Waddington had described in his famous 
landscape model the idea that during development, as cells divide they go through a 
series of “decisions”, as sliding down the slopes of a valley, that ultimately lead them 
to a precise spot, and can’t go back upwards (Waddington, 1957) (Fig.1.1). 
Briggs, King and Gurdon’s works represent the first dispute to the verticality of this 
model and suggest how cell fate decisions have the potential to be reversed and 
move up the hypothetical valley. 
 
 
Fig. 1.1 – Waddington landscape model of development. (Taken from Waddington, 
1957.) Epigenetics idea that cells restrict their potential as sliding down a valley and landing 
in different positions based on the “decisions” taken down the “developmental valley” forks. 
 
Gurdon’s work was reproduced in mammalian cells, first famously in sheep with the 
birth of Dolly, the lamb cloned from the nucleus of mammary gland cell (Wilmut et 
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al., 1997), then subsequently in mice (Wakayama et al., 1998). The relatively low 
rates of success from these studies lead some people to speculate that successful 
nuclei-transfer reprogramming relied on the involuntary selection of rare stem cell 
populations as nuclei donors. The final confirmation that fully differentiated, somatic 
nuclei transfer can generate fully functional adult organisms came from a work using 
mouse lymphocytes as donor cells. As each clonal B-cell line in the adult organism 
rearranges its immunoglobulin locus in specific and traceable combination, the 
authors were able to show that mice generated from B-cell nuclei showed, in every 
tissue examined, the exact genomic re-arrangements of the nuclei of origin 
(Hochedlinger & Jaenisch, 2002).  
 
1.1.2 Transcription factors regulate gene expression and can reprogram cell fate 
The nuclear reprogramming studies suggested that some factors contained within 
the egg cell cytoplasm were able to convert differentiated nuclei to a zygote-like 
state. To try and understand this phenomenon and figure out whether only egg cells 
possess this capacity, scientists attempted to fuse cells together using polyethylene 
glycol (PEG) to induce membrane fusion. Blau and colleagues used this technology to 
fuse together human amniocytes with mouse muscle cells and observed the 
formation of a heterokaryon made of multinucleated, non-dividing cells. After 24h, 
the human amniocyte nuclei had upregulated the expression of human muscle genes, 
and human muscle proteins were detected in the shared cytoplasm thanks to 
species-specific antibodies (Blau, Chiu & Webster, 1983). This work confirmed the 
existence of cell-type specific factors that can reprogram exogenous nuclei.  
4 years later, two studies were able to show that the overexpression of a single 
transcription factor can alter cell fate. In Drosophila, the overexpression of the 
Antennapedia gene at specific developmental stages altered the body segmentation 
and induced the formation of legs in place of antennae (Schneuwly, Klemenz & 
Gehring, 1987). Davis and colleagues were instead studying the in vitro conversion of 
fibroblasts into myoblasts by the addition of 5-azacytidine. They identified 3 genes 
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that were uniquely and highly expressed in myoblasts and showed that the single 
overexpression of one of those, MyoD, could force 50% of the fibroblasts to be 
converted into myoblasts (Davis, Weintraub & Lassar, 1987). 
Several studies further showed how cell identity can be redirected by gene 
overexpression. In 2000, lymphoid progenitor cells were converted into myeloid 
progenitors by exogenous expression of IL-2 and GM-CSF (Kondo et al., 2000). In 
2004, B-cells were converted into macrophages by the overexpression of CEBP-a  and 
CEBP-b (Xie et al., 2004).  
 
1.1.3 Reprogramming fibroblasts to a pluripotent stem cell state  
The previous studies had shown that nuclear transfer, cell-cell fusion or gene 
overexpression can reprogram differentiated cells into different types. It was unclear 
though which factors within oocyte cytoplasm could convert a differentiated nucleus 
into a pluripotent-like state. Takahashi and Yamanaka addressed this by compiling a 
list of 24 genes associated with pluripotency, self-renewal and proliferation in ES cells 
and tumour cells, and overexpressed them as a pool in mouse embryonic fibroblasts, 
showing that they could successfully generate cells with ES-like characteristics, 
termed induced pluripotent stem cells (iPSCs). By sequential depletion of each of the 
24 factors, they identified the combination of the 4 factors Oct4, Sox2, Klf4 and c-Myc 
as the minimal combination for successful iPS reprogramming (Takahashi & 
Yamanaka, 2006). While the first generation-iPSCs were not able to make live 
chimera mice, in 2007 generation of iPSCs with functions equivalent to ES cells was 
demonstrated by the formation of chimeric organisms, contribution of IPSCs to the 
germ layer, and the generation of live and healthy embryos that were entirely iPSC-
derived via tetraploid complementation (Okita, Ichisaka & Yamanaka, 2007; Wernig 
et al., 2007). 
The same result was achieved in human cells just one year after the first mouse iPSCs 
(Takahashi et al., 2007). This discovery, the ability to produce pluripotent cells that 
can make any cell type in vitro and the potential applications of these cells in vivo, 
 5 
opened up huge possibilities for clinical research, and opened up a whole new basic 
research field. John Gurdon and Shinya Yamanaka were awarded the Nobel Prize for 
Physiology and Medicine for “the discovery that mature cells can be reprogrammed 
to become pluripotent”, or as Takahashi described in a review paper “lowering gravity 




Fig. 1.2 – Takahashi’s revised Waddington model for cell identity transitions. 
(Taken from Takahashi, 2012). (a) The traditional Waddington model follows cell identity 
specialization downwards through a valley. The choices made at the forks will determine the 
cell fate – indicated as the position of the cell at the end of the differentiation (from green to 
blue). (b) In reprogramming to pluripotency, cells are brought back up the slope to the 
original state where cells still have the potential to go down any of the paths. (c) In 
conversion, like the conversion of fibroblasts to myoblasts or B-cells to macrophages (and 
indeed fibroblasts to neurons as discussed in the next paragraph), cells are able to jump 
between two crooks in the valley bed without the need to go up the slope. Overall, this shows 
that cell identity is a lot more fluid and changeable than previously thought. 
1.2 Induced neurons: overview and implications for clinical applications  
1.2.1 The first reported conversion from fibroblasts into induced neurons in vitro 
Following the work by Takahashi and Yamanaka, in 2010 the Thomas Vierbuchen 
from Marius Wernig lab took a similar approach to identify factors that could convert 
fibroblasts into neurons in vitro (Vierbuchen et al., 2010). A pool of 19 genes involved 
in neural development and epigenetic reprogramming was transduced into MEFs via 
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lentiviruses. To identify successful conversion and the emergence of neurons, they 
used MEFs from a Tau-eGFP knock-in mouse line that had previously been shown to 
selectively activate eGFP expression in neurons (Wernig et al., 2002). 12 days post-
transduction, the authors identified Tau-eGFP +ve cells with neuronal morphology 
that were also expressing Tubb3, a pan-neuronal marker. This indicated that some 
combination of factors among the 19 was able to reprogram fibroblasts into what 
they defined as “induced neurons” (iNs) (Fig.1.3a).  
To narrow down the responsible genes, they first tested the transcription factors 
Ascl1 and NeuroD1 individually and showed how Ascl1 is able, although at much 
lower efficiencies and generating extremely simple morphologies, to reprogram 
MEFs into iNs. They then proceeded to test Ascl1 in combination with each of the 18 
remaining candidates and showed how Brn2, Brn4, Myt1l, Zic1 and Olig2 increased 
the number of TUBB3 +ve cells (compared to Ascl1 alone) by at least 3-fold, though 
failed to induce neuronal reprogramming when transduced individually. Thus, these 
5 genes represented potential conversion facilitators. 
After excluding Brn4 for its similarities to Brn2, the authors defined a 5F pool made 
of Ascl1, Brn2, Myt1l, Zic1 and Olig2 and showed how this pool could generate within 
12 days post-transduction cells with complex neuronal morphology expressing Tau-
eGFP, TUBB3, MAP2, NEUN and SYNAPSIN1 (Fig.1.3b). To identify the genes strictly 
sufficient for the conversion, genes within the 5F pool were further narrowed down, 
until the combination of Ascl1, Brn2 and Myt1l was shown to be the most efficient in 
generating the highest number of neurons and the most complex neuronal 
morphologies (Fig.1.3c). Neurons obtained from this combination, referred to as 
“BAM”, showed the same neuronal markers as the 5F pool converted cells. They 
could also, upon astrocyte co-culture, form functional synapses, detected by 
excitatory postsynaptic currents (EPSCs) mediated by NMDA and AMPA receptors. 
Inhibitory postsynaptic currents were not detected in any of the neurons assessed. 
53% of these neurons expressed Tbr1, a marker of excitatory cortical neurons.  
The BAM combination was also able to efficiently generate neurons, with the same 
properties listed above, starting from adult tail tip fibroblasts, indicating the 
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robustness of this combination. Importantly, Marro and colleagues in 2011 were able 
to convert terminally differentiated hepatocytes into iNs using the same factors, 
indicating that their efficiency does not depend on MEF subpopulations or fibroblast-
specific chromatin environment (Marro et al., 2011). 
In terms of efficiency, the BAM combination gave the best neuronal conversion 
efficiencies. Neurons were counted at day 12 post-transduction as TUBB3 +ve cells 
with a thin process at least 3 times longer than the cell soma. The average of 30 
randomly-selected fields was used to estimate the total number of neurons in the 
dish. The ratio between the total number of neurons yielded at day 12 and the initially 
seeded MEFs offers a measure of the conversion efficiency. The BAM factors yielded 




Fig. 1.3 – The first reported induced neurons. (Adapted from Vierbuchen et al., 2010). 
(a) Tau-eGFP MEFs from non-neural tissues were transduced with a pool of 19 neural-related 
genes and epigenetic regulators and kept in neural media to induce the conversion of MEFs 
into neurons. The presence of neurons was assessed by eGFP fluorescence and Tubb3 
expression. The panels below show day 12 iNs expressing Tubb3 (left) and Tau-eGFP (right). 
(b) 5F derived iNs show complex morphologies and express TUBB3, Tau-eGFP, NeuN and 
MAP2. (c) BAM derived iNs express TUBB3 and show complex morphologies whether they’re 
derived from MEFs (left panel) or TTFs (middle panel). They also express MAP2 (in green) and 
SYNAPSIN 1 (in red) (right panel).  
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1.2.2 Transdifferentiated iNs were generated from different species, sources and 
into different neuronal subtypes 
One year later, a review paper by the Wernig lab provided a summary of the recent 
publications in the newly born induced neuron field (Fig.1.4).  
 
 
Fig. 1.4 – A few important iN publications, one year after the initial reported 
conversion. (Taken from Yang et al., 2011). This diagram highlights a few key publications 
reporting the forced conversion of neurons (or neural cells like NSCs) published just one year 
after the initial report by Vierbuchen and colleagues. It shows how the conversion was 
quickly achieved for human cells too, and how different factor combinations were adapted 
to generate specific neuronal subtypes.  
 
The first major point to highlight is that iNs were readily generated from human 
fibroblasts, but the BAM cocktail was shown to generate few, immature neurons and 
thus required the supplementation of extra factors. Pang and colleagues added 
NeuroD1 and showed that the neurons generated could indeed produce action 
potentials, and upon primary cortical neuron co-culture, generated spontaneous and 
evoked postsynaptic currents (Pang et al., 2011). Qiang and colleagues instead 
obtained similar results using the 5F pool cocktail of the Vierbuchen paper (Qiang et 
al., 2011). Both studies focused on human embryonic or postnatal fibroblasts. Later 
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on in the same year, Pfisterer and colleagues demonstrated that human iNs can be 
obtained, using the BAM cocktail alone, from distal lung fibroblasts of individuals 
aged between 23 and 65 years old, with similar efficiencies (2-4% of the initially 
seeded fibroblasts) compared to the embryonic and postnatal cells (Pfisterer et al., 
2011b). This highlighted the potential of these neurons to be used for personalised 
medicine, for both patient-specific disease modelling, but also potentially cell-based 
therapeutics. Importantly for this regard, in 2018 human iNs were derived from adult 
peripheral blood cells (T-lymphocytes), with similar efficiencies to the skin biopsy-
derived fibroblasts, making the derivation of patient-specific iNs in sufficient 
quantities even more simple and direct (Tanabe et al., 2018). 
 
The second major point is the observation that minor tweaks and additions to the 
reprogramming cocktail, for both mouse and human cells, allowed the derivation of 
specific neuronal subtypes. Dopaminergic neurons were obtained for instance by 
factors that specify their ventral mid-brain in vivo identity like Lmx1a and Foxa2, and 
have particular relevance for in vitro modelling and potential cell replacement 
therapies for Parkinson’s disease, the second most common neurodegenerative 
disease nowadays (Caiazzo et al., 2011; Pfisterer et al., 2011a).  
Similarly, induced motor neurons were obtained from both mouse and human 
fibroblasts by  supplementing the BAM cocktail with motor neuron specific factors 
(Son et al., 2011). They present both as potential research platform and clinical 
applications for motor neuron diseases such as amyotrophic lateral sclerosis (ALS) or 
spinal muscular atrophy (SMA).  
 
Induced dopaminergic neurons and motor neurons are just two examples of neuronal 
subtypes that have been since derived and characterised.  
Fig. 1.5 shows an overview of the different neuronal subtypes described in induced 
neurons in vitro and their master regulatory network. As reviewed by Masserdotti 
and colleagues (Masserdotti, Gascón & Götz, 2016), the search subtype specification 
has not only focused on supplementing the original BAM combination with regional 
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or neurotransmitter regulators, but has looked for alternative reprogramming factors 
altogether. Ascl1 and Neurog2 (Ngn2) are responsible for the differentiation of 
GABAergic and glutamatergic neurons from the ventral and dorsal neural progenitors 
of the telencephalon respectively, and have been shown to activate distinct neuronal 
gene networks (Pang et al., 2011; Wapinski et al., 2013; Zhang et al., 2013; Smith et 
al., 2016; reviewed in Colasante et al., 2019). Ascl1 represents in fact the main driver 
of the conversion  within the BAM combination, as it acts as a pioneer TF and can 
independently generate iNs (Vierbuchen et al., 2010; Wapinski et al., 2013; Treutlein 
et al., 2016). Ngn2 has also been extensively used as a main driver to derive iN from 
mouse and human pluripotent stem cells, although it’s unable to reprogram 
fibroblasts by itself (Chanda et al., 2014). With the help of small molecules though, it 
has been shown to act as a pioneer factor and is able to convert fetal and adult human 
fibroblasts into induced neurons (Smith et al., 2016).  
 
 
Fig. 1.5 – Induced neuron subtype specification. (Taken from Masserdotti, Gascón 
and Götz, 2016). The coloured nodes indicate the 4 major TF used as master regulators of 
induced neurons in vitro. Combination of other factors and/or miRNAs has been shown to 
direct neuronal subtype specification – indicated in the grey bobbles. The numbers reported 
in black circles refer to the reference numbers in the review paper that report the specified 
neuronal subtype generation. 
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1.2.3 Neuron reprogramming in vivo – implications for cell replacement therapies 
For the purpose of cell replacement therapies, direct conversion of neurons 
represents a particularly interesting system as it doesn’t pass nor require a 
proliferative stage (Fishman et al., 2015; Gascón et al., 2016) and it’s thus unlikely to 
pose a tumorigenic threat if cells are transplanted or converted in vivo. In 2013 
Torper and colleagues showed that human fibroblasts could be transduced with 
lentiviruses containing the tetO-BAM combination and transplanted within rat brains 
to achieve engraftment. By supplying doxycycline in the animals’ drinking water, they 
activated BAM expression and achieved conversion of the transplanted human 
fibroblasts into iNs with similar efficiency to the in vitro conversion (Torper et al., 
2013). They also showed how dopaminergic iNs can be induced in vivo, and how the 
same iNs can be induced by transplanting human astrocytes. Following on this work, 
they showed they could convert endogenous mouse brain astrocytes into induced 
neurons in vivo by delivering the BAM factors lentivirally. This publication highlighted 
the potential of in vivo reprogramming as a strategy for brain repair, and set-out the 
question of finding the right combination and balance of factors that would induce 
the generation of subtype-specific neurons able to integrate within the neural 
network at the location of reprogramming. 
A year later, Guo and colleagues reprogrammed glial cells into functional neurons in 
vivo, using retroviruses to deliver a NeuroD1 overexpression cassette into the mouse 
cerebral cortex (Guo et al., 2014).  They demonstrated how NeuroD1 could 
reprogram astrocytes into glutamatergic neurons, and NG2 glial cells into 
glutamatergic and GABAergic neurons, proving evidence on how different targeting 
strategies (using target cell specific promoters to induce TF expression) could 
generate in neuronal subtypes in vivo and could be exploited to obtain a subtype-
specific pure neuronal population.  
Direct generation of iN in vivo thus presents as a competing strategy for cellular 
replacement therapies for diseases of the CNS – a parallel approach to exogenous 
cell transplants that involve the engraftment of neural progenitors and their in vivo 
differentiation, and to endogenous brain repair that targets instead resident neural 
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progenitor cells to replace lost cells, or brain inflammatory cells to repair damage. All 
these strategies could play crucial roles in treating a whole range of 
neurodegenerative diseases that result in neuron loss like ALS, PD, Alzheimer’s, or 
even injuries. After the proof of concept studies have been released, research has 
focused and is still focusing on optimising the target cells to convert, the neuronal 
subtypes to induce and integrate, the transcription factor delivery and how to make 
it safe (non-integrating, less invasive, or possibly substitute it with small molecules) 
(Barker, Götz & Parmar, 2018).  
 
1.3 Induced neurons as a disease modelling platform 
1.3.1 Modelling neurological diseases in vitro – mimicking complexity and cellular 
age  
Human neurological diseases are extremely difficult to study, because of the intrinsic 
complexity of the human CNS, that is both hard to replicate in vitro and to model in 
animals (phenotypes like social behaviours or pain can be quite tricky to assess in 
mice and rats for instance).   
The relatively recent development of cerebral organoids (Lancaster et al., 2013), 
building on ESC to neuron differentiation protocols, has just begun to address one of 
the major hurdles of studying neurons in vitro, i.e. the difficulties of relating the 
synaptic properties and networks of isolated neurons or specific co-culture systems 
to the huge and coordinated networks of multiple cell types in vivo and in different 
brain regions. Organoids have been useful in modelling brain development and 
natural progenitor differentiation, migration and assembly into cortical layers of all 
neural cell types, as they’ve relied on pluripotent stem cells as a starting cell type. 
They’ve been also useful in reproducing disease phenotypes – by using patient-
derived iPSCs, the authors showed how the cerebral organoids mimic the 
pathogenesis of microcephaly much better than previous problematic mouse models 
(Lancaster et al., 2013; reviewed in Lancaster and Knoblich, 2014). 
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These models rely on the differentiation of pluripotent stem cells into neural 
progenitors and then neural cells. This necessary step introduces a big limitation in 
the study of neurological diseases related to aging, because the pluripotent state of 
ES cells and iPS cells associates them with an embryonic cellular “age”. As reviewed 
by Studer and colleagues, upon iPSC reprogramming, the cells reset many 
characteristics of aged cells, including notably epigenetic changes (DNA methylation 
and heterochromatin state), DNA damage marks like g-H2AX, protein aggregation 
state, mitochondrial DNA mutations and ROS, nuclear lamina composition and 
integrity, telomere length and markers of senescence (Studer, Vera & Cornacchia, 
2015). 
An example of their limitations to generate age-appropriate neurons for disease 
modelling was described in 2013: in vitro differentiated dopaminergic neurons 
derived from iPSCs from Parkinson’s patients failed to show significant 
neurodegenerative phenotypes like cleaved CASPASE-3 in condensed nuclei or 
shortening of dendrite length. These phenotypes were instead induced by forced 
expression of progerin, the truncated form of LAMIN A that is associated with 
premature aging and is responsible for Hutchinson–Gilford progeria syndrome (Miller 
et al., 2013). Similar results, again in dopaminergic neurons in vitro, were obtained 
by artificially aging hiPSCs via telomere shortening (Vera, Bosco & Studer, 2016). This 
suggested that induced aging might be a good tool to reveal disease-associated 
phenotypes in hiPSC-derived neurons, but introduced an extra, non-physiological 
step that might influence the relevance of in vitro aged neurons to in vivo neurons of 
old patients. Considering the global population is aging and neurodegenerative 
diseases are quickly becoming a huge burden for patients, families and healthcare 
providers around the world, they need to be urgently understood and addressed. It’s 
also worth noting how human  life-span is significantly different from other primates, 
let alone traditional animal models like rodents, and how the complex but common 
symptoms associated with dementia, like memory loss, confusion, loss of perception 
of time or space can be extremely challenging to define and monitor in animals 
(reviewed in Mertens et al., 2018). 
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Induced neurons instead present as an ideal platform to model neurological aging 
diseases, as they have been shown to maintain the cellular age of the fibroblasts from 
which they are derived (Mertens et al., 2015). Human fibroblast samples from 
patients aged 0-89 years were reprogrammed in parallel to iPSCs and iNs, confirming 
that iPSCs, regardless of the donor age, reset the aging hallmarks. The iN conversion 
instead showed how donor age does not impact conversion efficiency, but is revealed 
upon transcriptome analysis: iNs derived from >40 years old donors showed 
differentially expressed genes associated with neuron specific aging phenotypes like 
loss of synaptic plasticity and Ca2+ homeostasis. Interestingly, old iNs showed 
functional defects associated with aging, like leaky nuclear membrane and impaired 
nucleoplasm compartmentalisation. 
The same effects were seen in induced motor neurons derived either directly from 
human fibroblasts or induced from fibroblast-derived iPSCs: direct reprogramming 
maintained aging features such as increase numbers of DNA-damage associated 
γH2AX foci, increased SA-β-Gal activity and increased mitochondrial ROS (Tang et al., 
2017). This was further proof that the maintenance of cellular age was not specific 
for a subset of reprogramming factors or neuronal subtype. 
This aged phenotype was confirmed in mouse cells as well, as iNs derived from 1 year 
old mice tail tip fibroblasts (TTFs) showed epigenetic marks, DNA damage and stress 
response gene expression of aged TTFs, compared to iNs derived from differentiated 
iPSCs (Yang et al., 2015). 
A more thorough investigation made use of the “epigenetic clock”, an algorithm to 
predict cellular age based on DNA methylation focused on a subset of 353 key CpG 
sites that were determined to be good predictors of tissue donor age (Horvath, 2013). 
This algorithm was shown to associate iPSC epigenetic age with 0, consistent with the 
age-resetting already discussed. Striatal medium spiny iNs were derived from 
fibroblast samples aged from 3 days to 96 years old, and their epigenetic age was 
assessed with the described algorithm. This showed a great correlation (0.91) with 
the epigenetic age of the cells of origin, as well as a good correlation (0.75) with the 
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patient’s actual age, indicating that, at least on a DNA methylation level, iNs show 
minimal to no age resetting (Huh et al., 2016). 
 
1.3.2 Induced neurons recapitulate disease pathology in vitro 
The suitability of iNs to model diseases has been demonstrated soon after their 
establishment as a platform: MEF-derived iNs from mice carrying an autism-
associated mutation in the Neuroligin-3 gene showed impaired synaptic 
transmissions through AMPA glutamate receptors but not NMDA glutamate 
receptors nor GABAA receptors, consistent with the observations of the in vivo 
neurons of the adult animals (Chanda et al., 2013). This report also strengthened the 
concept that iN, even as a heterogeneous mix of neuronal subtypes derived from the 
original BAM cocktail, are functionally similar enough to in vivo neurons to allow the 
identification and characterisation of disease-specific changes at the synaptic level.  
Subtype-specific neurons have also been shown to respond to disease stimuli: 
induced motor neurons derived from MEFs from a mouse model of ALS showed 
reduced survival, and wild-type induced neurons co-cultured with glial cells from the 
ALS models also showed reduced survival, indicating that the induced motor neurons 
are suitable to study both cell-autonomous and non-autonomous disease 
phenotypes (Son et al., 2011).    
 
1.3.3 iNs model aging diseases in vitro 
A few publications have actually attempted to use the iN conversion to study aging 
associated diseases with age-appropriate neurons (reviewed in Mertens et al., 2018). 
Of note, Jovičić and colleagues have characterised the C9orf72 mutation associated 
with ALS and shown how patient derived iNs, compared to iNs derived from 
fibroblasts from healthy individuals, show defects in nucleocytoplasmic transport, 
consistent with the reported toxicity associated with the mutant forms of C9orf72 
(Jovičić et al., 2015). 
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Another group looking at ALS focusing specifically on induced motor neurons 
highlighted defects of patient-derived iMNs in nuclear localisation of the mutated 
FUS proteins and in forming neuromuscular junctions (Liu, Zang & Zhang, 2016). 
A study focusing instead on Huntington’s disease looked at differences in induced 
striatal medium spiny neurons (MSNs) derived directly from patient’s fibroblasts, or 
induced from fibroblast-derived iPSCs (Victor et al., 2018). They addressed this 
because previous iPSC-derived neurons failed to show protein aggregates and 
neuronal death typical of the disease unless artificially exposed to stressors like 
proteasome inhibitors. Directly reprogrammed MSNs showed the formation of 
huntingtin’s aggregates, DNA damage, declined mitochondrial function and 
spontaneous cell death – features that iPSC-derived MSNs from the same patients’ 
original fibroblasts failed to reproduce. They investigated further this disease model 
and found that, consistent with normal disease progression in patients, iMSNs from 
pre-symptomatic individuals carrying the HD mutation showed much milder disease 
phenotypes. Moreover, they were also able to show that induced cortical neurons 
derived from the same patients show much milder degeneration compared to iMSNs, 
consistent again with disease pathology in vivo.  This work overall highlights how 
direct neuronal reprogramming can be a powerful and precise platform to model 
neurodegenerative diseases with age-appropriate, subtype appropriate cells. 
 
1.3.4 Bringing iNs to the clinic: overcoming limitations of timing and cell numbers 
As discussed by Mertens and colleagues, there are a few major drawbacks that limit 
the suitability of this system for personalised medicine and disease modelling 
applications. One consideration is timing: though it bypasses the iPSC reprogramming 
stage, it can still take 2-4 weeks for iNs to be able to generate action potentials, and 
5-6 weeks more with astrocyte co-culture to show more mature electrophysiological 
features like spontaneous firing and postsynaptic currents. Some efforts in 
accelerating this maturation process have resulted in iNs showing spontaneous firing 
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within 25 days, though it remains to be examined if this is  limited to a subset of the 
neurons in culture (Ruetz et al., 2017).  
Another major limitation is cell numbers: whereas iPSC-derived neurons are derived 
from an infinitely expandable source, iNs are derived most commonly from adult 
fibroblasts, cells with limited expansion capacity as they can only undergo a certain 
amount of cell divisions before they become senescent and stop dividing. The limited 
expansion capacity of adult fibroblasts also makes them unsuitable for stable genome 
engineering for the purpose of modelling genetic disease phenotypes, as most stable 
manipulations require an expandable and clonal-derived cell line. 
Different groups have focused their efforts towards increasing neuronal yields and 
conversion efficiencies. Pereira and colleagues showed how delaying TF activation, 
i.e. allowing transduced cells to proliferate for up to 5 days before inducing TF 
expression, could artificially boost iN yields without the need to harvest more cells 
from biopsy samples (Pereira et al., 2014). They also showed how a cocktail of small 
molecules that inhibit SMAD signalling and activate Wnt signalling could significantly 
increase conversion efficiency and neuronal purity, while the combination of TF 
activation delay and small molecule treatment resulted in final iN yields greater than 
the originally seeded cells and a neuronal purity of over 20%. Further characterisation 
of the system, removal of genetic barriers and optimisation of culture conditions have 
improved available protocols, resulting in neuronal purities up to 50% and the 
estimated potential to derive 10 billion neurons from a single biopsy (Drouin-Ouellet 
et al., 2017).  
The derivation of iNs from blood derived T-lymphocytes (Tanabe et al., 2018) with 
comparable efficiencies to fibroblast derived human iNs (circa 6%) allowed the 
generation of circa 50’000 neurons from 1 ml of blood without need for cell 
expansion. The ease of access to patients’ blood samples compared to invasive 
biopsies strengthens the suitability of the iN platform for clinical investigations.    
 
While these studies have shown great promise, a greater understanding of the 
molecular mechanisms involved in the conversion process would facilitate the 
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identification of genetic barriers and tackle issues of heterogenicity between cells, as 
well as donor intrinsic variabilities, and would bring us closer to using iNs as a routine 
patient resource. 
 
1.4 Understanding and improving the iN system 
1.4.1 ChIPseq identifies Ascl1 as the pioneer TF driving the conversion 
It is difficult to obtain a genetic and molecular understanding of a process that 
generates diverse neuronal subtypes, starting from different cell types and using 
different reprogramming systems. For simplicity and relevance to this thesis, I will 
discuss the efforts that have led to the characterisation of the conversion of 
fibroblasts into pan-neurons using the BAM combination and Ascl1 as the pioneer TF. 
One of the earliest attempts at understanding the mechanisms underlying the 
conversion came from the Wernig lab itself. In 2013, they used ChIPseq and RNAseq 
to study different cell populations at day 0, day 2, day 13 and day 22 of the conversion 
(Wapinski et al., 2013). Gene expression at 48h in Ascl1 and BAM-transduced MEFs 
revealed how Ascl1 is the main driver of the conversion and acts as a transcriptional 
activator, by upregulating, as early as day 2, genes related to neuronal activity.  
ChIPseq analysis revealed that Ascl1 has the most binding sites within 48 BAM-
transduced MEFs, and that it doesn’t require the other two factors to interact with 
the genome. It is able to bind closed chromatin regions and thus presents itself as a 
pioneer TF. Interestingly, the loci targeted in MEFs are the same physiological targets 
that Ascl1 binds to in neural stem cells. In contrast, Brn2 in MEFs targets different 
sites compared to its endogenous loci in neural stem cells, and seems to be recruited 
by Ascl1 to help with chromatin remodelling and gene activation.  
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1.4.2 ATAC-seq shows major chromatin accessibility changes at 48h and 5 days of 
the conversion 
The fundamental role of Ascl1 in the conversion was confirmed using ATAC-seq to 
look at chromatin accessibility dynamics during the early stages of MEF to iN 
reprogramming. Upon Ascl1 transduction alone, chromatin remodelling happens 
extremely quickly, with significant changes at Ascl1-bound loci detectable 12h after 
TF induction. At 48h there is a clear picture: Ascl1 bound sites are now in an open 
chromatin state, and associated genes are upregulated, consistent with Ascl1 role as 
a transcriptional activator. Interestingly, chromatin opening regions are associated 
with neuron but also muscle GO terms. This is consistent with Ascl1 and MyoD both 
binding E-boxes motifs and indicates how Ascl1 might be promiscuously promoting a 
myoblast-favourable chromatin environment. 
At day 5, a major chromatin conformation switch is detected by ATAC-seq, and 
regulatory elements now accessible are associated with genes for neuronal processes 
and synaptic maturation. This precedes morphological and functional changes in the 
neurons, that are detected significantly by day 12 onwards (Vierbuchen et al., 2010; 
Wapinski et al., 2013). Sites that have instead become inaccessible relate to broader 
biological functions and extracellular matrix processes, closer to the profile of the 
original fibroblastic identity. Interestingly, day 5 cells that fail to become neurons (as 
assessed by the Tau-eGFP reporter) show an accessibility profile in between initial 
MEFs and day 5 iNs, as they fail to open regions associated with genes involved in 
synaptic maturation but instead maintain a fibroblast-like chromatin environment. 
As highlighted in Fig.1.6, the overall picture is that the iN reprogramming is 
happening relatively quickly in two crucial waves. Firstly, Ascl1 primes its target sites 
for neuronal induction within the first 48h. It then recruits the other factors, and by 
day 5 gene regulatory elements associated with neuronal maturation become 
accessible. This leads to morphological and functional stabilisation of Tau-eGFP +ve 





Fig. 1.6 – the pioneer TF Ascl1 drives gene activation in the MEF to iN conversion in 
2 major waves. (Adapted from Wapinski et al., 2017). Ascl1 recognises trivalent chromatin 
state on its physiological sites in MEFs leading to conformational changes and gene activation 
(Wapinski et al., 2013). The first wave of chromatin accessibility remodelling happens within 
48h with the activation of the Ascl1 target program. The other factors are then recruited to 
enhance the transcription of genes required for the stabilisation of neuronal identity, which 
occurs at day 5 and precedes morphological and functional changes in the iNs, which 
eventually reach full maturity by day 22.  
 
1.4.3 Single cell gene expression identifies cell subpopulations and alternate cell 
fates 
With the advances and optimisations of single cell RNA sequencing, a more thorough 
investigation of the iN conversion process allowed the identification of cell 
subpopulations and their dynamics (Treutlein et al., 2016). Ascl1-only induction was 
sufficient to downregulate, by day 2, genes involved in cell cycle and mitosis, 
consistent with the notion that cells that become neurons become post-mitotic 
within 48h and do not progress through a proliferative stage (Vierbuchen et al., 
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2010). Cells respond quite uniformly transcriptomically to Ascl1 induction, indicating 
that the heterogenicity observed at later stages must be due to subsequent events. 
Upregulated genes are involved in neuronal programming, including cytoskeletal 
reorganisation, synaptic transmission and neurite projection development.  
Investigation of cell transcriptomes at day 5 revealed how high levels of Ascl1 
expression correlate with high induction of Tau-eGFP reporter, and that cells that fail 
to reprogram underwent Ascl1 silencing. There is also an upregulation, in Tau-eGFP-
ve cells, of myoblast identity genes, consistent with Ascl1 promiscuous binding 
described before.   
Analysis of BAM-reprogrammed cells at day 22 revealed 3 distinct major 
subpopulations: iNs, as defined by Tau-eGFP expression and Syp expression, 
fibroblasts (marked by Eln expression) and myoblasts (defined by Tnnc2 expression). 
Very few of the cells reprogrammed with Ascl1 alone instead manage to mature to 
iNs, and show a predominant myogenic transcriptional profile. Consistently, Brn2 and 
Myt1l expression was low in BAM-reprogrammed cells with myoblast expression at 
day 22. This confirmed the predicted roles of Brn2 and Myt1l in directing and 
stabilising neuronal identity.  
Interestingly, they also identified intermediate, transient cell populations that 
upregulate neural progenitor associated genes like Nestin and Sox9 early on in the 
conversion, and then disappear as iNs mature. These cells never activate canonical 
neural stem cell markers like Sox2 or Pax6, but nonetheless, this shows the existence 
of transient transcriptional stages that are quite distinct from both starting MEFs and 
target iNs.  
A further study looking at identifying Myt1l genomic binding sites in iNs revealed how 
this previously relatively uncharacterised factor acts as a transcriptional repressor 
and binds, in neurons and fibroblasts, to non-neuronal, open chromatin loci, 
fundamentally preventing the activation of any non-neuronal program, for instance 
by silencing the Notch signalling pathway (Mall et al., 2017).  
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The ATAC-seq and scRNA-seq datasets were used to build a TF interaction network 
model that governs iN generation, placing Ascl1 at the top of the hierarchy (Wapinski 
et al., 2017). TFs are classified in tiers based on their expression at day 5, 13 and 22, 
and the way they are interconnected is based on their predicted binding sites on 
promoters of the other TFs – overall predicting which TFs induce and regulate which. 
This model was used to select 6 TFs to in MEF to iN reprogramming based on their 
expression levels and connectivity to Ascl1. Only two of those, Sox8 and Dlx3 were 
able to induce iNs when in presence of Myt1l, indicating that gene networks and 
pathway models generated from sequencing datasets won’t necessarily predict gene 
function.  
 
Overall, these studies provided an overview of the gene regulatory networks that 
orchestrate the cell identity change from a fibroblast into an induced neuron. Ascl1 
is the master regulator of the conversion, while Brn2 and Myt1l stabilise neuronal 
fate and limit alternate routes respectively. A few effector and target genes have 
been identified by looking at the networks described, but their role hasn’t always 
been functionally validated. Moreover, these types of approaches have a harder time 
identifying potential genes that instead prevent or slow down cell identity changes. 
In the next section, I’ll describe how a genetic loss-of-function screening approach 
could address this challenge. 
 
1.5 Genetics screens allow us to understand biological processes and 
the relationships between genes 
1.5.1 A brief history of genetic screens 
In 1993, Prof. William Sullivan, trying to explain to his students the difference 
between genetics and biochemistry, wrote an interesting and funny essay on the 
rationale behind mutational genetics. This famous piece presents two colleagues, Bill 
the biochemist and Doug the geneticist, observing a car factory and wondering how 
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all the people and materials going inside the factory every morning eventually results 
in automobiles driving out by the end of the day. 
Compared to Bill’s strenuous work of carefully taking cars apart and studying what 
they were made of, Doug’s approach was particularly straightforward and required 
relatively little effort: every morning he’d tie-up the hands of one of the workers 
going in, and, in the evening, he would observe the cars coming out of the factory 
and check what they were missing (Sullivan, 1993).  
Translating this into biology’s terms, Doug’s work is the equivalent of performing 
genetic knock-outs to understand the role of each gene in one specific process by 
impairing their function. When Doug started tying up the hands of multiple workers 
at once, he was, in a way, performing a genetic screen.  
 
The first genetic screens in eukaryotes made use of yeast biology, using the budding 
yeast Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces pombe as 
model organisms to characterise basic principles of eukaryotic cell biology. Thanks to 
their life-cycle, surviving as both haploids and diploids, they are particularly suitable 
to discover the phenotype of recessive mutations in their haploid form, and maintain 
them to allow further characterization in their diploid form (this is a particularly 
interesting aspect when considering performing genetic knock-out screens in 
mammalian, diploid, cells). Screens originally relied on chemically induced 
mutagenesis, introducing DNA aberration via chemical agents, followed by 
phenotypic screening and identification of the causal genetic mutation.  
Genetic screens using chemically-mutagenized yeast strains allowed the discovery of 
cell division cycle genes and eventually led Leland H. Hartwell, Tim Hunt and Sir Paul 
Nurse to being awarded the Nobel Prize in 2001 (Hartwell, Culotti & Reidt, 1970; 
Nurse, 1975). Chemical mutagenesis has been extensively used for screening 
purposes in multicellular eukaryotes as well, and has facilitated, to mention a few 
important milestones, the characterisation of sexual development in C. elegans 
(Ferguson & Horvitz, 1985), of segmentation and development in Drosophila 
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(Nüsslein-Volhard & Wieschaus, 1980), and of embryogenesis in zebrafish (Driever et 
al., 1996; Haffter et al., 1996).  
 
Although these types of classical genetic screens are useful in identifying gain-of-
function mutations (that would not instead be detectable by a loss-of-function, 
“Doug-like” knock-out approach) and are not burdened by sequence biases, one their 
major hurdles is the extensive work required to map and identify the genetic 
mutations causing the phenotypic changes.  
To overcome this, random mutagenesis technologies were developed that rely on 
disrupting genetic sequences by the insertion of DNA itself, using transposons or 
retroviruses as vectors. These approaches have been developed and optimised in 
mammalian cells, with a focus on mouse ES cells, with the objective of using 
mutagenesis screens to characterise the function of all the coding genes in the mouse 
genome  (Hicks et al., 1997). Referred to as tagged sequence mutagenesis, or gene 
traps, they work by delivering within cells a promoterless reporter and/or selectable 
marker, preceded by a splice acceptor sequence and followed by a polyA signal. This 
sequence gets randomly integrated within the genome and, when it gets inserted 
within a gene intron, leads to a fusion transcript expressed by the endogenous 
promoter of the gene targeted. This results in a truncated and generally non-
functional version of the protein, and the expression of the reporter. The advantage 
is that the targeted gene can be easily identified by sequencing and mapping the loci 
flanking the inserted tag (reviewed in Friedel & Soriano, 2010). Nonetheless, to 
observe a phenotype of recessive genes, mouse lines from the gene trapped ESC 
clone need to be generated and crossed to obtain homozygous lines and animals. 
This strategy has been used extensively, and several gene trap ES cell line banks and 
databases have been established (Nord et al., 2006; Roma et al., 2007; Taniwaki et 
al., 2005). 
 
As mentioned above though, revealing a recessive phenotype in mammalian cells can 
be particularly tricky due to their diploid nature. Although haploid ES cells have been 
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developed and shown to be suitable for genetic screens to allow the easy 
identification of recessive phenotypes, the derivation of differentiated cells often 
requires diploidy (Elling et al., 2011; Leeb et al., 2014), and thus these haploid cells 
have been unsuitable to derive differentiated haploid lines or primary cells, like MEFs, 
to perform large-scale screenings on. 
 
1.5.2 Modern tools for gene knock-out and genome engineering 
In recent years, high-throughput genetic screens have been employing the biology of 
RNA interference (RNAi) to achieve gene expression knock-down. RNAi was first 
identified as a molecular mechanism in C. elegans (Fire et al., 1998). It is a process 
that involves double-stranded small RNAs targeting mRNAs based on homology and 
tagging them for degradation, thus effectively inducing expression knock-down, 
though the efficiency of knock-down itself will depend heavily on each RNA species 
and sequence biases. Compared to classical screens, an RNAi-based screening 
approach has the advantages of having a quick and easy genetic readout, as it’s 
sufficient to sequence the mRNAs in the treatment group and identify the ones 
missing as responsible for the phenotype being analysed (reviewed in Boutros and 
Ahringer, 2008). It also crucially overcomes the need to mutagenize or trap both 
alleles of diploid cells to reveal recessive phenotypes, as it targets directly gene 
expression. The ease of use of these types of screens has facilitated unprecedented 
feats like in vivo screening or screening multiple species in parallel. Nonetheless, 
using this strategy for genetic screens presents one major hurdle, as it has a relatively 
high rate of off-target effects that increase noise when analysing datasets and 
increases the complexity of identifying the mRNA responsible for the phenotype. 
Moreover, the efficiency of knock-down can be extremely variable among small RNAs 
targeting the same mRNA, which makes it harder to use them as internal controls for 
off-target effects. Small hairpin RNA (ShRNA) expression can also interfere with 
miRNA expression and function as they rely and would compete for the same 
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processing machinery (reviewed in Mohr, Bakal and Perrimon, 2010; Mohr et al., 
2014).  
 
The discovery and adaptation of zinc fingers, TALENs and CRISPR/Cas9 systems made 
genetic targeted knock-out quicker, easier and cheaper than the traditional methods 
relying on homologous recombination, especially for mammalian models and cells. 
This can bypass some of the issues that knock-down poses, but ultimately answers a 
different biological question, as RNAi will only reveal phenotypes that are affected 
significantly by gene expression levels rather than the complete absence of 
expression resulting from knock-out. Moreover, the temporal dynamics of RNAi are 
also significantly different from knock-out, as the mRNA downregulation via RNAi 
does not impact the endogenous and untargeted mRNA transcription.  
 
Genome engineering mediated though Zinc fingers (ZF)-nucleases (Urnov et al., 2005) 
and TALEN (Transcription activator-like effectors nucleases) (Christian et al., 2010) 
works on a shared principle: bringing Fok1 endonuclease to a desired target locus by 
fusing the nuclease with ZF or TALE DNA binding domains with designed sequence 
specificity. If cells are provided with a DNA template flanked by homology arms, DBS 
induced by Fok1 can be repaired by homologous recombination and can be exploited 
to engineer or knock-in DNA sequences within a target locus. Alternatively, cells will 
repair the DBS via Non Homologous End Joining (NHEJ) that will lead to a high rate of 
indels resulting in missense mutations by introducing premature stop codons in 
coding sequences of genes. (Bibikova et al., 2002). This way, Zinc Finger nucleases 
(ZFNs) and TALENs can be used to induce gene knock-out in a way that is much 
quicker and easier than before (reviewed in Hsu, Lander and Zhang, 2014). ZFs and 
TALE modules recognise to 3bp and 1bp sequences respectively, and thus they 
require a multi-modular assembly in order to target specific loci effectively. Both 
require extensive protein engineering, which can be labour-intensive and expensive. 
This is one of the major reasons CRISPR/Cas9 took over so quickly on ZFs and TALENs 
– as its DNA recognition relies on RNA-DNA base pairing.   
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1.5.3 CRISPR/Cas9 discovery 
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. They 
were first identified in the iap gene in E.coli, consisting of a series of 29bp repeats 
interspaced by five non-repetitive sequences of 32bp (Ishino et al., 1987). In 2000, 
they were classified as a family of repeat elements widely present in roughly half of 
bacterial species and 90% of archaea (Mojica et al., 2000), and eventually labelled 
CRISPR in 2002 (Jansen et al., 2002). The same work highlighted the presence of well 
conserved genes, often adjacent to the repeat elements, and defined them as 
CRISPR-associated, cas. This gene family was initially characterised and subdivided in 
3 major different systems that rely on different DNA binding and processing 
strategies (reviewed in Makarova et al., 2011). More up-to-date classifications 
subdivide the CRISPR-Cas systems in two classes that contain overall 6 system types. 
The major differences between the classes is that class 2 systems rely on a single 
multidomain effector protein to induce DNA cleaveage – Cas9 is the best 
characterised effector protein within class 2 (reviewed in Mohanraju et al., 2016). 
 
The evolutionary role of these sequences and genes started to become clear in 2005, 
when it was shown that these repeats had extrachromosomal origin (Bolotin et al., 
2005) and were derived from viruses (Mojica et al., 2005). Mojica and colleagues also 
showed how viruses can’t infect archaea that contain, within the repeat spacers, the 
virus genome. In 2007, working with Streptococcus thermophilus for the production 
of dairy products, Barrangou and colleagues performed a series of experiments to 
show that bacterial strains infected with bacteriophages became rapidly immune to 
the phage strains they were exposed to and incorporated part of the phage genome 
in the CRISPR1 locus by adding extra spacer sequences (Barrangou et al., 2007). This 
represented the first direct evidence that CRISPR loci are involved in bacterial 
immunity. Since then, extensive characterisation of this mechanism has brought us a 
detailed understanding on how bacteria and archaea use CRISPR-Cas complexes as a 
primitive immune system (Jackson et al., 2017). An overview of the major 




Fig. 1.7 – CRISPR-mediated phage immunity. (Adapted from Jackson et al., 2017). 
Following phage infection and the insertion of foreign nucleic acid within the host cytoplasm, 
Cas1 and Cas2 proteins incorporate a fragment of the nucleic acid within the CRISPR spacer 
array. The spacers are transcribed as crRNAs and incorporated within the effector complex, 
that will use the gRNA sequence to identify homology within the foreign nucleic acid and 
degrade it.  
 
Briefly, Cas1 and Cas2 proteins are responsible for integrating the phage genome 
within the spacer array of the CRISPR locus. The spacer array is then transcribed into 
RNA, though the processing of these CRISPR-RNAs (crRNA) is specific to the system 
subtype. crRNAs are integrated in the effector complex (made up of a single protein 
for class II CRISPR systems) and guides the effector to recognise the phage foreign 
nucleic acid thanks to base-pair homology. Upon recognition, the foreign genetic 
material is cleaved by the nuclease(s).  
To avoid cleavage of their own genome, prokaryotes rely on the PAM sequence 
(Proto-spacer Adjacent Motifs). This is a 2-3bp motif that is located right adjacent to 
proto-spacers in the foreign nucleic acids injected by phages. The PAM sequences 
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recognised are specific for the CRISPR/Cas system. The effector proteins, once in 
complex with the crRNA, will only cleave DNA if the PAM is present (Mojica et al., 
2009). This is particularly relevant for the applications of CRISPR/Cas9 to mammalian 
genome engineering, discussed below.  
Fig.1.8 below zooms in on the expression and RNA processing step of type 2 CRISPR 
systems, focusing on CRISPR-Cas9. The processing of the polycistronic pre-crRNA 
relies on a trans-activating tracrRNA that recognises the repeat sequence in the 




Fig. 1.8 – Type 2 CRISPR-Cas9 specific mediated immunity to phage infections. 
(Adapted from Makarova, Zhang and Koonin, 2017). In the adaptation step, Cas1 and Cas2 
proteins integrate proto-spacer sequences from the invading DNA into the CRISPR spacer 
array. The non-coding trans-activating tracrRNA recognises the repeat sequences in the 
polycistronic pre-crRNA and recruits the bacterial RNAse III to cleave it, transitioning into the 
crRNA maturation step. The crRNA is loaded onto Cas9 while still in complex with the 
tracrRNA. The tracrRNA is required for crRNA-guided Cas9 cleavage activity. Upon phage re-
infection, the invading DNA is detected by the Cas9-tracrRNA-crRNA complex and is 
degraded by Cas9 (Jinek et al., 2012). 
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1.5.4 Translating CRISPR/Cas9 to genome engineering  
The first attempt at using CRISPR-Cas9 as a cross-species tool occurred in 2011, 
when Sapranauskas and colleagues transformed the CRISPR array and Cas9 
from Streptococcus thermophilus into E.coli and demonstrated how it confers it 
immunity to plasmid transformation and lambda phage infection (Sapranauskas et 
al., 2011). A year later, Cas9 from Streptococcus pyogenes was purified and shown to 
cleave target DNA in vitro when guided by crRNA (Jinek et al., 2012). The same work 
showed how the tracrRNA and crRNA could be fused into a chimaeric single 
transcript, referred to as single gRNA (sgRNA) that allows Cas9 to cleave any dsDNA 
that contains the PAM sequence -NGG adjacent to the crRNA homologous region. 
The authors suggested how this system, requiring expression of only two standard 
proteins (Cas9 and bacterial RNAse III) and a single RNA transcript, was advantageous 
compared to ZFs and TALEs as it was easier and cheaper to customise thanks to its 
relying on DNA design and synthesis rather than protein engineering.  
 
Again, only one year later, SpCas9-mediated genome engineering was achieved in 
human and mouse cells (Cong et al., 2013; Mali et al., 2013).  
Cong and colleagues, from the lab of Prof. Feng Zhang, showed that mammalian 
RNAses were able to process the pre-crRNA without the need for exogenous bacterial 
RNAse III to be introduced, which made the system even simpler. After codon-
optimisation for mammalian expression of SpCas9, and the addition of NLS to 
enhance Cas9 localisation to the nucleus, they optimised a strategy consisting of a 
single expression vector driving Cas9 expression thanks to the EF1a promoter, and 
sgRNA expression thanks to the U6 promoter. This construct was transfected and 
shown to be functional in both mouse and human cells, and it allowed multiplexed 
genome engineering by providing the cells with a crRNA array targeting independent 
loci. 
Mali and colleagues, from the lab of Prof. George Church, also relied on U6 promoter 
for the expression of the sgRNA, but expressed codon-optimised, NLS-containing 
SpCas9 under the control of the CMV promoter. By transfecting the constructs in 
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human 293T cells, they showed that they can achieve template-mediated 
homologous recombination (HR) following Cas9-mediated DBS as early as 20h post 
transfection – as assessed by the expression of a GFP reporter engineered within the 
hAAVS1 locus. By targeting the ubiquitously expressed PPP1R12C gene in three 
different human lines using two independent gRNAs, they showed that Cas9’s ability 
to induce NHEJ can be quite variable and depend on both cell line and gRNA used 
(efficiencies ranging from 10% to 25% for the two separate gRNAs in HEK cells, 13% 
and 38% in K562 leukaemia cells and 2% and 4% in PGP1 iPS cells). The only reported 
technical restriction they claim is the requirement for the -NGG PAM sequence, which 
should represent only a minor limitation as it should occur, considering both DNA 
strands, every 8bp on average. 
 
As reviewed by Almendros and colleagues (Almendros, Kieper & Brouns, 2019), 
SpCas9 is still the most used Cas effector protein for mammalian genome editing, 
though extensive efforts have been dedicated to optimising its efficiency and to 
minimise its off-target activity. This is particularly important for therapeutic 
applications, where off-target effects can’t be controlled for by using multiple gRNAs 
against the same gene (which is sufficient for most research applications) but can 
have severe consequences on biologicals and/or edited embryos. 
A few strategies to address this involved improving gRNA site selection by 
computationally predicting, identifying and minimising off-target sites. Moreover, 
Cas9 mutagenesis of nuclease domains converting them into nickase domains and 
inducing genome engineering using double gRNAs targeting opposite strands allowed 
more precise editing (nicks are repaired with much higher fidelity than DBS) 
(reviewed in Tycko, Myer and Hsu, 2016). Engineering an improved Rec3 domain to 
improve Cas9 proofreading activity was also shown to enhance Cas9 specificity (Chen 
et al., 2017). 
 
The latest efforts in CRISPR-mediated genome engineering have focused on finding 
ever smaller effector proteins that would allow easier packaging and delivery through 
 34 
lentiviruses for instance, that at the same time have non-restrictive PAM sequences 
to allow easy gRNA site selection. Of note, Nme2Cas9 from the meningococcus 
Neisseria meningitidis coding sequence is only 3.2kb – compared to the 4.4kb of 
SpCas9, has a permissive PAM sequence (N4CC) and has been shown to efficiently 
edit human cell genomes when delivered through lentiviral constructs (Edraki et al., 
2019).  
 
The possibilities that CRISPR-Cas9 has opened are extremely broad, not only focusing 
on the nuclease activity of the protein, but on the easily customisable targeting 
properties of its DNA-binding domain. Fig.1.9, taken from a review paper from the 
Zhang lab from 2014, highlights a few of the potential applications for Cas9 described 
soon after its application to mammalian cells had been published. Lentiviral 
transduction that can reach extremely high efficiencies has facilitated sgRNA delivery 
and CRISPR/Cas9 applications directly within cells and tissues. DNA labelling and 
inducible regulation are also mentioned as prominent areas of potential Cas9 
application. 
Particularly interesting is the use of catalytically dead Cas9 (dCas9) bound to an 
activator domain to induce gene expression. It was first achieved in human cells by 
tagging dCas9 to the activator domain VP64 and targeted to the promoters of 8 
different genes. Gene expression induction was verified by RT-qPCR, which showed 
that the highest expression levels were achieved by synergistic effects of targeting up 
to 4 sgRNAs to the promoter region of each gene (Perez-Pinera et al., 2013). When it 
was first established, it was proposed as an alternative way to induce gene expression 
(compared to more traditional plasmid or lentiviral delivery of the cDNA under an 
exogenous promoter) and it set out to be a rapid and efficient way to activate 
multiple genes at once by delivery of a single protein and an array of sgRNAs. In 2016, 
this system was used to efficiently generate iNs from MEFs by targeting the 
promoters of Ascl1, Brn2 and Myt1l with a combination of 4 sgRNAs per promoter, 




Fig. 1.9 – Cas9 potential applications. (Taken from Hsu, Lander and Zhang, 2014). (a) Cas9 
RuvC and HNH domains confer the protein its nuclease activity. By selectively mutating one 
or the other, Cas9 can be converted into a strand-selective nickase. (b) By mutating both 
domains, Cas9 can be converted into a double nickase that can reproduce DBS by 
appropriately spacing the target site of each nickase. This increases the specificity of DBS as 
they rely on two independent gRNAs. (c) Cas9 and sgRNA within the same expression 
plasmids can be introduced as a single construct within target cells. (d) Purified Cas9 protein 
and sgRNA in vitro transcribed molecules can be directly introduced into zygotes to allow fast 
generation of transgenic mice models. (e) Lentiviral delivery of Cas9 and sgRNA allows 
efficient introduction of the components into somatic cells and tissues. (f) gRNA libraries can 
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be cloned as a pool into expression plasmids and transduced within cells (together with Cas9, 
or within cells constitutively expressing Cas9), that are then exposed to selective pressure to 
identify the effect of CRISPR-Cas9-induced genetic KO on the desired selected-for phenotype. 
This approach, applied to the conversion between MEFs and induced neurons, is the focus of 
this thesis – more details are given at the end of this chapter in the “Thesis Aims” section. (g) 
dCas9 can be coupled to effector domains to selectively activate or suppress gene 
expression. This can be used to understand the role of promoters or enhancers by designing 
sgRNAs against those loci. (h) Tagging dCas9 with fluorescent reporters can be used to follow 
chromatin dynamics and track the behaviour of specific loci during chromosome 
rearrangement, or nuclear lamina association, or the assembly of transcription factories and 
so on. (i) Inducible genetic regulation can be achieved by splitting up Cas9 into heterodimer 
domains and relying on chemical or optical induction to initiate protein assembly and 
inducing its activity. 
 
1.5.5 CRISPR/Cas9 in genetic screening 
Building on the work of the Zhang and Church labs, in 2014 3 seminal papers 
described the first CRISPR/Cas9-mediated loss-of-function genetic screenings in 
mammalian cells (Koike-Yusa et al., 2014; Wang et al., 2014; Shalem et al., 2014).  
In all three papers gRNAs were delivered as a lentiviral pool – and expressed under 
the control of the U6 promoter. The gRNA sequences themselves, integrated within 
the host genome thanks to the lentiviral delivery, would serve as barcodes to allow 
NGS to count the number of cells selected for or against a particular gRNA.  
Wang and colleagues established an engineered stable line with constitutive 
expression of Cas9. This resulted in circa 97% of on-target  indels, with the majority 
of DBS resulting in small deletions (<20bp) leading to non-functional proteins, and 
minimal off-target editing (as assessed by sequencing of predicted off-target sites).  
gRNA design relied on -NGG, targeting constitutive coding exons, as early as possible 
within the coding sequence to introduce premature stop codons and trigger 
nonsense-mediated mRNA decay, and filtered for the lowest amount of predicted 
off-target sites within the human genome. Multiple sgRNAs were designed per gene 
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– to account for different editing abilities of gRNAs and to ensure that, in the analysis 
step, a false-negative or false-positive gRNA read count could be controlled-for by 
looking at read counts of gRNAs targeting the same gene. 
They also discuss the highly variable efficacies of gRNAs by looking at multiple gRNAs 
targeting the same genes. GC content, targeted exon position and targeting the 
transcribed vs non-transcribed strands all seemed to be factors involved in gRNA 
efficacies. gRNA purine/pyrimidine content in the 3’ end was also a strong predictor 
for efficacies. Together, these data were used to generate a genome-wide sgRNA 
targeting library of predicted high-efficiency.  
 
Shalem and colleagues instead delivered Cas9, the sgRNA and a puromycin selection 
marker within a single lentiviral construct. This makes it easier to perform genome 
engineering and genetic screens in any cell without the need to generate a Cas9-
expressing line first, but is susceptible to more variability as the locus of lentiviral 
integration can potentially affect Cas9 expression and lead to heterogeneous levels 
in the examined cells, with consequences on editing efficiencies. 
The library they designed, called GeCKO (for Genome-scale CRISPR-Cas9 knock-out), 
targets 5’ constitutive exons with, on average, 4 gRNAs per gene, designed using 
similar considerations in terms of off-target predictions as the Wang paper.  
They used this library to perform a genome-wide CRISPR-Cas9 screen looking at 
identifying genes involved in PLX drug resistance in A375 cells and compared the 
result with a RNAi screen for the same resistance in the same cell line, showing better 
consistency in gRNA behaviour compared to shRNAs. They also validated up to 5 
gRNAs for top-ranking genes using deep sequencing and verified that 23/25 sgRNAs 
resulted in >95% allele modification.  
 
Whereas the works by Wang and Shalem and their colleagues focused on human cells 
and generated genome-wide gRNAs libraries targeting the human genome, Koike-
Yusa and colleagues performed a similar genome-wide screen on mouse embryonic 
stem cells instead. Similarly to Wang and colleagues, they produced a mESC line 
 38 
constitutively expressing Cas9 under the control of the EF1a promoter, and 
transfected cells with sgRNAs, showing a higher knock-out efficiency from the Cas9-
expressing line, compared to wt cells that received Cas9 expression via transfection 
of a separate plasmid.  
For screening purposes, the gRNAs were delivered as a pool within a lentiviral 
construct driving gRNA expression under the U6 promoter, as the previous two 
studies. The library was designed with 5 gRNAs per protein-coding genes in the 
mouse genome.  
 
All three studies show evidence of the success of CRISPR/Cas9 loss-of-function 
positive selection screens, by exposing the cells to drugs or toxins to identify genes 
involved in susceptibility to those agents. Cells in which susceptibility genes have 
been knocked-out after being targeted by gRNAs will survive. This set-up exposes the 
cells to strong selective pressure and will result in low background, as cells that fail 
to acquire a resistance phenotype by genetic KO will die off, whereas surviving cells 
will proliferate and biologically “amplify” the representation of the gRNAs that target 
susceptibility genes within the surviving cell population.  
 
The studies by Shalem et al. and Wang et al. also show evidence of the success of 
loss-of-function negative selection screens. This type of screen looks for essential 
genes involved in a process by exposing cells to selective pressure and looking for 
gRNAs that are underrepresented or depleted within the final cell population. The 
two studies wanted to investigate genes essential for cell viability: they transduced 
the cells with gRNA libraries and allowed them to proliferate for several cell 
doublings. Cells that received gRNAs targeting genes essential for survival will die off. 
By looking for underrepresented gRNAs in the pool of surviving cells, genes involved 
in cell viability can be identified. Compared to positive selection screens, this 
approach is likely to reveal a broader range of genes – some genes might be 
completely essential, while the knock-out of others might just slow down 
proliferation. This was in fact the case for the Shalem and Wang papers, and their 
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analysis focused on the most strongly depleted gRNAs to identify essential genes – 
revealing in fact genes involved in DNA replication, gene transcription and 
translation. 
 
The analysis of the NGS dataset itself had relied on customised algorithms or, in the 
case of Shalem et al., the RIGER algorithm previously developed to rank enrichment 
of shRNAs from RNAi screens (Luo et al., 2008). In 2014, the MAGeCK algorithm 
(Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout) was developed 
specifically to analyse NGS screening datasets containing gRNA read counts from 
CRISPR-Cas9 screens, overcoming the limitations of previous algorithms focused on 
oligonucleotide barcodes from microarray data, different sequencing depths, 
different mapping of sequences to genes and pathways, and taking into 
consideration for instance the number of gRNAs targeting each gene.  
 
These seminal studies highlighted how translatable CRISPR-Cas9 technology was, and 
how the right tools had allowed with relative ease to perform genome-wide screens 
on mammalian cells with more hits, and more robust hits, compared to traditional 
RNAi screens. To summarise a few key points: 
1. they showed how Cas9 integration within cell lines allows strong editing 
efficiencies and full genetic KO in mammalian diploid cells within one day of 
gRNA integration 
2. they showed that lentiviral delivery of gRNAs, compared to transfection, 
allows robust gRNA expression 
3. they showed that a single, lentivirally-delivered copy of the gRNA expression 
construct is enough to induce efficient DBS 
4. they established genome-wide sgRNA libraries for human and mouse cells – a 
great resource for all labs working on those species. The Yusa lab in 2016 
improved on their mouse genome-wide gRNA library by perfecting sgRNA 
design and minimising off-targets (Tzelepis et al., 2016). This library was used 
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in this project to select gRNAs against the chosen gene subset – more 
information is provided in Chapter 3. 
 
Since then, many labs have used CRISPR-Cas9 screens to investigate a myriad of 
different biological processes, as reviewed by several publications (Kweon & Kim, 
2018; Joung et al., 2017; Doench, 2018). Screens have not only focused on loss-of-
function phenotypes, but thanks to all the mutagenesis on Cas9 and the optimisation 
of gRNA targeting, they have been used for gene activation or repression, DNA 
methylation or de-methylation, histone modifications and even DNA base editing.  
In the context of in vitro derived neurons, a recent CRISPR activation screen targeted 
circa 2500 predicted transcription factors and DNA binding factors with a total of 
55’000 gRNAs to identify genes that, when overexpressed, would convert mouse 
ESCs into neurons (Liu et al., 2018).  
They then overexpressed their top 14 hits in MEFs to check whether they could 
convert them into iNs, revealing that Ngn1, and a combination of other factors and 
BAM factors, can convert to some extent fibroblasts into iNs.  
This approach is particularly interesting as it highlights a quite stringent library 
selection (targeting only 2500 genes) that is based on biased gene predicted function 
(DNA binding and transcription activation), but not gene expression.  
 
Overall, the CRISPR-Cas9 screening technologies represent a powerful tool to 
investigate the function of multiple genes at once in the context of a specific 
biological process. I decided to apply this technology to identify and investigate which 
genes are involved in the in vitro conversion between MEFs and iNs.  
  
 
1.6  Aims of this thesis 
The aim of this thesis was to identify genes involved in the direct conversion between 
fibroblasts and neurons and use this information to make the process more 
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deterministic, thus increasing the efficiency of the conversion and neuronal purity of 
the culture. 
To achieve this, I designed a CRISPR/Cas9-mediated screening strategy to investigate 
gene roles by looking at loss-of-function effects. The experimental design is outlined 
in Fig.1.10 below. Cas9-expressing MEFs transduced with the BAM factors to allow 
conversion into iNs were also transduced with a pooled lentiviral gRNA library 
targeting a subset of genes that, based on their gene expression, are likely to be 
involved in the process.  
Thanks to the lentiviral delivery, gRNAs transduced within MEFs allow gene KO while 
being integrated within the host genome and propagated as cells grow and convert. 
After 15 days, the neurons were isolated from the rest of the cell types within the 
culture, and, using Next Generation Sequencing (NGS), the distribution of the gRNAs 
integrated within the pool of neurons was analysed (how to isolate, using flow 
cytometry, the iNs from the heterogeneous conditions is also addressed in Chapter 
3). 
The distribution of gRNAs within the neuronal genomes should allow the 
identification of essential genes or facilitators of the conversion, as well as potential 
roadblocks that hinder the conversion.  
The former should be identified by a depletion of their targeting gRNAs, since cells 
that received a gRNA against an essential conversion gene would have been less likely 
to become neurons, and thus those gRNAs would be present in fewer copies in the 
sequencing data.  
Vice versa, the latter should be identified by an enrichment of their targeting gRNAs, 
since MEFs that received a gRNA against a conversion roadblock would have higher 
chances of converting into a iN, and thus those gRNAs would be present in more 
copies in the sequencing data. The MAGeCK algorithm was used to combine the 
behaviour of individual gRNAs targeting the same gene and identifying genes that are 
overall enriched or depleted, and thus potential roadblocks or enhancers of the 
conversion. 
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Chapter 3 addresses the system set-up: how to isolate the neurons, and how the 
library of genes to screen against was designed and prepared. 
Chapter 4 addresses the screen process and its validation, and discusses the role of 
Sf3a1 in the conversion. 
Chapter 5 addresses the characterisation of 20 individual genes selected based on 
their known role in the conversion and highlights the role of Stxbp1 in iN survival. 
 
 
Fig. 1.10 – Screen experimental design. Cas9-MEFs transduced with the BAM factors 
were converted into iNs. A pooled gRNA lentiviral library transduced together with the 
factors allowed gRNA integration within the host genome and Cas9-mediated gene KO. 
Neurons after 15 days from the start of the conversion were isolated and the gRNAs 
integrated within their genomes were sequenced and their distribution quantified. In red is 
represented a gRNA targeting a potential conversion roadblock gene. Upon KO, the MEFs 
that receive this gRNA would have a better chance of becoming neurons, thus this gRNA 
would be enriched within the neuronal genomes.  
In green is represented a gRNA targeting a potential essential gene for the conversion. This 
gRNA would prevent the MEFs that receive it to convert into iNs, thus it would not be found 
in the neuronal pool and would be underrepresented in the sequencing data from neuronal 
genomes. 
In yellow is represented a gRNA targeting a gene that has no effect on the conversion, and 
whose KO would not impact the conversion. Thus, this gRNA would be equally represented 
compared to the original gRNA distribution in the lentiviral pool.  
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1.7 A note on in vitro neuronal identity 
Overall, neuronal identity is defined by 4 major, equally important characteristics. 
Firstly, morphology: neurons are recognizable by the presence and defined length of 
dendrites and a single neurite sprouting from the cell body. This feature was used by 
the first iN publication (Vierbuchen et al., 2010) to identify and quantify iNs via 
imaging. They defined a neuronal morphology as a cell having a neurite whose length 
is at least 3 times the diameter of the cell body. 
Of course neuronal morphology changes and increases in complexity as the cell 
matures and creates connections with its neighbor. The criterion used by the first 
publication has become widely used as a minimal morphological criterion to identify 
an in vitro induced neuron.  
In this thesis, I’ve used this criterion to identify and quantify iNs in my culture system. 
 
Secondly, the expression of a subset of specific markers that are exclusively 
expressed by cells with neuronal morphology in the culture and can distinguish iNs 
from fibroblast, myoblasts or neural but non-neuronal cells. Among the most 
commonly used, and first used by the Wernig lab in 2010, are Tubb3, Map2, NeuN, 
Tau, Synapsin. Expression of these genes marks any newly converted iN regardless of 
the expression of subtype-specific markers. 
In this thesis, I’ve used these markers to identify and quantify iNs in my culture 
system. I haven’t addressed the subtype identity and the heterogenicity of neuronal 
phenotypes in the culture. It’s important to highlight this as my results are potentially 
impacted by the different neuronal subtypes but I don’t have a way of examining this 
further with the tools and platforms discussed here. 
 
Thirdly, electrophysiological properties of the cellular membrane are a defining 
feature of a neuron. A neuron has distinctive resting membrane potential and has to 
be able to fire an action potential when the membrane is stimulated with a voltage 
above a certain threshold. 
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This feature has been addressed by most of the publications on iNs. The original 
paper reported electrophysiological activity of the iNs upon co-culture of the cells 
with astrocytes or ex-vivo cortical neurons from day 13 onwards of the conversion. It 
is important to note that before the iNs reach this stage of maturation, they should 
be identified as immature iNs – as lacking functional evidence of neuronal electrical 
characteristic behaviour. 
Electrophysiological studies are not present in this thesis, as they were beyond its 
scope. It has to be mentioned hence that it is likely my assessment of iNs, that relies 
on morphology and marker expression alone, includes a heterogeneous mixture of 
cells of electrical immature nature. 
 
Lastly, a neuron should be defined by its subtype. As I discussed in section 1.2.2, 
extensive work has been done to generate pure populations of iNs of a specific 
subtype that express markers relative to the neurotransmitter and pathway the 
neurons produce and partake in. The original 2010 publication on iNs reported cells 
reprogrammed with Ascl1, Brn2 and Myt1l as having heterogeneous subtype 
identity. Presence of GABAergic neurons, glutamatergic neurons was assessed and 
quantified both via immunofluorescence and electrophysiological responses. 
Dopaminergic neurons seemed to be absent. Several of the cells identified as iNs 
lacked the expression of subtype-specific markers. It’s important to remember this 
when defining an induced neuron and using these cells for disease modelling or drug 
testing. 
In this thesis, I did not address the neuronal subtype identity of the iNs produced as 
it went beyond the scope of the study. It’s then important to note that the cells I 
define as iNs or pan-iNs are marked by morphology and expression of canonical 
neuronal markers, but are likely to be a mix of cells with specified subtype identity 
and cells lacking one.  
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Chapter 2 Materials and methods 
2.1 Cell culture 
2.1.0 General notes 
All cell cultures were maintained at 37ºC, 5% CO2 in normoxic conditions. All media 
and reagents, unless where specifically stated, were warmed up to 37ºC in a water 
bath before being added to cells. 
Cell centrifugations were performed on a tabletop centrifuge for 3 minutes at 
1300rpm.  
Cell thawing was performed by warming up the frozen vials at 37ºC in a water bath 
for 1 minute before adding the solution of thawing cells to 10ml of warm medium. 
Cells were then spun, resuspended in appropriate medium and plated at the 
appropriate density in culture flasks, dishes or wells. 
Cell freezing was performed by harvesting the cells using 0.25% Trypsin-EDTA, 
washing in 10% FCS medium and resuspending spun pellets in FCS + 10% DMSO. Cells 
were frozen down in Mr. Frosty™ Freezing Container (ThermoScientific) at -80ºC for 
24h before being moved to LN2 long term storage. 
 
2.1.1 Cell culture reagents 
HEK medium 
 
- Glasgow Minimal Essential Medium (GMEM, Sigma G5154)  
- Fetal Calf Serum (FCS) (10%) (Life Technologies) 
- Non-essential amino acids (1X, Gibco 11140-035)  
- L-Glutamine (2 mM, Invitrogen) 





- Glasgow Minimal Essential Medium (GMEM, Sigma G5154)  
- Fetal Calf Serum (FCS) (10%) (Life Technologies) 
- Non-essential amino acids (1X, Gibco 11140-035)  
- L-Glutamine (2 mM, Invitrogen) 
- Sodium pyruvate (Invitrogen) 
- Penicillin/Streptomycin (100 units/100 μg, Sigma P4333)  
- β-mercaptoethanol (ThermoFisher Scientific, 31350010) 
 
Conversion medium (CM) 
 
- Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12 Ham (Sigma 
D8437) 
- Glucose (Sigma G8644) 
-  MEM NEAA 100x (Gibco 11140-035) 
-  Pen-Strep (Gibco 15140-122) 
- BSA Solution 0.012% (Gibco 15260-037) 
- β-mercaptoethanol 50mM (Gibco 31350-010 (20ml))          
-  B27 Supplement 50x (Life Technologies 17504-044) 
-  N2 Supplement 100x (Life Technologies 17502-048) 




- Fetal Calf Serum (FCS) (Life Technologies) – 90% 




- Trypsin-EDTA (0.25%, Gibco 15090-046) 
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- PBS (Sigma, D8537) 
 
2.1.2 Cell lines used  
- Cas9 MEFs – isolated as described below (paragraph 2.1.3). MEFs were 
isolated from mice crosses between wild type animals and animals from the 
C57BL/6 KYEC Rosa26+/sNLSCas9 line, obtained from the lab of Dr. Kosuke Yusa. 
This line is heterozygous for the Rosa26 locus as one locus harbours the 
coding sequence for SpCas9 containing a single nuclear localisation signal 
(sNLSCas9). A homozygous mouse line containing two copies of SpCas9 
became available only at the end of the project and thus was not used for the 
work presented in this thesis. 
 
- HEK293T – lentivirus packaging line 
 
2.1.3 MEF isolation 
Mice crosses were set-up between female WT animals and male C57BL/6 KYEC 
Rosa26+/sNLSCas9 animals. Embryos were isolated from culled mothers at E14.5 and 
kept in cold PBS supplemented with 2% Pen/Strep (Sigma P4333). Under a dissection 
microscope heads, internal organs, spine and tail were removed. A portion of fetal 
liver was kept aside for genotyping. The remaining tissue was incubated in 0.5ml 
0.25% Trypsin / 2 mM EDTA for 15 minutes at 37ºC, and then mechanically 
disassociated by passing it through an 18-gauge needle. The suspension was added 
to 10ml of MEF medium to allow trypsin quenching. Each embryo was handled 
individually, and the final solution of 10.5ml was plated into a 10cm3 dish. The next 
day the medium was changed to remove residual trypsin. Cells were allowed to 
expand for 48h from seeding, then pooled based on genotyping results and frozen. 




2.1.4 MEF genotyping 
DNA extraction solutions:  
1) Lysis buffer: 25mM NaOH / 0.2 mM EDTA 
2) Neutralisation buffer: 40mM Tris-HCl (pH 5.0) 
 
The portion of fetal liver kept per embryo was added to 30µl of lysis buffer and 
incubated at 95ºC for 20 minutes. After rapid cooling to 4ºC, 30µl of neutralisation 
buffer were added to the samples, followed by thorough vortexing. 1µl of this lysate 
was used for the genotyping PCR in a 15µl final volume as shown in Table 2.1. Table 
2.2 explains the PCR running conditions. Amplicons were then analysed on a 2% 
agarose gel. Primer sequences are in Table 2.3. 
 
Cell lysate 1 ul 
2.5 mM dNTP 1.2 ul 
DreamTaq Buffer 10X 1.5 ul 
DreamTaq Polymerase (Thermo Scientific) 0.075 ul 
20 µM F primer 0.375 ul 
20 µM R primer 0.375 ul 
dH2O 10.475 ul 









4C cooling  
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Table 2.2 – PCR running conditions 
 
Cas9-U2 CTCTCCCAAAGTCGCTCTGA Rosa26 F 
 
Cas9-L2 ACCCCAGATGACTACCTATCCT Rosa26 Wt R 395bp amplicon 
Cas9-L3 GAAAGACCGCGAAGAGTTTGTC  Rosa26 Cas9 R 317bp amplicon 
Table 2.3 – Cas9 genotyping primer sequences.  
 
2.1.5  MEF freezing  
Based on genotyping results, cells derived from embryos carrying the Cas9 transgene 
were pooled together upon harvesting. Cells were lifted by adding 1ml 0.25% Trypsin 
/ 2 mM EDTA to the dish. After 5 minutes incubation at 37ºC, the solution was 
quenched with 9ml MEF medium. Cells were centrifuged for 3 minutes at 1300rpm, 
counted and then aliquoted as 2.5x106 cells per cryovial in freezing medium and 
stored in LN2 long term.  
 
2.2  Lentiviral production 
The lentiviral particles used in this work were produced using a 2nd generation 
packaging system, where the gag, pol and rev packaging sequences are expressed 
from the psPAX2 vector, while the encapsulation sequence from the VSV-G env gene 
is expressed from the pMD2.G vector. The sequence of the construct of interest to 
transduce is contained within flanking self-inactivating long terminal repeat (LTR) 
regions.  Source of vectors can be found in table 2.18. 
 
2.2.1  HEK culture 
HEK from communal lab batches frozen at as 5x106 cells per vial were thawed, seeded 
in a t150 flask and allowed to grow for 2-3 days.  
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HEKs were routinely passaged upon reaching 80% confluency by lifting them with 
0.25% Trypsin / 2 mM EDTA and re-seeding them to a density of 1:5 to 1:10 of the 
original one, every 3-4 days. 
Early passage batches were expanded and frozen at a density of 5x106 cells per 
cryovial in freezing medium and kept in LN2.  
 
2.2.2 HEK seeding and transfection 
One day before transfection, HEKs were lifted, counted, and seeded at a density of 2 
million cells per 10cm2 dish. The next day, cells were transfected with the transfer 
vector plus psPAX2 and pMD2.G using the calcium phosphate protocol. Plasmids and 
water were mixed to a final volume of 437µl, then 63µl of 2M calcium chloride were 
added to the mix (126mM final concentration). The solution was quickly vortexed. 
While vortexing, 500µl of HBS (8 g NaCl, 0.2 g Na2HPO4-7H2O, 6.5 g HEPES) were 
added dropwise to allow the formation of homogeneously sized precipitate. After 10-
minute incubation at room temperature, the solution was added dropwise to the HEK 
dish, then shaken to ensure even distribution of the transfection mix.  
The next day, the HEK supernatant was removed and changed for 7ml GMEM. 
 
2.2.3 Virus harvesting and freezing 
Viruses were harvested at 48h and 72h post-transfection. After the first harvesting, 
7ml GMEM were added to the cells to allow for the second collection. The 
supernatants were filtered through 0.22µm PES filters and stored at 4ºC up to 24h 
before pooling, aliquoting, and transported in dry ice to long-term storage at -80ºC.   
 
2.2.4  Virus concentration 
For the tetO-Ascl1, Brn2, Myt1l and hUb-rtTA constructs, lentiviral particles from 
supernatant were concentrated to allow co-transduction of the 4 factors within cells 
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in small volume amounts. Filtered fresh supernatants were mixed with Lenti-X™ 
Concentrator (TaKaRa #631232) in a volume ratio of 3:1 and incubated overnight at 
4ºC. The next day, the solutions were centrifuged for 2h at 4ºC at 1500rpm. This 
allows lentiviral particles bound by the Lenti-X concentrator polymer to be spun 
down. The supernatant was then discarded and 1/100th of the original supernatant 
volume of GMEM was added and incubated overnight with the lentiviral pellets at 
4ºC. The next day the pellets were gently resuspended, aliquoted and transported in 
dry ice to -80ºC for long-term storage.  
 
2.2.5  Virus titration 
Lentiviral titre was assessed by transduction into MEFs and analysis -either IF or flow 
cytometry depending on the construct at 48h.  
Both processes gave an accurate estimate of a functional titre – i.e. the volume of 
lentiviral solution required to transduce a specified percentage of MEFs, rather than 
an estimate of actual lentiviral particles in the supernatant. 
Predicted MOI was estimated and adjusted during transductions based on % of 
transduced cells during functional titrations, following the mathematical formula for 
probability and MOI. For instance, MOI 1 corresponded to a transduction efficiency 
of 60%. 
24h before transduction, MEFs were seeded in 12wells at a density of 50’000 cells 
per well, the same density as a conversion experiment. On the day of transduction, 
lentiviral aliquots were thawed by a short incubation at 37ºC, then mixed with GMEM 
to obtain the desired dilution and Polybrene (Merck-Millipore, TR- 1003-G) at a final 
concentration of 10 μg/ml. 
 
For sgRNA vectors – which harbour an EF1a-BFP reporter, MEFs were transduced 
with lentiviruses either undiluted or at a concentration of 1:3 and 1:6 of the original 
stock. Cells were incubated with lentiviruses for 4h, then the medium was reverted 
to MEF medium. 48h post-transduction, flow cytometry was used to assess the % of 
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transduced cells by examining BFP reporter activation. Each sgRNA vector batch was 
tested individually and against every new MEF batch to minimize experimental 
variation.  
 
tetO-Ascl1, Brn2, Myt1l were co-transduced with hUb-rtTA vectors in MEFs using 
10+10, 5+5 and 2.5+ 2.5 µl of concentrated lentiviral solutions. Cells were incubated 
with the viral particles for 4h, then the medium was reverted to MEF medium. The 
next day, doxycycline at a concentration of 2μg/ml was added to induce TF 
expression. After 48h, cells were assayed by immunofluorescence to estimate the 
percentage of transduced cells.  
Titre of the hSyn1-dsRed construct was estimated by transducing converting cells at 
day 3. Cells were incubated with the lentiviral particles for 4h, then the medium was 
reverted to TM. At day 15, the number of iN co-expressing Tubb3 and dsRed was 
assayed by immunofluorescence.  
 
2.3  Conversion experiments 
Every conversion experiment involved thawing with a fresh vial of MEFs, as serial 
passaging of MEFs induced cell senescence and reduced the quality of conversion. 
MEFs were thawed on day -4 before transduction and fed the next day. On day -1 
cells were lifted, counted and seeded at a density of 50’000 cells/cm2 in 1ml of MEF 
medium per 12 well.  
The next day, cells were transduced with lentiviral particles containing cDNA 
sequences for tetO-Ascl1, tetO-Brn2, tetO-Myt1l and hUb-rtTA at MOI5, resuspended 
in GMEM supplemented with 10μg/ml Polybrene (Merck, TR-1003-G). Cells were 
incubated with the transduction mix for 4 hours, then the medium was changed to 
MEF medium. The next day, cells were given another medium change and provided 
with MEF medium supplemented with doxycycline (2μg/ml, Sigma D9891).  
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On day 3, the medium was changed to conversion medium (CM) supplemented with 
2μg/ml doxycycline. Medium was changed every 2-3 days after then until the end of 
the experiment.  
  
2.3.1  Pilot Screening 
Cas9-MEFs were seeded at a density of 100’000 cells per 6well as per a standard 
conversion experiment, one day before transduction. Cells were then transduced 
with the BAM factors and rtTA at MOI5, plus gRNAs against Ascl1 (#1 and 2), intron1 
of Pecam1 and Zeomycin so that 2250 MEFs out of the total 100’000 cells seeded 
would be infected per gRNA. This mimicked the screen coverage within a single 6well 
– pilot was performed in duplicate 6wells. As a control, the same gRNA mix was 
transduced into Cas9-MEFs who did not receive the reprogramming factors. One day 
post-transduction, doxycycline was added to induce TF expression. After 72h, 
converting MEFs were transduced with hSyn1-dsRed at MOI5 to mark iNs. At day 15, 
dsRED+ve neurons were sorted via flow cytometry, genome harvested, and gRNA 
presence was assessed with qPCR, using Brilliant III Ultra-Fast SYBR PCR (Agilent) as a 
reaction mix, and run in the LightCycler480.  gDNA was also harvested from control 
wells of non-converting, gRNA transduced MEFs.  
A common forward promoter was used for all gRNAs – it anneals to the U6 promoter 
within the expression construct. The reverse promoter represents the reverse 




Common U6 F TACGATACAAGGCTGTTAGAGA 
Ascl1 gRNA #1 CCGGGAGCATGTCCCCAAC 




Table 2.4 – list of gRNA primer sequences used for pilot screening. 
 
2.3.2  Screening  
9 million Cas9-MEFs per replicate were seeded in 15x6wells to a density of 100’000 
cells per well one day before transduction. Cells were then transduced with BAM 
factors and rtTA at MOI5, and the lentiviral gRNA library pool at MOI3. 24h post-
transduction, doxycycline was added to the media to induce TF expression – this was 
termed day 0. On day 3, cells were transduced with hSyn1-dsRed, then the medium 
was switched to neural conversion medium. On day 15, cells were flow-sorted to 
isolate the dsRED+ve and dsRED-ve populations. A representation of the gating 
strategy is shown in Fig.2.1 below.  
 
Fig. 2.1 – gating strategy for the screening samples. First, cells are separated from 
debris and aggregates based on the SSC-A/FSC-A plot. Then, singlets are identified based on 
FSC-H/A ratio. Dead cells are excluded based on the absence of signal from Draq7 (Abcam), 
detected on the R780/60 channel. These are then gated on BFP+ve cells (that received and 
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express the gRNA cassette), detected on the V450/50 channel. Finally, two gates within 
BFP+ve cells are drawn to sort dsRED-ve and dsRED+ve cells, detected in the YG582/15 
channel. Plots are taken from one of the three replicates. 
 
2.4 Flow cytometry and FACS 
Flow cytometry materials  
- Flow cytometry buffer 
o PBS (Sigma, D8537) 
o Fetal Calf Serum (FCS) (Life Technologies) – 2% 
- Live/dead marker Draq7 (ab109202), 1μM final concentration 
- Antibodies 
o Rat a-GMP6A (OriGene AM26432AF-N), 1:250  
o Rabbit a-Syp (LSBio aa225-253), 1:1000 
o Mouse a-Snap25 (Abcam ab66066), 1:1000 
o Goat a-Rat IgG AF568 (ThermoFisher A21434), 1:1000 
o Donkey a-Mouse IgG AF568 (ThermoFisher A10037), 1:1000 
o Donkey a-Rabbit IgG AF488 (Abcam ab150073), 1:1000 
 
2.4.1 Cell harvesting and staining for flow cytometry 
To prepare cells for flow cytometry, wells were washed once with PBS, then 0.5ml 
Trypsin-EDTA was added onto the monolayers and incubated at 37ºC for about 5 
minutes. MEF medium containing 10% FCS was added to the wells to quench Trypsin 
(at least 4x the Trypsin volume). Cell suspensions were spun down and washed in 
PBS, then processed for staining or resuspended directly in FACS buffer containing 
Draq7 (for live samples). 
Staining for GPM6A was performed on live cells: the primary antibody was incubated 
for 15’ on ice in FACS buffer. After 3 washes, cells were stained with the secondary 
antibody for 5’ on ice in the dark, again in FACS buffer. Cells were then washed 3 
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times, resuspended in FACS buffer containing Draq7 and brought to analysis to the 
FACS machines. 
Staining for Syp and Snap25 was performed on fixed cells: cells suspensions were 
fixed for 10’ at room temperature with 4% PFA, then permeabilised for 20’ at room 
temperature with 0.1% Tween-20 in PBS, then blocked for 30’ at room temperature 
in 5% BSA in PBST (0.1% Tween-20 in PBS). Antibody staining was then performed in 
the same conditions as described above, except 5% BSA was used as a staining 
solution containing antibodies, and PBS was used to wash and to process cells in the 
FACS machines. 
 
2.4.2 Flow cytometry analysis and laser settings for fluorochromes  
Right before flow cytometry, samples were passed through a 40 μM mesh filter (BD) 
to avoid machine clogging due to cell clumping. FACS sorting was performed on the 
BD FACS Aria II by the SCRM flow cytometry team (Dr. Fiona Rossi, Dr. Claire Cryer, 
Dr. Bindy Heer, Dr. Andrea Corsinotti). Flow cytometry analysis was performed on the 
BD FACS Fortessa. Compensation was performed manually when required using the 
built-in DIVA software (BD). Tables 2.5 and 2.6 below summarise the lasers and filters 








Table 2.5 – BD Aria II lasers and filters for cell sorting 
 
BD FACS Aria II 
 
Excitation laser 






582±15  dsRED  










Table 2.6 – BD Fortessa lasers and filters for flow cytometry analysis 
 
2.5 Imaging Cytometry 
2.5.1 Immunofluorescence staining 
Staining solutions 
- Fixing solution: 4% PFA (Sigma-Aldrich) in PBS 
- Permeabilizing solution: 0.1% TritonX (ThermoScientific) in PBS 
- PBST: 0.1% Tween-20 (Fisher BioReagents) in PBS 
- Blocking solution: 5% BSA (Sigma-Aldrich) in PBST 
 
Primary antibodies 
- Mouse a-Tubb3 (clone #Tuj-1), (R&D Systems MAB1195), 1:1000 
- Rabbit  a-Tubb3 (Abcam ab18207), 1:1000 
- Mouse a-MAP2 (Sigma-Aldrich M1406), 1:500 
- Rabbit a-RFP (Abcam ab62341), 1:250 
- Rat a-GMP6A (OriGene AM26432AF-N), 1:500 
- Rabbit a-Syp (LSBio aa225-253), 1:1000 
- Mouse a-Snap25 (Abcam ab66066), 1:1000 
- Mouse a-Gria2 (Abcam ab106515), 1:500 








   







780±60    Draq7 
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- Mouse a-Syt1 (Abcam ab77314), 1:2000 
 
Secondary antibodies 
- Donkey a-mouse IgG AF568 (ThermoFisher A10037), 1:1000 
- Donkey a-rabbit IgG AF568 (ThermoFisher A10042), 1:1000 
- Donkey a-rabbit IgG AF488 (Abcam ab150073), 1:1000 
- Goat a-Rat IgG AF568 (ThermoFisher A21434), 1:1000 
 
Cells in monolayers were washed once with PBS, then fixed for 15’ at RT in 4% PFA. 
They were then permeabilised for 1h at RT in permeabilising solution, then blocked 
for at least 3h at RT in blocking solution. Primary antibodies were diluted in blocking 
solution and incubated overnight at 4ºC. Cells were then washed 3 times with PBST, 
then incubated for 45’ with secondary antibodies diluted in blocking solution, at RT 
in the dark. DAPI (ThermoFisher D3571) to visualise cell nuclei was added together 
with the secondary antibodies at a final concentration of 1μg/ml. Cells were washed 
again 3 times with PBST and then imaged in PBS. Between imaging, plates were kept 
at 4ºC to maintain fluorescence, up to 10 days.  
 
2.5.2  Imaging with Celigo Cytometer 
Whole well images were obtained using the Celigo Cytometer (Nexelcom). Table 2.7 
below summarises the laser conditions of the machine 
 
Channel Excitation Dichroic Emission 
Blue 377/50 409 470/22 
Green 483/32 506 536/40 
Red 531/40 593 629/53 
Table 2.7 – Celigo Cytometer laser settings. 
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2.6 Library selection, cloning, preparation for NGS and analysis 
2.6.1 Gene Ontology analysis 
Gene Ontology analysis of the genes included in the library was performed using the 
online tool on the PANTHER DB website using standard settings 
(http://pantherdb.org) (Mi et al., 2019). Analysis was performed for both biological 
processes and molecular function. Terms were ranked on -log(p value). P-value is 
calculated by PANTHER as the probability of a GO term being represented in a given 
list considering its frequency of representation in a background genome of reference.  
 
2.6.2 Oligo library cloning and preparation for NGS 
Oligoes were ordered as a ssDNA pool from TWIST Bioscience and resuspended to a 
final concentration of 1ng/µl in AE buffer (Qiagen) (10 mM Tris-Cl, 0.5 mM EDTA; pH 
9.0). PCR was used to amplify and generate dsDNA oligoes. PCR mix and conditions 
are represented in tables 2.8 and 2.9. The final amplicon structure is a 79-mer oligo 





where N19 represents each specific gRNA. Primers were taken from Dr. Kosuke Yusa’s 
protocol (Koike-Yusa et al., 2014).  
 
12.5 ul Q5 Hot Start High-Fidelity Master Mix 
(2X) 
1 ul  Library oligoes (1ng/ul) 
1.25 ul F-mer U1 + L1 Primer (10uM) 
10.25 dH20 
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25ul total  
Table 2.8 – Oligo library 1st PCR mix 
 
98C 10s  
98C 10s 
X10 64 15s 
72 15s 
72 2min  
Table 2.9 – Oligo library 1st PCR conditions 
 
Cycle number was determined by qPCR saturation curves from 5µl of reaction 
supplemented with 1X SYBR and run in the Light Cycler 480.   
 
The PCR product was cleaned with Oligonucleotide Removal Kit (Qiagen). Correct 
band size and purity was confirmed by gel electrophoresis through a 2% agarose gel. 
Fragments and pKLV2(W-)U6sgRNA5-sEF1aBFP-W library backbone were digested 
overnight with Bbs1 (NEB) at 37ºC, conditions are reported in the tables 2.10 and 







Table 2.10 – Library backbone digestion 
5ug  pLV backbone 
5ul NEB buff 2 
0.5ul BSA 100X 
5ul Bbs1 
Up to 50ul dH20 
40ul Annealed and cleaned-up library 
10ul NEB buff 2 (10X) 
1ul BSA 100X 








Table 2.11 – Library dsDNA oligoes digestion 
 
Linearized backbone was run through a 1% agarose gel and purified using   Zymoclean 
Gel DNA recovery Kit (Zymoclean, D4001). Digested dsDNA oligoes were run through 
a 20% PAGE gel to isolate the middle fragment of 26bp and containing the gRNA 
sequence to be ligated from the flanking regions necessary for amplification only. The 
26bp fragment was cut out and eluted from PAGE gel by incubation in PAGE elution 
buffer (10mM magnesium acetate tetrahydrate, 0.5M ammonium acetate, 1mM 
EDTA pH 8.0) for 3h at 37ºC in a 800rpm shaker.  
Eluted solution was purified with QIAquick nucleotide removal kit (Qiagen) but using 
MiniElute columns (Qiagen). 
Ligation was set-up overnight at 16ºC using 100ng of backbone and 1:4 molar ratio 
of backbone to insert, using fresh T4 Ligase buffer and T4 Ligase (2M units/ml). 
Ligated product was eluted in water using ZymoResearch DNA clean and 
concentrator kit. 2ng were electroporated into NEB electrocompetent bacteria 10-b. 
The pool of electroporated bacteria was inoculated into 500ml LB broth 
supplemented with Ampicillin (100 μg/mL) and incubated overnight at 37ºC. Library 
plasmid pool was isolated from bacteria through Maxiprep (Qiagen). 
 
2.6.3 Plasmid and screen library preparation for NGS 
Plasmid library samples and screen library samples from dsRED+ve and dsRED-ve cells 
shared the same amplicon and thus were prepared following the same protocol. 1ng 
plasmid DNA was used for plasmid technical replicates. 181.1ng gDNA were used for 
Up to   100ul dH20 
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Where N19 represents the gRNA sequences, and the stretches in red are the regions 
of homology for primer annealing for the 1st round of PCR. This round is needed to 
add sequence adaptors that will anneal to Illumina Nextera primers.  
PCR1 primers are shown below. In red, overlapping regions to the amplicon above. 
F:    
R:   
 
PCR was run with Q5 Hot Start High Fidelity Polymerase 2x mix and primers at 0.2μM 
in a final volume of 50μl with the conditions shown in Table 2.12. Cycle number was 
determined by qPCR saturation curves from 5µl of reaction supplemented with 1X 
SYBR and run in the Light Cycler 480.   
 
98C 30s  
98C 10s 
X13 64 15s 
72 20s 
72 2min  
Table 2.12 – NGS library preparation, 1st PCR conditions. 
 
PCR product was gel-purified from a 2% agarose gel with Zymoclean Gel DNA 
recovery Kit. 1ng was then used as template for the 2nd PCR reaction, required to add 











Illumina Nextera primers from Nextera® XT Index Kit anneal to the blue and orange 
stretches. i5 and i7 indexes included in the adapters to allow multiplexing are 
incorporated in the primer pairs. The final amplicon including indexing structure is 








Where Nextera primer sequences are underlined.  
PCR was performed with 2X Kapa HiFi HotStart ReadyMix (KAPA KK2602) and 10X 
Nextera Primers to a final volume of 50µl. The 2nd PCR conditions are outlines in 
tables 2.13 below. Cycle number was determined by qPCR saturation curves from 5µl 
of reaction supplemented with 1X SYBR and run in the Light Cycler 480.   
 
98C 30s  
98C 10s 
X7 64 15s 
72 20s 
72 2min  
Table 2.13 – NGS library preparation, 2nd PCR conditions.  
 
PCR products were purified with Agencourt AMPure XP (SPRI) magnetic beads 
(Beckman Coulter, A63881. Individual libraries quality and quantification was 
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performed with Qubit and TapeStation. They were then pooled to equimolar 
amounts to a final concentration of 10µM and sent for NextSeq.  
 
2.6.4 NextSeq 
NextSeq was performed at the EMBL Genomics Core Facility by Dr. Vladimir Benes’s 
team and with the help of Dr. Jelena Pistolic and Dr. Dinko Pavlinic. The run was 
performed as a single end read, paired index deconvolution with custom read primer 
and custom i5 read primers reported below, supplied at a 100µM concentration.  
Custom read primer: 5'-TCGTCGGCAGCGTCTCTTGTGGAAAGGACGAAACACCG-3' 
Custom i5 read primer:  5'-CGGTGTTTCGTCCTTTCCACAAGAGACGCTGCCGACGA-3' 
 
Read run was interrupted after with 19 cycles to selectively read the unique gRNA 
sequence within the amplicon.  
2.6.5 MAGeCK analysis of NextSeq results 
Analysis of gRNA read counts from .fastaq files was performed by Dr. James Ashmore 
using the default MAGeCK settings (Li et al., 2014). gRNA read counts within each 
sample were first normalised against total read counts per sample. Then, a negative 
binomial model was used to assign a p-value to each gRNA based on the difference 
in read counts between treatment sample and control sample, and the p-value was 
used to rank each gRNA. An a-RRA algorithm was then used to associate the 
behaviour of gRNAs targeting the same gene and identify, by identifying skews in 
gRNAs from the uniform null distribution. The significance of this skew was used to 
rank enriched and depleted genes. The treatment vs control sample comparison was 
performed between iN (treatment) and plasmid (control), iN (treatment) and non-
neuronal cells (control), and non-neuronal cells (treatment) and plasmid (control).  
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2.7 Gene Expression analysis 
RNA was isolated from whole wells or sorted cells RNAeasy Mini Kit (Qiagen 74104) 
following manufacturer instructions. After quantification, it was converted into cDNA 
using SuperScript™ VILO™ Master Mix (Invitrogen 11755050), following 
manufacturer instructions. 2ng of cDNA (estimated from RNA quantification) were 
used per qPCR reaction. qPCR reactions were prepared using Brilliant III Ultra-Fast 
SYBR PCR 2X mix (Agilent) in final volume of 10µl within 384-well plates. Primers were 
added to a final concentration of 0.25µM. Plates were run in the LightCycler480. 
Table 2.14 below lists the primers used for gene expression qPCR in this study. 
 
Primer name Sequence 
Gria2 F GGGGACAAGGCGTGGAAATA 
Gria2 R GTACCCAATCTTCCGGGGTC 
Map2 F CAGAGAAACAGCAGAGGAGGT 
Map2 R TTTGTTCTGAGGCTGGCGAT 
Snap25 F TTCATCCGCAGGGTAACAAA 
Snap25 R GTTGCACGTTGGTTGGCTT 
Stmn3 F AGCACCGTATCTGCCTACAAG 
Stmn3 R TGGTAGATGGTGTTCGGGTG 
Tubb3 F CAGATAGGGGCCAAGTTCTGG 
Tubb3 R GTTGTCGGGCCTGAATAGGT 
Nestin F CTCAGATCCTGGAAGGTGGG 
Nestin R GCAGAGTCCTGTATGTAGCCA 
Fibronectin F CGAAGAGCCCTTACAGTTCCA 
Fibronectin R ATCTGTAGGCTGGTTCAGGC 
TBP F GGGGAGCTGTGATGTGAAGT  
TBP R CCAGGAAATAATTCTGGCTCA  
Table 2.14 – gene expression qPCR primers 
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2.8 Molecular Biology 
2.8.1 sgRNA cloning 
Individual sgRNA cloning made use of the genome-wide sgRNA library generated by 
Tzelepis and colleagues (Tzelepis et al., 2016) containing 19bp sequences. These 
sequences were ordered as individual complementary oligoes, with 5’ adaptors to 
allow ligation into the pLV-U6-gRNA backbone as follows: 
 
+ Strand: CACCGN19 – where N19 is the stretch on the +ve strand from the library itself 
- Strand: AAAC(N19(rc))C – where (N19(rc)) is the reverse complement of N19 
 
Oligoes were mixed to equimolar amounts, heated up to 95ºC and allowed to cool 
gradually to create a double stranded fragment with ligation-ready overhangs. 
The lentiviral backbone was digested with BbsI (NEB R0539) to linearize it, then gel-
purified and ligated with the annealed gRNA fragment at a 3:1 oligo : vector ratio. 
Ligation products were transformed into chemically competent bacteria. Individual 
colonies were inoculated and amplified to isolate plasmids via miniprep. Plasmid 
integrity was confirmed using restriction digestion patterns. Presence of the correct 
sgRNA was confirmed via Sanger Sequencing. 
 
2.8.2 Stxbp1 cDNA cloning for overexpression  
Adult mouse whole-brain total RNA was obtained by processing a 0.5cm3 section of 
2-month old mouse brain using the RNAeasy Mini Kit (Qiagen 74104) following 
manufacturer instructions. RNA was then converted into cDNA using SuperScript™ 
VILO™ Master Mix (Invitrogen 11755050), following manufacturer instructions. 50ng 
of cDNA (estimated from RNA quantification) were used per PCR reaction as template 
for the amplification of Stxbp1a/b cDNAs. PCR primers and conditions are reported 
below in tables 2.15 and 2.16. The primers contain EcoRI restriction sites for digestion 















4C cooling  
Table 2.16 – Stxbp1 cDNA amplification PCR conditions 
 
PCR products were run through a 1% agarose gel using electrophoresis and confirmed 
the amplification of fragments of the correct expected size (1.6kb). After gel 
purification, the fragments were digested for 1h at 37ºC with EcoRI to create 
compatible ends for ligation. At the same time, the pLV-tetO-Ascl1 plasmid was 
digested with EcoRI to excise Ascl1 cDNA and gel-purified to obtain a digested 
backbone ready for ligation. Inserts and backbone were ligated to a molar ratio of 3:1 
overnight at 16ºC, and then transformed into competent bacteria. Colonies were 
selected and plasmids isolated via mini-prep. Correctly cloned vectors were verified 




PCR amplicons for TIDE analysis were designed using Primer Blast software 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) so that they would amplify a 
genomic region of about 400bp containing the gRNA sequence roughly equidistant 
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from both ends. They were selected for specificity and similar annealing 
temperatures,  and verified to amplify a single genomic product by gel 
electrophoresis. PCR conditions are shown in Table 2. below. PrimeStar 2X MasterMix 
(Takara Clontech) was used to amplify the fragments, and 50ng genomic DNA were 









4C cooling  
Table 2.17– TIDE PCR conditions 
 
Amplicons were column-purified using Zymoclean DNA Clean and Concentrator Kit 
(Zymoclean, D4003) and sent for Sanger Sequencing at Source Bioscience, using the 
forward amplification primer as a sequencing primer. Sequencing mixes contained 1 
ng/μl per 100 bp size of PCR product, primer was provided separately at 1.6 pM. 
Chromatograms from edited and wild-type cells were uploaded on the TIDE website 
(https://tide-calculator.nki.nl) with default settings (Brinkman et al., 2014).  
 










2.9 General molecular biology techniques 
2.9.1 Ligation 
Ligation was performed at 16ºC for 1h (gRNA ligation) or overnight (PCR product 
ligation). 50ng of linearized purified vector were mixed with the insert at the specified 
ratio. 1µl T4 Ligase (NEB) and 1µl 10X T4 Ligase buffer (NEB), and water was 




Transformation was performed in chemically competent homemade DH5α E.coli. 
Bacterial aliquots of 25µl were thawed on ice for a couple of minutes before being 
supplemented with DNA. 5µl of ligation product was used to transform ligations, 1ng 
of plasmid DNA was used to transformed closed plasmids that needed to be 
amplified. After 2 minutes of incubation on ice, bacteria were heat-shocked at 42ºC 
for 45 seconds, then returned on ice for 3 more minutes. 4 volumes of LB broth were 
then added to the samples (100µl for the 25µl aliquots) and tubes were incubated 
for 1h at 37ºC to allow expression of the antibiotic resistance gene carried within the 
plasmid. The total volume was then plated on LB agar plates containing the 
appropriate antibiotic for selection. Plates were incubated overnight at 37ºC before 
colony picking.  
 
2.9.3 Plasmid amplification and verification 
A single colony was picked from bacteria plates and inoculated within LB broth 
containing the appropriate antibiotic. Colonies were inoculated in 3ml for mini-prep 
if the plasmid was being constructed, or in 50ml for midi-prep for plasmid 
amplification. They were incubated overnight at 37ºC within shakers (200rpm) to 
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allow bacterial expansion. The next day, they were processed with Qiagen Miniprep 
or Midiprep kits following manufacturer instructions to isolate plasmid DNA. 
Plasmid integrity was verified with restriction enzyme digestion followed by gel 
electrophoresis. 100ng of plasmid DNA was digested for 1h at 37ºC in a final volume 
of 10µl with appropriate restriction enzymes and buffers (NEB), then run on 1% 
agarose gel to examine band pattern. 
For gRNA cloning and PCR product cloning, Sanger sequencing from Source 
Bioscience was used to verify correct gRNA/product sequence. Sequencing mixes 





2.10 List of plasmids 
Name Source 
pLV_FUW-tetO-Ascl1 Addgene plasmid # 27150 
pLV_FUW-tetO-Brn2 Addgene plasmid # 27151 
pLV_FUW-tetO-Myt1l Addgene plasmid # 27152 
pLV_FUW-M2rtTA Addgene plasmid # 20342 
pLV_hSyn1-dsRed Addgene plasmid # 22909 
psPAX2 Addgene plasmid #12260 
pMD2.G Addgene plasmid #12259 
pKLV2(W-)U6sgRNA5-sEF1aBFP-W  Dr. Kosuke Yusa  
Table 2.18 – plasmids used in this study 
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2.11  List of gRNAs 
2.11.1  Control gRNAs 
Name gRNA sequence 
Zeomycin (non-targeting gRNA) GCGAACTTCCGGGACGCCTC 
Pecam1_intron1 CCTCTTGGGTTCTTTGTGAC 
pg53_g2 AATAAGCTATTCTGCCAGC 
Table 2.19 – Control gRNAs 
 
2.11.2  gRNAs in Chapter 4 

























Table 2.20 – gRNAs used in Chapter 4 
 
2.11.3  gRNAs in Chapter 5 




































































Chapter 3 Optimising the Induced Neuron conversion system 
for a CRISPR/Cas9 KO screen 
3.1  Introduction 
In order to perform a CRISPR/Cas9 KO screen in the iN system, I needed to address 
two major questions: how to isolate the iNs from the culture system, and how to 
select a subset of candidate genes to screen for.  
 
The pan-neuronal marker Tubb3 and the post-mitotic neuronal marker Map2 are two 
of the most common markers used to identify induced neurons in the conversion 
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contexts, both in mouse and human cells, as two of the earliest markers to be 
upregulated and marking virtually all neurons, irrespective of their subtype 
(Vierbuchen et al., 2010; Pfisterer et al., 2011a; Pang et al., 2011; Son et al., 2011). 
These markers have been used to confidently quantify iNs from immunofluorescence 
experiments, as they highlight the full morphology of the neuronal cells and can be 
used to assess cell body size but also neurite lengths – a criterion used in the original 
2010 paper by Vierbuchen and colleagues to define a neuronal cell.  
The proteins though are intracellular and their application as markers for flow 
cytometry can be quite tricky (Turaç et al., 2013). Intracellular flow cytometry in 
general requires cells permeabilization and is prone to issues with antibody non-
specificity (Demaret et al., 2017), and would not have been very straightforward to 
adapt to such a heterogeneous system. 
The Wernig lab has made use of a Tau-eGFP reporter line, generated first to select 
ESC-derived post-mitotic neurons (Wernig et al., 2002). Tau-eGFP was confirmed to 
selectively label Tubb3+ve/Map2+ve induced neurons and hence used to isolate iN 
for flow cytometry for their RNAseq experiments in subsequent papers (Vierbuchen 
et al., 2010; Wapinski et al., 2013; Treutlein et al., 2016). 
We were unable to obtain the Tau-eGFP mESC line (Tucker, Meyer & Barde, 2001) 
that would have allowed us to obtain chimaeric MEFs through morula aggregation.  
I set out to identify alternative reporters, testing a subset of genes specifically 
expressed in iNs for which I could find flow-cytometry appropriate antibodies. I then 
moved on to characterise the activity of the human Synapsin1 promoter as a specific 
marker for iNs. 
This promoter is broadly active in neuronal cells of the central and peripheral nervous 
system, but not in other neural cells, and was described to be selectively active in 
various mammalian neuronal cell lines  (Thiel, Greengard & Sudhoft, 1991). A 470bp 
fragment of this promoter was shown to selectively mark neurons in rats (Kügler, Kilic 
& Bähr, 2003) and mice (McLean et al., 2014). Moreover, it was also used to mark 
human ESC-derived neurons in vitro (Patzke et al., 2015).  In the MEF to iN conversion 
system, it had been previously used to mark the most mature (morphologically and 
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functionally) iNs in the heterogeneous mix of reprogrammed cells, (Black et al., 2016; 
Adler et al., 2012) to allow identification of neurons for electrophysiological studies. 
Nonetheless, its temporal activation and its use for flow-cytometry isolation of iNs 
has not been addressed in those two studies. It presented as a good candidate marker 
for its ease of use, and I decided to characterise its expression in this system. 
 
To perform the genetic screening, I decided to take advantage of the CRISPR/Cas9 
system established in the lab. The recent advances in this technology made it highly 
suitable for genetic screenings, taking over the more traditional RNAi approach that 
was burdened with variable knockdown (KD) of transcripts and high off-target effects 
(Jackson & Linsley, 2010; Boutros & Ahringer, 2008).  
Genome-wide CRISPR/Cas9 screens have been successfully performed in murine and 
human cells (Zhou et al., 2014b; Shalem et al., 2014; Wang et al., 2014; Koike-Yusa et 
al., 2014) and allowed the identification of specific gene networks and pathways. 
Further improvements, such as optimisation of the gRNA scaffold, lentiviral gRNA 
delivery and controlled and homogeneous Cas9 expression have enhanced the power 
of the technology and allowed the identification of broader gene subsets with 
statistical robustness (Tzelepis et al., 2016). 
Considering the low neuronal yields of the conversion and the processing times 
required to harvest and sort the iNs from a large-scale culture, I decided to select a 
library of candidate genes that are likely to play a role in the conversion, instead of 
using a genome-wide gRNA approach. Using gene expression as a predictor of gene 
function, I made use of sc-RNAseq dataset from the Wernig lab (Treutlein et al., 2016) 
to select a subset of genes to screen against. The gRNA sequences per each gene 
were selected from the mouse genome-wide library previously used in the lab for a 
different screening project (Kaemena, Beniazza et al., submitted) obtained from our 
collaborator Dr. Yusa (Tzelepis et al., 2016) 
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3.1.1 Aims of the chapter 
The aims of this chapter are to establish the iN system as a platform for performing 
the CRISPR/Cas9 screen. I started by verifying the compatibility of the set-up with the 
Cas9 expressing MEFs and Cas9 activity.  
I then tested a series of candidate genes as selective reporters for isolating neurons 
from the heterogeneous culture. I selected the human Synapsin1 promoter and 
validated that its activity is specific for iN and shows very little leakiness from MEFs 
in conversion medium.  
The second part of the chapter is focused on generating a gRNA pooled plasmid 
library to perform the screen. Based on neuronal yields and recommended coverage 
from previous works from our collaborator Dr. Kosuke Yusa and previously published 
CRISPR/Cas9 screens, a targeted pool of 1203 genes was selected based on their 
expression across the conversion. gRNA sequences were cloned as a pool into the 
appropriate vector for expression, and the quality of this library was assessed with 
NGS.  
 
3.1.2  Notes   
1) The gRNAs used in this chapter target the Zeomycin resistance gene, Pecam1 
(intron 1) and p53.  
The Zeomycin gRNA is used as a control for the Cas9 genome-scanning activity 
that has the potential to impact cell behaviour, and it is referred to as a non-
targeting control, since the mouse genome does not contain a Zeomycin 
resistance gene. The Pecam1 intron 1 gRNA – referred to as Pecam1 or Pe1 – 
targets the 1st intron of the Pecam1 gene. This control, targeting an intronic 
region, is made to control for Cas9 activity and the effects of DNA double 
strand break (DBS) on the conversion and I include it when quantifying the 
neuronal conversion efficiency by flow cytometry. Though Cas9 activity and 
DBS will always be specific for each gRNA’s genomic location, the Pecam1 
intron1 gRNA has been previously used in the lab as a neutral control in MEF 
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to induced pluripotent stem cells (iPSCs) reprogramming experiments, as it 
was shown to not impact the reprogramming efficiency. I have verified that it 
acts as a neutral control for MEF to iN conversion experiments as well, by 
comparing the neuronal conversion efficiencies in non-transduced samples 
and samples transduced with either Zeomycin gRNA or Pecam1 gRNA.  
P53 KO is known to induce MEF proliferation. The p53 gRNA used has been 
verified to be functional previously in the lab and has been shown to induce 
the proliferation phenotype expected. I chose to test p53 KO to verify the 
robustness of the Cas9-iN system, because this KO has a clear and observable 
phenotype that I could easily monitor and confirm visually. I also wanted to 
verify the role of p53 KO based on what has been previously reported about 
p53 in neuronal conversions – explained in more detail later on. 
 
Below are the sequences for all three gRNAs: 
a. Zeomycin: GCGAACTTCCGGGACGCCTC 
b. Pecam1:  CCTCTTGGGTTCTTTGTGAC 
c. P53 gRNA #2: AATAAGCTATTCTGCCAGC 
 
3.2   Results 
3.2.1  Setting up the iN conversion system with our MEF line 
The first thing I wanted to verify is whether our Cas9 expressing MEFs were capable 
of conversion with efficiencies and neuronal qualities similar to the original reported 
system by Vierbuchen and colleagues in 2010.  
As shown by the schematic in Fig. 3.1a, the lentiviral vectors, obtained through 
Addgene, allow the expression the 3 Wernig transcription factors (TFs) under the 
control of the tetOn promoter, thus requiring the addition of rtTA and doxycycline to 
activate TF expression. rtTA was expressed separately by co-transducing the cells 
with the pLV-hUb-rtTA vector, leading to constitutive rtTA expression thanks to the 
human Ubiquitin promoter. 
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I transduced the MEFs with the 3 TFs and rtTA at MOI5 and induced their expression 
with doxycycline 24h after transduction (Fig.3.1b). I then tracked the appearance of 
neuronal cells by the expression of markers Tubb3 and Map2 at day 5, 15 and 22 of 
the conversion by immunofluorescence. As previously reported, I observed cells with 
TUBB3/MAP2 expression with immature neuronal morphology, thin projections and 
little branching as early as day 5. By day 15, the somas of the neuronal cells have 
started to cluster together, and the clusters are interconnected by a network of highly 
branched projections. At day 22, the clusters have grown bigger and the connections 
thicker (Fig.3.1.c) 
I quantified the neuronal purity in the culture comparing the numbers of neurons vs 
the overall nuclei present via immunofluorescences. Although the stochastic nature 
of lentiviral transduction and conversion both make the system quite variable, I 
obtained an average of 18% of cells of neuronal identity – as assessed by the 
expression of TUBB3. The efficiency of conversion was estimated based on the initial 





Fig. 3.1 – the MEF to induced neuron conversion system. (a) Schematic representation 
of the lentiviral expression vectors for transduction of the converting TFs and rtTA. Promoter 
sequence tetO, hUb; cDNAs: Ascl1, Brn2, Myt1l, rtTA; WPRE: Woodchuck Hepatitis Virus 
Posttranscriptional Regulatory Element.  (b) Explanatory diagram of a conversion 
experiment. E14.5 MEFs are transduced with the lentiviral particles one day after seeding. At 
day 0, doxycycline is added to the culture medium to induce expression of Ascl1, Brn2 and 
Myt1l. Converting cells progressively acquire neuronal morphology and expression of 
neuronal markers.   (c) Immunofluorescence at day 5, 15 and 22 post-induction of the TFs 
shows cells with neuronal morphology that progressively becomes for complex, and express 
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the pan-neuronal marker TUBB3 and the post-mitotic neuronal marker MAP2  (d) 
Quantification of the neuronal purity at day 15 of the conversion, shown as % of neuronal 
cells over total number of cells per field. 10 fields were analysed per experiment, error bars 
represent STDEV. (e) Quantification of the conversion efficiency towards neurons at day 15 
of the conversion. The conversion efficiency is calculated as the total number of neurons per 
well over the initial number of seeded MEFs and represents the neuronal yield of the 
conversion. Total number of neurons are estimated based on 10 fields per experiment. The 
yields of three individual experiments are shown separately to highlight variability.  
 
To verify the compatibility of this system with our platform for CRISPR-Cas9 KO, I 
decided to knock-out p53 and monitor the effects on the conversion efficiency and 
neuronal yield. P53 was chosen based on the described effect of its KO on MEF 
proliferation, and on availability of tested gRNAs. In the context of iNs, p53 knock-
down has been shown to increase the efficiency of conversion from human 
fibroblasts to induced dopaminergic neurons (Jiang et al., 2015), and its knock-out 
has been shown to be sufficient for the conversion of human and mouse fibroblasts 
into induced neurons (Zhou et al., 2014a).  
I transduced Cas9-MEFs with the gRNA against p53, together with the TFs at day -1 
(as control, I used the non-targeting gRNA against Zeomycin). This resulted in an 
initial wave of MEF over-proliferation compared to the control gRNA, as expected. 
Doxycycline was added at day 0, and by 48h post-induction, the proliferation, 
assessed visually, halted. At day 15 cells with neuronal morphology and expression 
of neuronal markers were present in both samples, confirming that genome editing 
by CRISPR/Cas9 KO does not impact the ability of cells to convert into neurons. The 
purity of neurons in the culture was very mildly decreased upon p53 KO (Fig.3.2c), 
while the slight increase in yield is reasonably due to the initial cell proliferation. This 
is consistent with previous reports in human cells showing that the neuronal yield of 
the conversion can be increased by activating TF expression after a few days of 
transduction, to allow cell proliferation and increase the number of cells harbouring 
the TFs expression cassettes and thus able to reprogram (Pereira et al.,2014). I did 
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not observe an increase in neuronal conversion efficiency nor total neuronal yield in 




Fig. 3.2 – CRISPR/Cas9 KO does not impact the conversion. (a) Schematic of the gRNA 
lentiviral construct. gRNA expression is driven by the U6 promoter. The expression of a BFP 
reporter within the same cassette is driven by the Ef1a promoter. gS: sgRNA scaffold 
sequence. WPRE: Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element. (b) 
Whole well images of a conversion experiment. Cells were transfected with either the 
Zeomycin gRNA as a non-targeting control, or a previously tested gRNA against p53. (b) 
Quantification of neurons at day 15 of the conversion, shown as % of neuronal cells over total 
number of cells per field. 10 fields were analysed per replicate, n=2. (c) Quantification of the 
conversion efficiency towards neurons at day 15 of the conversion. The conversion efficiency 
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is calculated as the total number of neurons per well over the initial number of seeded MEFs 
and represents the neuronal yield of the conversion. 10 fields were analysed per replicate, 
n=2. Error bars indicate standard deviation. 
3.2.2  Identifying a marker to selectively isolate iNs from the culture: testing available 
antibodies 
The marker to isolate the induced neurons from the culture needed to be highly 
selective and suitable for flow cytometry. To start with, I made use of the available 
sc-RNAseq dataset (Treutlein et al., 2016) to identify genes expressed exclusively in 
day 22 neurons. I then further reduced the list to proteins against which commercial 
antibodies were available. The mRNA expression of the candidate markers is shown 
in Fig.3.3a. 
Antibodies against these candidate markers were first tested for their specificity by 
immunofluorescence on day 22 of the conversion (Fig.3.3b). All antibodies except the 
one against SYT1 specifically labelled neurons, as shown by the labelled cells co-
expressing TUBB3. Antibodies against GPM6A, SNAP25 and SYP were chosen to be 
further tested in flow cytometry based on their good signal/background ratio. 
Unfortunately, the antibody against GMP6A failed to identify a significant and distinct 
neuronal population via flow cytometry, as highlighted by the minor shift in the signal 
peak in Fig.3.4c. The signal was already not quite strong via IF, and, although flow 
cytometry is more sensitive in detecting low signal, it’s possible that the antibody 
binding is suboptimal in suspension conditions and flow cytometry buffer.  
The antibody against SNAP25 showed a more significant shift, though still failing to 
detect a separate population. The same shift was unfortunately detected in MEFs 
that had been subjected to the same conversion medium for 22 days, indicating that 
the signal detected by flow cytometry is non-specific (Fig.3.4d). A similar result was 
obtained using the antibody against SYP: although this antibody was able to identify 
a second, independent peak from the iN culture, the same peak was also identified 
in MEFs, suggesting again that the signal is non-specific. This high background 
detected via flow cytometry, and not detected via IF, is probably due to the higher 
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Fig. 3.3 – Isolating iNs using available antibodies. (a) Gene expression of the selected 
neuronal markers, Tubb3, Map2 and the housekeeping genes Gapdh and Tbp – from 
Treutlein et al., 2016. (b) Immunofluorescence of iNs at day 22 of the conversion. (c) Flow 
cytometry profile of iNs at day 22 of the conversion, stained for GPM6A. The secondary 
antibody was conjugated to AlexaFluor568, the signal is shown on the horizontal axis. Signal 
in grey represents secondary-Ab only staining control.  (d) Flow cytometry profile of iNs (left) 
and MEFs in TM medium (right) at day 22 of the conversion, stained for SYP. The secondary 
antibody was conjugated to AlexaFluor488, the signal is shown on the horizontal axis. Signal 
in grey represents secondary-Ab only staining control.  (e) Flow cytometry profile of iNs (left) 
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and MEFs in TM medium (right) at day 22 of the conversion, stained for SNAP25. The 
secondary antibody was conjugated to AlexaFluor568, the signal is shown on the horizontal 
axis. Signal in grey represents secondary-Ab only staining control. 
3.2.3  Identifying a marker to selectively isolate iNs from the culture: hSyn1 promoter 
Synapsin1 is expressed in neuronal cells of the CNS in humans. Its 470bp promoter 
has been shown to be selectively active and be able to drive reporter gene expression 
in in vivo and ex vivo mouse neurons compared to other cells of the CNS (McLean et 
al., 2014). It has also been shown to be selectively active in neuronal cells derived by 
hESC reprogramming via Ngn2-overexpression (Patzke et al., 2015), and to mark the 
morphologically and functionally mature MEF-derived iNs (Black et al., 2016; Adler et 
al., 2012). Those two studies though did not investigate how broad is its expression 
within the conversion system, nor how early it can be detected. They also do not 
show any data regarding its use as a potential marker for isolation of neurons via flow 
cytometry. 
I decided to address all these points and properly validate this construct for the 
purpose of iN isolation via FACS.  
I obtained the hSyn1-dsRed construct from Addgene (Plasmid #22909). The hSyn1-
dsRed expression cassette is already inserted into a pLV plasmid for packaging and 
transduction with lentiviral particles. 
 
The diagram in Fig.3.4a summarizes the experimental procedure. Cells undergoing 
MEF to iN conversion were transduced at day 3 with lentiviral particles carrying the 
hSyn1-dsRed construct. By day 6 dsRED expression could be detected selectively from 
cells with pro-neuronal morphology. The expression levels increased progressively, 
as observed by the bright dsRED +ve cells with advanced neuronal morphology at day 
15 of the conversion (Fig3.4b). At this point, dsRED expression was assessed with flow 
cytometry (Fig3.4c). dsRED expression levels presented as a broad spread rather than 
a distinct peak/cluster. This can be explained by two aspects: 
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1) The construct is inserted into the cells via lentiviral transduction, leading to 
different copy numbers and genomic locations of the construct, which will 
likely result in variable expression levels of dsRed.  
2) The induced neurons are heterogeneous and likely have intrinsically different 
levels of hSyn1 promoter activation 
 
When non-converting MEFs were transduced with the same construct at day 3 and 
cultured under the same conditions as converting cells, very few cells show 
expression of dsRED at day 15. This shows that the hSyn1 promoter has very little 




Fig. 3.4 – Isolating iNs using hSyn1-dsRed reporter activation. (a) Schematic diagram 
of a conversion experiment using the hSyn1-dsRed reporter. TF activation is induced in MEFs 
at day 0, one day post-transduction, as usual to initiate the conversion. At day 3, converting 
cells are transduced with lentiviral particles containing the hSyn1-dsRed construct. (b) dsRED 
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signal in cells with neuronal morphology is detected as early as day 6. By day 15 cells with 
clear neuronal morphology are showing selective dsRed expression. (c) Flow cytometry 
profiles of iNs (left) or MEFs in TM media (right) transduced with hSyn1-dsRed at day 3. A 
distinct population of dsRED +ve cells is only identified in the iN sample.  
 
To verify that the hSyn1-dsRed expression is really being activated by neuronal 
reprogramming and not just the overexpression of the BAM factors, I looked into the 
activity of Ascl1, the pioneer master TF of the conversion (Wapinski et al., 2013). 
Ascl1 is a TF belonging to the basic helix-loop helix (bHLH) family and binds the E-box 
motif (Bertrand, Castro & Guillemot, 2002), preferentially the sequence CAGCTG 
(Wapinski et al., 2013). This specific E-box motif is not contained in the hSyn1 
promoter, but the generic E-box motif CANNTG can be found twice within the 
promoter (as highlighted in Fig.3.5a). To exclude that dsRED expression is being 
driven simply by Ascl1 binding on the hSyn1 promoter, I converted MEFs into iNs 
using tetO-Ascl1 and hUb-rtTA only, and looked at Ascl1 expression levels across the 
conversion using immunofluorescence (Fig.3.5b,c). At day 2 post-transduction, the 
majority (>90% cells) express relatively high levels of Ascl1. By day 15, cells that were 
transduced at day 3 with the hSyn1-dsRed construct and converted into induced 
neurons show neuronal morphology and dsRED expression. While many cells have 
downregulated Ascl1 expression, there is a significant number of cells that is still 
expressing Ascl1 at relatively high levels but did not activate dsRED expression. This 
suggests that Ascl1 overexpression is not sufficient to activate the hSyn1 promoter 




Fig. 3.5 – Ascl1 overexpression alone is not driving hSyn1-dsRed reporter activation. 
(a) hSyn1-dsRed construct sequence. hSyn1 promoter in blue, dsRed cDNA sequence in red. 
Highlighted in orange are the identified E-Box motifs in the hSyn1 promoter. (b) 
Immunofluorescence of Ascl1 expressing cells at 48h post TF expression induction with 
doxycycline. >90% cells are expressing Ascl1 (quantifications not shown) (c) 
Immunofluorescence of Ascl1 and dsRED expressing cells at day 15 of the conversion 
(converting cells were transduced at day 3 with hSyn1-dsRed). White arrows indicate non-
neuronal (dsRED -ve) cells expressing Ascl1. Cells with neuronal morphology are co-
expressing Ascl1 and dsRED, but a significant number of cells expressing highly Ascl1 has not 




To check that dsRED expressing cells are indeed induced neurons, I verified the co-
expression of TUBB3 via immunofluorescence (Fig.3.6a). More than 95% of cells 
expressing dsRED also co-express TUBB3, as quantified in Fig.3.6b.  
The dsRED+ve neurons were isolated by flow cytometry to assess the expression of a 
panel of neuronal and fibroblastic marker genes (Fig. 3.6c,d,e). dsRED +ve cells show 
higher expression of the neuronal markers Gria2, Map2, Snap25, Stmn3 and Tubb3 
compared to dsRED -ve cells, indicating that dsRED +ve cells are of clear neuronal 
nature, though dsRED -ve cells are bound to contain neuronal cells that failed to 
activate dsRED, as well as cells that received the BAM factors and reprogrammed only 
partially, thus it is expected that they show expression of neuronal markers at higher 
levels than wt MEFs (Fig.3.6c). Compared to wt MEFs, both dsRED +ve and -ve cells 






Fig. 3.6 –hSyn1-dsRed selectively marks neuronal cells. (a) Immunofluorescence for 
dsRED and TUBB3 expression at day 15 of the conversion. (b) Quantification of dsRED +ve 
cells expressing TUBB3. Results are the average of 10 independent fields in 2 biological 
replicates (c) Cells at day 15 of the conversion sorted for dsRED expression via flow cytometry 
express neuronal markers – as assayed by qRT-PCR – at higher levels than MEFs and dsRED -
ve cells. Error bars represent STDEV, n=3.  (d) Cells at day 15 of the conversion sorted for 
dsRED expression via flow cytometry have downregulated MEF markers Nestin and 
Fibronectin, as assayed by qPCR. Error bars represent STDEV, n=3. 
 
To verify that the functionality of this construct is not affected by the CRISPR/Cas9 
KO system, I repeated the p53 KO experiment shown in Fig.3.2 with cells transduced 
with hSyn1-dsRed at day 3. Cells with neuronal morphology and dsRED expression 
appeared by day 6 in both control and KO wells. The neuron purity in the culture, 
assessed by the % of dsRED cells at day 15 of the conversion shows no significant 
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difference from the control gRNA (Fig.3.8). This is consistent with the neuronal 




Fig. 3.7 – p53 KO phenotype investigated with hSyn1-dsRed construct. Day 15 flow 
cytometry profiles of iNs transduced with hSyn1-dsRed at day 3 and transduced at day -1 
with gRNAs. The y axis represents fold enrichment over the % of iNs upon transduction with 
the Zeomycin non-targeting gRNA. Pecam1 is included as an intronic targeting, neutral 
control (n=3). Error bars indicate standard deviation. 
 
Overall, these data show that hSyn1-dsRed construct can be used to selectively label 
and isolate induced neurons from the remaining cell types in the conversion culture, 
and it is compatible with the CRISPR/Cas9 KO system to be used for the screen.  
 
3.2.4 Defining the screening conditions and selecting a library of genes to test 
The next task was to identify the optimal screening conditions and calculate how 
many genes could actually be feasible to test in this set-up.  
Based on previously published results from our collaborator Dr. Kosuke Yusa (Koike-
Yusa et al., 2014; Tzelepis et al., 2016) and previous work performed in our lab 
(Kaemena, Beniazza et al., submitted for publication), we wanted each gene to be 
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covered by at least 5 gRNAs (to account for different editing efficiencies of the 
guides), and each gRNA ideally to be represented in at least 200 cells. The genome-
wide gRNA library used in the papers mentioned above contains 90’000 gRNAs 
covering 18’000 genes in the mouse genome. To achieve the coverage desired, we 
would need to obtain and isolate 18 million induced neurons. Considering the 
average yield and purity of the conversion, processing these many cells through flow 
cytometry was not feasible. This led us to rule-out the genome-wide approach and 
decide to select a biased but smaller subset of genes to investigate.  
 
To select the genes, I made use of the sc-RNAseq dataset analysing the iN conversion 
published in 2016 (Treutlein et al., 2016). I selected differentially expressed genes 
(DEG) (>3 fold upregulated or downregulated) between the different populations of 
the conversion across time. I focused on genes that are likely to be involved in the 
conversion and maturation process of the induced neurons. Table 3.1 summarizes 
the cell types highlighted and how they were described/assigned in the original 
paper. Day 22 cells are classified based on their Tau-GFP reporter signal and the 




Table 3.1 – Description of the cell types identified and described in the sc-RNAseq 
dataset. 
 
The table 3.2 below lists the comparisons from which DEG were initially selected. The 
full final list of 1203 genes can be found in Appendix 1.  
 
Day Label Marker





iN Tau-eGFP  +ve, Syp  +ve
Myoblast Tau-eGFP  -ve,  Tnnc2 +ve 





Nominator  Denominator Criterion for choosing this 
comparison 
d2 induced vs MEFs early transcriptional response to 
Ascl1 induction 
d2 induced vs d2 intermediate high to low Ascl1 response 
d5 iN vs d2 induced activation of post-mitotic neuronal 
markers 
d5 iN vs d5 fail neuronal vs non neuronal early 
transcriptional response 
d22 iN vs d5 iN transcriptional differences between 
late and early iNs 
Table 3.2 – Summary of the comparisons used to select the library genes. The column 
on the right describes the criterion used to select the specific comparison, i.e. I decided to 
select DEG between MEFs and day 2 induced cells to identify genes involved in the early 
response to BAM induction. Those are likely to be involved in downregulating MEF identity 
genes and upregulating neuronal reprogramming genes, and are thus interesting candidates 
to include within the screen, as they are likely to play a key role in cell identity switch.  
 
Fig3.8 describes the biological and molecular role of the genes in the library as 
estimated by gene ontology enrichment analysis, performed via PANTHER (Anon, 
2019; Mi et al., 2019) .  
There is a strong bias towards neural/neuronal function, but also broader terms 
indicating development, differentiation, cell communication and metabolism. These 
two main categories represent the two main aspects of the original 2016 study. The 
first 5 days of conversion focus on the cell identity change between MEFs and iN and 
include genes necessary to shut off the fibroblast identity as well as modify the 
metabolism requirements and membrane plasticity in order to morph and sustain 
neuronal activity. The second part focuses on the in vitro maturation of established 
iNs, which includes neurite growth and branching, development and maturation of 
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synapses as the neurons contact and form networks, and eventually the development 
of spontaneous firing (Vierbuchen et al., 2010; Treutlein et al., 2016).  
 
From a molecular point of view, the majority of GO terms are related to signalling, 
receptor activity and membrane-bound proteins, which reflects the importance of 
these processes for neuronal development and function. Other terms include DNA 
binding/TF activity, indicating that many of the genes included in the library are 




Fig. 3.8 –Gene Ontology enrichment analysis for the library genes. Analysis was 
performed on the 1203 genes using PANTHER.  (a) Biological processes analysis, top 25 
terms (out of 77). (b) Molecular function analysis, top 25 terms (out of 82). 
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3.2.5 Library cloning and quality check 
The library of individual gRNAs was ordered as a single-strand DNA oligo pool 
synthesized by TWIST Bioscience. The gRNA sequences, 5 gRNAs per gene, were 
obtained from the mouse genome-wide library published by Dr. Kosuke Yusa’s lab 
(Tzelepis et al., 2016). To clone it into the pLV gRNA expression vector (from Fig.3.2), 
I followed previously published protocols, with minor edits (Koike-Yusa et al., 2014).  
The ss DNA oligo pool was made double stranded by PCR using primers annealing to 
the 5’ and 3’ shared sequences. The optimal number of cycles was determined by 
qPCR (Fig. 3.9a) to be 10. After PCR, a small aliquot of the product was run on a 2% 
agarose gel to confirm the presence of a single product at 79bp (Fig.3.9b). The PCR 
product was then column purified and digested with Bbs1 to isolate the gRNA-
containing sequence to be ligated into the backbone. Due to the small size of the 
fragments after digestion, a PAGE gel was required to resolve the individual bands. 
The middle band corresponding to the 26bp containing the gRNA sequence pool was 
isolated and the DNA was extracted (Fig.3.9c). 
Standard ligation was performed overnight into the pre-digested backbone and the 
resulting pool of plasmids was transformed into competent bacteria. The plasmid 
pool was then amplified, extracted and prepared for NGS.  
To test our sequencing strategy, 3 technical replicates of the plasmid aliquot were 
prepared for sequencing, as outlined in the diagram of Fig.3.9d. The first step was to 
amplify the target sequence from the plasmid by PCR with primers containing 
overlapping ends to the Illumina Nextera kit. The number of cycles to be used was 
determined by PCR to be 16 (Fig.3.9e). The PCR product was run on an agarose gel to 
verify its size and purity, then extracted and eluted and re-verified (Fig.3.9e,f). It was 
then used to perform the second round of PCR, in which the i5 and i7 indexes from 
the Illumina Nextera kit were added to the final amplicon.  
 
The individual libraries were purified with SPRI magnetic beads, pooled, and the 
quality of the pool was verified using TapeStation (Fig3.9g), then sent for sequencing 







Fig. 3.9 – Library cloning and preparation for NGS. (a) Amplification curves from qPCR. 
(b) PCR product from the 1st round of PCR run on a 2% agarose gel. The 2 left lanes are loaded 
with NEB 50bp ladder. (c) PAGE gel purification of the Bbs1-digested PCR amplicon pool from 
the first step of library cloning. The middle band at 26bp represents the correct fragment to 
be extracted and eluted. Ladders on the right are - left to right – NEB 50bp and ThermoFisher 
O’range 10bp ruler. (d) Amplification curves and agarose gel resolution of the 1st round of 
PCR for the preparation of NGS sequencing amplicons from the plasmid pool library. This 
fragment contains the gRNA sequences and 5’ and 3’ homology sequences to Illumina 
adaptors/barcodes. Ladder marker is NEB 1Kb+.   (e) 2% agarose gel resolution of the second 
PCR product, after addition of Illumina adaptors. Ladder marker is NEB 1Kb+.  (f) TapeStation 
results from the pooled library ready for Illumina Miseq. 
 
All three technical replicates show a gRNA coverage, with the majority of gRNAs 
having around 250x coverage as estimated by the density distribution. The three 
replicates correlate well to each other as shown by the comparative distribution plots 
for P1vsP2, P2vsP3 and P1vsP3 (Fig.3.10a). When the replicates are normalized and 
averaged to combine gRNA read counts, the mode of the frequency distribution is 
242, and the majority (96%) of gRNAs are represented within 10-fold difference in 
frequency, which is in line with what has been previously reported for similar gRNA 




Fig. 3.10 – Library technical replicates sequenced with MiSeq show good library 
quality and gRNA coverage. (a) Density plots and correlation plots for each of the technical 
replicates show consistent average read count density and good correlation between each 
of the replicates. (b) log10 distribution of each gRNA counts – normalised and averaged from 
the three replicates. >95% of the gRNAs are within 10-fold of the average count density, 
consistent with previously published libraries.  
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These data overall indicate a good quality gRNA library ready to be packaged and 
transduced into cells.  
 
3.3 Discussion 
3.3.1 hSyn1-dsRed reporter marks iNs of all stages of maturation 
The original iN conversion publication defines an induced neuron as cells with a 
circular soma with a neurite at least three times the length of their body (Vierbuchen 
et al., 2010). This is because a few fibroblasts express Tubb3 at low but detectable 
levels (as assessed by IF), and thus the presence of this marker is a necessary but not 
sufficient condition to identify a true neuronal cell. Map2 expression is a more 
selective criteria when assessed by IF, though it is still present at low levels in non-
neuronal fibroblastic cells (Vierbuchen et al., 2010; Wernig et al., 2002). 
The hSyn1 promoter has been previously used to mark directly reprogrammed iNs 
from human and mouse cells (Adler et al., 2012; Black et al., 2016; Drouin-Ouellet et 
al., 2017), and has been described as targeting a subpopulation of neurons with more 
complex morphologies and more mature electrophysiological properties. Here I’ve 
reported the activity of hSyn1 in driving dsRed expression in neuronal cells as early as 
day 6, when cells have still an immature neuronal morphology, with single or double 
neurite extensions, and have been reported to lack the ability to evoke action 
potentials and postsynaptic currents (Vierbuchen et al., 2010; Wapinski et al., 2013). 
In vivo, Synapsin1 expression increases during neural development and neuronal 
differentiation, spiking during synaptogenesis. P5 mouse pups show about 25% of 
adult expression levels, that increase by day 10 to 50% and reach full expression at 1 
month of age (Bogen et al., 2009).    
In vitro, endogenous Syn1 is active in N2a mouse neuroblastoma cells, though its 
expression increases significantly upon differentiation and maturation of the cells 
into neurons (Paonessa et al., 2013). Syn1 is also expressed in human neuroblastoma 
cells, where its expression is limited by REST and is upregulated during neuronal 
differentiation (Lietz, Cicchetti & Thiel, 1998).  
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The previous studies using hSyn1 in iNs do not mention how many of the iNs express 
dsRed, nor how early its expression can be detected. It stands to reason that these 
kinds of questions were not addressed because outside of the publications’ scope, 
however it is possible that hSyn1-dsRed expression would have been detected from 
broader cell populations than reported. Adler and colleagues mention how dsRed 
expression was an excellent predictor of which cells would be able to produce evoked 
action potentials (24/26), but then describe how all other electrophysiological 
properties measured (resting membrane potential, action potential thresholds, 
amplitudes and numbers) were heterogeneous within those cells. Consistent with 
this, they mention how dsRED intensity correlated with the number of consecutive 
action potentials that the cells were able to fire. They also fail to show the 
electrophysiological properties of non-dsRED+ve iNs (Adler et al., 2012).  
 
It would be interesting to verify whether activation levels of the exogenous hSyn1 
promoter can be correlated to electrophysiological properties of the cells, i.e. if the 
intensity of the dsRED signal as assessed by FACS or quantitative fluorescence could 
be used to predict features like neuronal membrane potential or action potential 
evoked responses or the ability of the cells to spontaneously fire. Lentiviral 
transduction of the hSyn1-dsRed construct would create artefacts in this 
investigation, as integrated copy numbers and integration locus can potentially 
influence the levels of expression of dsRed. An engineered cell-line with the hSyn1-
dsRed targeted within a safe, non-silenced locus would presumably lead to more 
consistent and homogeneous dsRed expression levels – or at least, the levels would 
not be dependent by lentiviral-derived artefacts, but from intrinsic heterogenicity of 
the iNs. Bright dsRed expression could be investigated as a potential reporter for iN 
maturation phenotype in a clearer and more quantifiable way.   
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3.3.2 hSyn1-dsRed reporter marks iNs with comparable efficiencies to Tubb3 and 
other iN markers 
In this thesis, I have been using the hSyn1-dsRed construct as a pan-neuronal marker 
after showing that it overlaps with virtually all Tubb3 +ve neurons via IF. I’ve shown 
how the conversion efficiency and purity of the process in my hands are comparable 
to what has been previously reported, but it is worth discussing how efficiency and 
purity has been calculated in published works.  
Tau, Tubb3 and Map have been used to identify all MEF-derived iNs, regardless of 
the markers’ molecular function, but differences in their roles are actually reported 
and suggest how certain conditions reveal marker promiscuity or conversely 
specificity to subpopulation of neuronal cells. For instance, while circa 95% of Tau-
eGFP +ve cells are also Tubb3+ve when iNs are generated with the BAM cocktail, the 
percentage falls to less than 50% when iNs are derived from Ascl1-only 
reprogramming, suggesting Tau might be promiscuously marking cells with an 
induced neuronal fate regardless of whether they acquire subsequent Tubb3 
expression (Treutlein et al., 2016). This was also characterized while studying Myt1l 
function: the DNA-binding region of Myt1l was fused to the repressor domain EnR, 
and then used to reprogram MEFs into iNs. Compared to wt Myt1l, this mutant form 
generates the same number of Tau-eGFP neurons, but only 30% of Tubb3+ve cells 
(Mall et al., 2017). This highlights the importance of marker choice to characterise a 
phenotype, as in this example EnR-Myt1l is both enhancing (as assessed by Tau-eGFP) 
and not enhancing (as assessed by Tubb3) Ascl1 reprogramming abilities. 
Similarly, Map2 seems to be a more stringent marker than Tubb3, as neuron counts 
from the same visual fields consistently report about 10% fewer Map2+ve cells than 
Tubb3+ve cells. (Wapinski et al., 2013, 2017). Interestingly though, in in vitro cultured 
primary hippocampal neurons Myt1l knock-down leads to a decrease in protein levels 
of Tubb3, while Map2 levels remain unchanged (Mall et al., 2017). There seems to be 
a relatively unexplored relationship between Myt1l function and Tubb3 expression 
that it’s important to keep in mind when assessing neuronal conversions.  
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Assessing neuronal conversion purity with flow cytometry also requires particular 
attention. Keeping in mind the considerations about Tau mentioned above, sorting 
Tau-eGFP positive cells is likely to result in cells of neuronal nature but of 
heterogeneous maturity and marker expression, as discussed for Tau-eGFP sorted 
cells reprogrammed with Ascl1 alone which also contain myoblast-like populations 
according on their gene expression profile (Treutlein et al., 2016). 
PSA-NCAM is also commonly used to mark fibroblast-derived iNs (Kim et al., 2011; 
Barbagiovanni et al., 2018). Barbagiovanni and colleagues reprogrammed iNs from 
MEFs using the BAM cocktail and report a neuronal purity at day 13 and 21 of the 
conversion of 60% and 70% respectively. Similarly, Adler and colleagues reported a 
66% neuronal purity by day 12 as assessed by hSyn1-dsRed reporter activity (Adler et 
al., 2012). Visual examination of immunofluorescence images from my work and 
other published works on MEF-derived iNs at day 13 and 21 suggests this might be 
partially an artefact, as by comparing DAPI nuclei counts to Tubb3+ve cells, the ratio 
does not reflect, and is in fact much lower than 60% to 70% (about 15% in this work, 
Fig.3.1 and Fig.3.4). This could be due to differences in cell death that would result in 
an enrichment of surviving neuronal cells compared to non-reprogrammed cells. It 
could also be the result of processing the cells for flow cytometry, as the iN clusters 
are much easier to detach from the cell culture dish compared to the fibroblastic cells 
that form sheet-like patches and require more mechanical effort to fully go in 
suspension. This also induces more cellular stress and causes a good portion of them 
to die off. I’ve found careful cell handling and consistent protocols for the cell lifting 
step to be crucial for consistent and reliable quantification of iNs via flow cytometry. 
This led me to have comparable, within the limits of replicate variability, neuronal 
quantifications between IF and flow cytometry. That being said, flow cytometry is a 
lot more sensitive, and considering the early activation of hSyn1-dsRed reported, it is 
likely that, like Tau-eGFP, some of the dsRed+ve iNs that I assess by flow cytometry 
would have incomplete reprogramming and heterogenous expression of Tubb3 or 
Map2. It’s important to highlight this and stress how identity and quantification of 
the iN conversion should be verified with more than one neuronal marker. 
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3.3.3 Library selection based on gene expression, gene networks or TF target sites 
The library I designed contains strong biases towards neuronal genes. This may limit 
the discovery of novel genes or pathways involved in the conversion process, as many 
genes are already known to be involved in neuronal development. Moreover, 
expression levels and patterns are not always good predictors of the relevance of 
genes for the biological process of interest (Wapinski et al., 2017, Kaemena, Beniazza 
et al., submitted), so by selecting genes based solely on their expression, we are 
potentially missing out on a number of important genes.   
On the other hand, the library bias towards neuronal genes will hopefully increase 
the likelihood that gene hits from the screen will have a broader biological relevance 
to neuronal development/differentiation and not just cell identity conversions.  
Gene expression is just one of the ways to choose a subset of genes to investigate. 
Two recent publications studying in vitro neuronal differentiation and conversion 
decided to take a more functional approach instead and chose to screen for known 
or predicted TFs, reasoning that they’d be likely to be involved in cell fate decisions. 
Liu and colleagues performed a CRISPR activation screen by designing 55,561 gRNAs 
targeting the promoters of all predicted TFs and DNA binding proteins based on an 
available dataset (Liu et al., 2018). They performed the screen in mESCs, engineering 
the cell line for expression of the CRISPRa components, but also to engineering a 
Tubb3 reporter system that allowed them to use MACS to sort out the neurons from 
the culture. They then validated their top hits on the MEF to iN conversion. Based on 
their gRNA ranking algorithm, they identify 74 genes as inducers of neuronal fate, 
and, importantly, 41 out of 74 showed the same expression levels in ESCs and 
neurons, confirming how change in gene expression is not a necessary condition for 
gene relevance or function. Out of their 14 top hits though, only Ngn1 was able to 
generate Map2+ve Tubb3+ ve iNs by itself, whereas the presence of Brn2, Ezh2 and 
Foxo1 increased iN conversion efficiency by Ngn1 significantly. They importantly 
showed how Brn2+Ezh2 could generate neurons together, while neither can generate 
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neurons alone, and described how Ezh2, Foxo1, Ngn1 and Brn2 interact within the 
Wnt/b-catenin signalling pathway. Ezh2 is part of the PCR2 complex and it is 
suggested to promote neuronal fate by repressing other identities. This highlights the 
strength of this TF oriented approach in making novel associations between genetic 
pathways and iN conversion. 
Tsunemoto and colleagues also selected a list of 59 TFs (bHLH and POU containing) 
and arranged them into couples to generate a final library of 598 cDNA pairs that 
were cloned into dox-inducible vectors and delivered lentivirally into MEFs 
(Tsunemoto et al., 2018). 13% of the cDNA pairs generated Map2/Tubb3+ve iNs. They 
then narrowed down their analysis on 5 combinations that included a TF that had not 
been associated with iNs before. The combinations include the factors Neurog3, 
Ascl2, Brn3c, Neurod2, Atho1 and Pit1, all genes associated with neuronal function, 
but also Oct4 – one of the master regulators of pluripotency and particularly of 
induced pluripotency (Takahashi & Yamanaka, 2006). This is another example of how 
molecular function can be a good predictor of the gene’s ability to reprogram iNs 
regardless of their expression or even biological relevance. 
In terms of different library design strategies, it would have been an interesting 
alternative to perform a CRISPR/Cas9 loss-of-function screen targeting TFs, as it 
would probably have a higher specificity for cell fate orchestrators and, because of 
the nature of loss-of-function screens, likely reveal roadblocks to cell fate plasticity. 
The intersection of the TF database (Liu et al., 2018) and the CRISPR KO gRNA 
genome-wide library (Tzelepis et al., 2016) would allow a straightforward selection 
of gRNAs without the need for de-novo design.  
Making use of recently published datasets, it would have also been interesting to 
select TFs to screen for from the computationally generated TF network regulating 
iN generation and specification at day 5, 13 and 22 of BAM-mediated conversion 
(Wapinski et al., 2017). The association of TFs with a specific time-point would make 
this network particularly suitable to investigate, with a loss-of-function screen, which 
TFs are actually required at each time point and how their presence affects neuronal 
induction and maturation.  
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Similarly, based on the work by Mall and colleagues on the newly discovered role of 
Myt1l as a suppressor of non-neuronal genes (Mall et al., 2017), a loss-of-function 
screen targeting Myt1l-bound genes (from the ChIPseq dataset) would have good 
chance to reveal roadblocks genes that hinder the conversion towards iN by directing 
cells to alternative fates or resisting cell identity changes at all.  
 
3.3.4 Library selection based on gene function and known pathways 
A more biased approach to selecting a library would be to select genes within 
pathways that have been associated with direct neuronal reprogramming already. 
This is less likely to reveal novel mechanisms, but has higher chances of identifying 
hits. It would be a useful approach to characterise novel genes within the known 
pathways, or assign novel roles to known genes. 
For instance, oxidative stress has been identified as a major barrier in direct neuronal 
reprogramming from both astrocytes and fibroblast (Gascón et al., 2016). As ROS 
production had been already implicated in hematopoietic cell fate decisions 
(reviewed in Maryanovich and Gross, 2013) and neurons rely on different 
mechanisms for energy production compared to astrocytes and fibroblasts (oxidative 
metabolism vs anaerobic glycolysis typical of proliferative cells), Gascón and 
colleagues showed how between day 2 and day 4 of conversion, the majority of non-
converting cells die off due to oxidative stress in the form of ferroptosis. The rapid 
switch to oxidative metabolism required by post-mitotic neurons leads to an 
accumulation of ROS and lipid oxidation, which most cells can’t tolerate. This 
investigation revealed the essential role of Bcl-2 in reducing ROS and promoting 
direct neuronal reprogramming. Thus, oxidative stress pathways and associated 
genes would represent a good subset to screen against in a loss-of-function genetic 
screen. 
 
Recently the transcriptional repressor REST has been described as a neuronal 
reprogramming roadblock (Drouin-Ouellet et al., 2017). This repressor works by 
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preventing gene expression of neuronal genes in non-neuronal cells, and the authors 
showed how REST knock-down significantly enhances reprogramming efficiency of 
adult human fibroblasts, partly through the upregulation of neural miRNAs miR-124 
and miR-9, but also through upregulation of specific genes involved in synaptic 
formation and plasticity. 
Thus, it is likely that REST targets could also represent reprogramming roadblocks, 
and it would be interesting to perform a loss-of-function screen against them to 
identify novel regulators and pathways that hinder this cell identity change. 
 
Direct neuronal reprogramming has also been achieved for mouse and human cells 
by exposing fibroblasts to a cocktail of small molecules (Hu et al., 2015; Li et al., 2015).  
Li and colleagues showed how the combination of the small molecules Forskolin, 
ISX9, CHIR99021, and SB431542 acts in a synergistic way to generate, over 21 days, 
Tubb3+ve cells with neuronal morphology with a 30% culture purity. The substitution 
of SB431542 with I-BET151 led to 90% Tubb3+ve cells, but these cells were 
heterogeneous for other neuronal markers and had mixed subtype identity, with 
both VGLUT1- and GABA-positive neurons similarly represented. By selective removal 
of one molecule at a time, they identified ISX9 as the master inducer of neuronal 
identity, and I-BET151 as the master suppressor of fibroblast identity.  
Hu and colleagues used a more complex combination of small molecules that 
included VPA , CHIR99021, Repsox, Forskolin, SP600125, GO6983 and Y-27632. In a 
similar fashion to the previous study, they identified CHIR99021 and SP600125 to be 
the ones responsible for neuronal fate induction, as their absence from the small 
molecule cocktail drastically reduces the neuronal conversion efficiency. 
Characterising and understanding what the predicted targets of each of these 
molecules are would allow the identification of new pathways that control neuronal 
fate. Many of these compounds have quite broad roles though: for instance, 
SB431542 is an inhibitor of TGF-b signalling, a process involved very broadly in cell 
identity, differentiation and development (reviewed in Hata and Chen, 2016). It had 
already been associated with neuronal differentiation through the famous dual-
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SMAD inhibition protocol developed to efficiently derive neurons in vitro from 
pluripotent stem cells (Chambers et al., 2009). Similarly, CHIR99021 is an inhibitor of 
GSK3, part of the WNT signalling pathway that regulates development, but also adult 
stem cells maintenance and differentiation, and cancer (reviewed in Nusse and 
Clevers, 2017). It is famously part of the 2i conditions (2 inhibitors) that can maintain 
iPSC in vitro in the absence of LIF (Silva et al., 2008). 
It would be interesting to characterise the function of the target genes of these 
molecules to understand which actors within these broad and interconnected 
pathways come together and specify neuronal fate.  
 
3.4 Summary  
In this chapter I’ve set-up the experimental platforms and materials required to 
perform a CRISPR/Cas9 KO screening in MEF-derived iNs. 
 
Firstly, I verified the system’s compatibility with CRISPR/Cas9-mediated KO. Cas9-
expressing MEFs are capable of converting into iNs, and Cas9 activity does not disrupt 
the conversion. P53 knock-out leads to initial cell proliferation and increases total 
neuronal yields consistent with previously reported data. 
 
Secondly, I characterised the hSyn1 promoter as selectively active in iNs within the 
heterogeneous cell populations emerging from the conversion, as shown by 
observation of cells of neuronal morphology (live imaging), which co-express the pan-
neuronal marker TUBB3 (immunofluorescence) and are selectively present in wells 
undergoing neuronal conversion and not in MEFs exposed to neuronal conversion 
medium (assessed by flow cytometry). dsRED+ve sorted cells express neuronal 
markers and downregulated fibroblast markers. The hSyn1 promoter is not activated 
by Ascl1 overexpression alone, but by the cell identity switch between MEF and iN 
overall.  
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This will allow the isolation of iNs from the culture by sorting dsRED+ve cells via flow 
cytometry, a step necessary when performing the screening in order to identify which 
gRNAs were integrated within the neuronal genomes and potentially impacted 
neuronal conversion efficiency.  
 
As the conditions did not allow for an unbiased, genome-wide approach, I selected a 
subset of genes to screen against. The genes were chosen based on their expression 
in neuronal cells across the conversion, making use of the sc-RNAseq dataset 
(Treutlein et al., 2016).  
GO analysis revealed that these genes are mostly involved in neuronal identity and 
development, as expected based on the selection process, but also include broader 
functions regulating cell identity switches, cell differentiation and metabolism, and 
TFs regulating cell behaviour at a transcriptional level.  
The final library consisted of a total of 1203 genes covered by 6000 gRNAs. The gRNAs 
were ordered as a pool of oligoes and cloned into the lentiviral backbone for 
transduction and U6-controlled expression. The quality of the library and the gRNA 
amplicon sequencing strategy were verified by NGS using MiSeq.  
 
The next steps were to test the screening conditions in a small-scale pilot screen to 
verify whether the expected coverage was sufficient to pick up known phenotypes 











Chapter 4  Performing the CRISPR/Cas9 KO screen in MEF to iN 
conversion and analysing the results to identify hits 
4.1 Introduction 
Once the culture system and neuron reporter had been established, I decided to test 
the experimental conditions of the screen in a small-scale setting to check whether I 
could detect gRNA enrichment and depletion. I set up a pilot test using the KO of 
Ascl1 as a candidate control to check for gRNA depletion: if a MEF is transduced with 
gRNAs against Ascl1  it should not be able to be reprogrammed into a neuron because 
the gRNA should KO the exogenous Ascl1, which is part of the BAM cocktail (Ascl1 is 
a single exon coded gene and the gRNA targets both endogenous and exogenous 
Ascl1 copies).  
Pilot testing was followed by performing the CRISPR/Cas9 screen itself. The lentiviral 
gRNA pool was transduced together with the BAM converting factors. At day 15 post-
induction of the BAM factors, induced neurons were identified and sorted using the 
hSyn1-dsRed construct. Both dsRED+ve and dsRED-ve populations were collected and 
analysed. gRNAs integrated within the cells were PCR amplified and sequenced to 
identify how each gRNA was represented within each population. 
Sf3a1 was identified as an important gene in the conversion: its KO leads to a 
reduction in the efficiency of conversion. This gene is involved in pre-mRNA 
processing, and its role in the conversion is discussed in the final section of this 
chapter.  
 
4.1.1 Aims of the chapter 
The main aim of this chapter is to perform the screen and validate the screen result 
hits individually.  
 111 
To achieve this, it was first necessary to try and verify that the screening conditions 
were appropriate to detect known phenotypes in a pilot experimental setup – which 
is the starting point of the chapter. 
The second major part discusses the screen sequencing results and the different 
analysis used to interpret the data. A few individual gRNAs were selected from these 
results to be individually validated. This testing revealed that Sf3a1 KO reduces the 
percentage of cells successfully able to convert to iNs. 
The final part focuses on the validation of Sf3a1 and some characterization of its role 
in the iN conversion.  
 
4.1.2 Notes 
1) gRNAs discussed in this chapter were selected from the previously published 
mouse genome-wide gRNA library that our collaborator Dr. Kosuke Yusa 
previously used to perform genome-wide screening (Tzelepis et al., 2016). 
 
2) NGS was performed in collaboration with EMBL Genomics Core Facility with 
the help of Dr. Vladimir Benes, Dr. Jelena Pistolic and Dr. Dinko Pavlinic.  
 
3) NGS analysis through MAGeCK and data plotting was performed by Dr. James 
Ashmore.  
 
4.2  Results 
4.2.1 Pilot testing the screen conditions 
To verify if the screening conditions were sufficient to detect enrichment/depletion 
of individual gRNAs, I first performed a pilot screen. The aim was to reproduce the 
screening conditions in small-scale and verify whether the planned coverage would 
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be sufficient to identify enrichment or depletion of gRNA sequences within neurons 
vs non-neuronal cells. 
Considering neuronal yield based on the hSyn1-dsRed reporter discussed in the 
previous chapter I aimed to use, for the full-scale screen, 15 6-well plates per 
replicate to obtain a coverage to 450 iNs per gRNA. This upper limit was restricted 
due to the estimated processing time of cell preparation and FACS. 
In the pilot test, I wanted to transduce 2250 starting MEFs per gRNA (resulting in 450 
transduced iNs per gRNA based on 20% conversion efficiency) within one well of a 6-
well plate and verify whether I could detect the depletion of Ascl1 gRNA copies using 
qPCR. I chose to knock-out Ascl1 because in the absence of Ascl1, Brn2 and Myt1l 
can’t reprogram MEFs into neurons (Vierbuchen et al., 2010). 
 
Lentiviral particles containing Ascl1 gRNAs #1 and #2, a non-targeting control gRNA 
designed against the Zeomycin sequence and a targeting control gRNA against an 
intronic sequence of Pecam1 were titrated so that I could infect 2250 MEFs of the 
100’000 seeded in one 6-well. Both control gRNAs were predicted to not affect the 
conversion process and as such, should be present at similar levels in both hSyn1-
dsRed+ iNs and control MEF samples. At day -1, Cas9-MEFs received the BAM factors 
at MOI5 and the gRNAs mentioned above to the specific low titre. At day 0, dox was 
added to the medium to induce the expression of the BAM factors and start the 
conversion. At day 3, cells were transduced with hSyn1-dsRed to mark iNs. iNs at day 
15 were sorted for dsRED expression, their genome extracted, and the presence of 
the gRNA within the genome was assessed by qPCR using the gRNA sequence itself 
as a reverse primer and an oligo annealing to the U6 common promoter as a universal 
primer for all the gRNAs being tested in the pilot (Fig. 4.1a). As a control sample I 
used non-converting MEFs transduced with the lentiviral particles carrying gRNAs at 
the same concentrations, but no BAM factors. 
The expectations were that cells undergoing neuronal conversion that receive the 
gRNA against Ascl1 – which also targets the exogenous copies of Ascl1 transduced via 
lentivirus – would fail to become iNs. Thus, when analysing the genome contents of 
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iN, we should expect a depletion of the Ascl1 gRNAs as compared to control 
transduced MEF. In these control MEF, Ascl1 KO should not induce a loss of Ascl1 
gRNA from the genomic pool as it is not expressed in MEFs and thus is not likely to 
be required for their normal growth/survival.  
 
 
Fig. 4.1 – Pilot test to verify screen conditions. (a) Diagram of the pilot test. 
Transdifferentiating cells are transduced with gRNAs against Ascl1 and Zeomycin (control) at 
the expected coverage that will be used for the screen. iNs are sorted, genome is extracted, 
and qPCR is used to assess the enrichment levels of each guide. As control, non-converting 
MEFs are transduced with the same gRNAs at the same coverage and analysed in the same 
way. (b) Pilot test results based on gRNA representation in each sample as assessed by qPCR. 
Y axis shows the fold enrichment of each gRNA between neurons (dsRED+ve cells) and non-
converted MEFs.  
 
The results of these pilot tests are shown in Fig.4.1b. When comparing the fold 
enrichment of each gRNA between iNs and MEFs, both Ascl1 gRNAs are represented 
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in a comparable amount to the neutral control gRNAs Zeomycin and Pecam1. This is 
surprising as Ascl1 gRNAs should not be present in iNs.  
 
There are a number of possible explanations for this. The first thing I wanted to verify 
is whether the gRNAs against Ascl1 are efficient in driving Cas9-mediated KO. I 
selected gRNA #1, the one that seems to be represented the highest, to test its indel 
and KO abilities.  
 
I transduced Cas9-MEFs with Ascl1 gRNA #1, together with tetO-Ascl1 (and hUb-rtTA) 
at MOI5. I wanted to verify if, under optimal conditions for both gRNA expression and 
exogenous Ascl1 expression, I could generate a KO phenotype that would result in 
the failure to reprogram MEFs into neurons.  
Doxycycline was added 24h post-transduction as usual to induce Ascl1 expression, 
and cells were allowed to reprogram for 15 days. At day 15 they were fixed and 
stained to check for TUBB3 expression. Results of this are shown in Fig. 4.2a: 
compared to a control sample where cells are transduced with the Zeomycin gRNA, 
when cells are transduced with Ascl1 gRNA #1, very few neurons could be detected, 
indicating that under this condition this gRNA is able to knock-out exogenous Ascl1 
to impair the conversion. 
 
Next, I wanted to test whether a single copy of the gRNA (which is representative of 
the pilot conditions) was able to induce indels efficiently. To achieve this, I transduced 
Cas9-MEFs with the gRNA at MOI=0.3, and then verified the presence of indels using 
TIDE (Brinkman et al., 2014). This algorithm uses chromatograms from sanger 
sequencing to identify the percentage of edited sequences compared to a reference, 
wild type amplicon, and quantifies the percentage of indels introduced by a specific 
gRNA. 
I flow-sorted the cells based on expression of a BFP reporter contained within the 
gRNA lentiviral expression vector (see Fig.3.2 for more details) 72 hours post-
transduction and extracted the genomic DNA. I then amplified a 500 bp region within 
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exon 1 of Ascl1 from edited cells (and from non-transduced cells as a control) and 
sequenced this amplicon with Sanger sequencing. The chromatograms represent a 
pool of the genome editing occurring in each cell, so the TIDE software will use this 
information to align the edited sequences to the reference amplicon and assess the 
frequency of indels with a 1 bp resolution (https://tide.deskgen.com/ - Accessed on 
15/04/18). 
Results of this analysis are shown in Fig.4.3b: this gRNA, when transduced as a single 
copy within non converting cells, is able to induce indels with an efficiency of 92%.  
 
The pilot conditions involved the gRNA being transduced as a single copy in cells with 
7 overall copies of Ascl1 coding sequence – 2 endogenous, 5 exogenous (most 
frequently, due to the lentiviral transduction of BAM factors with MOI5 each). To 
verify whether under these conditions the gRNA was still able to induce indels 
efficiently, I repeated the TIDE experiment, but transducing Cas9-MEFs with Ascl1 
gRNA #1 at MOI=0.3 and tetO-Ascl1 (and hUb-rtTA) at MOI5, activated Ascl1 
expression 24h post-transduction with  doxycycline and then harvested genomic DNA 
48h later from BFP+ve sorted cells. 
Results are shown in Fig.4.3c: under these conditions, the ability of this gRNA to 
induce indels is practically nullified, possibly because the number of copies of Ascl1 
to edit is too high. 
This suggests that within the context of the pilot screen, the low copies of Ascl1 gRNA 
would not have been enough to KO Ascl1 and prevent MEF to iN conversion, thus it 




Fig. 4.2 – Ascl1 KO efficiency depends on Ascl1 copy number. (a) Day 15 iNs 
reprogrammed with Ascl1 alone and stained for TUBB3 expression (in red), DAPI in blue to 
mark nuclei. Whole well images show strong signal when cells are transduced with Zeomycin 
gRNA (MOI5), but very few neurons when Ascl1 gRNA #1 is transduced at MOI5. (b) TIDE 
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analysis for Cas9-MEFs transduced with Ascl1 gRNA #1 at MOI=0.3, 72h after transduction. 
MOI=0.3 is sufficient to induce 92% indels at the start of Ascl1 exon 1 (where the gRNA is 
targeting). (c) TIDE analysis for Cas9-MEFs transduced with Ascl1 gRNA #1 at MOI=0,3 and 
tetO-Ascl1 at MOI5, 72h after transduction. Indel efficiency is reduced to 0.5% when that 
many copies of Ascl1 cDNA are present in the cell.  
 
Overall this data suggests that using one of the reprogramming factors as a control 
for pilot testing was not ideal, as the insertion of multiple copies of the cDNA of the 
factor make it hard for CAS9 to edit them all when provided with a single gRNA copy.  
 
I then went looking for a different candidate control gene that I could use in a pilot 
setting to test my strategy. I decided to test the pan-neuronal marker Tubb3 itself, 
hypothesizing that cells unable to turn on this marker would fail to proceed with 
neuronal reprogramming. First, I needed to verify whether Tubb3 KO would lead to 
reprogramming failure. I tested 5 gRNAs against Tubb3 in an iN conversion 
experiment. gRNA #5 showed a clear KO phenotype as reported by 
immunofluorescence at day 15 of the conversion (Fig.4.3a). Generation of TUBB3+ve 
cells was almost completely blocked by the gRNA, indicating a complete KO at a 
protein level. MAP2 staining is still detected mainly in cell bodies, although at a lesser 
extent, and seems to indicate the presence of neurons.  
Considering that the ultimate goal was to verify the presence of neurons with the 
hSyn1-dsRed reporter, I repeated the conversion experiment with Tubb3 gRNAs #5 
and transduced the cells with the hSyn1-dsRed at day 3. Cells were then analysed at 
day 15 with flow cytometry to quantify the presence of iNs based on dsRED 
expression (Fig.4.3b). 
Compared to the control gRNA, Tubb3 KO results in a 0.3 fold decrease in iNs (from 
about 30% to 20% dsRED+ve cells), indicating that the majority of cells lacking Tubb3 
are still functionally able to turn on hSyn1-dsRed, and thus Tubb3 KO was not a 




Fig. 4.3 – Tubb3 KO is unsuitable for pilot testing. (a) Day 15 iNs stained for expression 
of TUBB3/MAP2. Converting Cas9-MEFs were transduced with gRNA against Zeomycin (left) 
or Tubb3 (gRNA #5, right) at MOI5.  (b) Day 15 flow cytometry of iNs. Converting Cas9-MEFs 
were transduced with gRNA against Zeomycin or Tubb3 at MOI5, and transduced at day 3 of 
the conversion with hSyn1-dsRed. Cells are gated on expression of dsRED (to mark iNs) and 
BFP (that is contained within the gRNA expression construct and marks cells transduced with 
the gRNA). Data represent one of 2 experiments.  
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4.2.2 Performing the screen 
Being unable to find an appropriate control to perform more testing, I decided to 
proceed with the screen while maximising the coverage of iNs per gRNA, maintaining 
the estimated 450 iNs per gRNA. 
A schematic of the screening process and FACS profiles for the screen are shown in 
Fig.4.4a. 
I transduced a total of 9 million Cas9-MEFs per replicate with Ascl1, Brn2, Myt1l, rtTA 
at MOI5 together with the library virus pool at MOI3 – this should lead to an average 
of 3 gRNAs per cell and about 90% cells transduced with the library pool. 
Doxycycline was added to induce BAM expression 24h after transduction (day 0). 
After 3 days, cells were transduced with hSyn1-dsRed construct to mark iNs. At day 
15 cells were sorted based on their dsRED expression – both dsRED+ and dsRED- 
populations were collected and processed. The labelling of the samples in the next 
figures refers to “iNs” or “neurons” as dsRED+ cells, and “fibroblasts” as dsRED- cells, 
though this second population includes any cell that is non-neuronal at day 15, so 
fibroblast-like cells but also myoblast-like cells and cells of mixed identity based on 
what is known about the conversion from RNA-seq datasets. 
Genomic DNA was extracted from these populations and libraries prepared by 2 
consecutive rounds of PCR alongside 3 technical replicates prepared from the 
plasmid gRNA library into libraries to be sequenced in parallel. The 1st PCR amplified 
the gRNA from the genome or plasmid backbone in the case of the plasmid library. 
The purified PCR amplicon was then further amplified in a second PCR to attach 
Illumina sequencing adaptors and barcodes for multiplex sequencing. Library quality 
was verified with TapeStation, showing a single strong peak at the expected amplicon 




Fig. 4.4 – Screen setup and library preparation. (a) Explanatory diagram of the screen 
setup. Cas9-MEFs were transduced with the BAM factors and the library pool at day -1. 
Doxycycline was added the next day to induce BAM expression. At day 3, cells were 
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transduced with hSyn1-dsRed to mark iNs. At day 15 dsRED+ve and -ve cells were sorted, 
genome was extracted, and libraries were prepared by sequential PCRs, then purified, pooled 
and sent for NextSeq. (b)FACS gating strategy and plots for the final gate from one of the 3 
screen replicates. Single live, BFP+ve cells were harvested based on dsRED signal within the 
gates shown on the right. The neuronal purity is estimated at 15%, but the gate for dsRED+ve 
cells was set to exclude cells with low-intensity signal. (c) TapeStation results of pooled 
libraries ready for sequencing. Left panel: TapeStation gel electrophoresis. Right Panel: 
chromatogram with flanking ladder markers. The small secondary peak at around 450bp is 
probably a result of concatamers, but the amount is quite small (<5%) and should not affect 
the amount of reads obtained from the main amplicon. 
 
4.2.3 Screen results failed to show any significantly enriched or depleted gene 
The sequencing results were analysed with the MAGeCK software. Briefly, this 
algorithm takes as input raw FASTAq files and outputs total read counts for each 
gRNA species present. It then checks within each gene how the 5 gRNAs have 
behaved in terms of enrichment or depletion between the test sample and the 
control sample, and based on their p-value and FDR assigns an FDR to each gene and 
determines if the genes present in the library show statistically significant enrichment 
or depletion. 
Fig.4.5 shows the output table summaries for the comparisons between iN and 
plasmid library, iN and fibroblast, fibroblast and plasmid library. In all three cases, no 
genes were determined to be statistically significantly enriched or depleted (FDR 




Fig. 4.5 – MAGeCK output tables show no significantly enriched or depleted gene in 
any comparisons. Output tables from MAGeCK for the neuron vs plasmid, neuron vs 
fibroblast and fibroblast vs plasmid comparison. Taking into account 3 replicates per sample, 
no gene had gRNAs with statistically consistent behaviour to result in enrichment or 
depletion with FDR <0.05.  
 
This indicates that there is no gene that has gRNAs being enriched or depleted 
consistently and at a statistically significant level across the replicates. This could 
technically be due to a number of possible reasons. Firstly, it could be that KO of none 
of the genes targeted by the gRNA library leads to an enrichment or depletion of iNs 
numbers as detected by hSyn-dsRed. This is unlikely, considering the presence in the 
library, for instance, of p53 – known to induce MEF proliferation upon KO, whose 
gRNAs should have been picked up as enriched at least in the comparison between 
fibroblasts and plasmid library (read count analysis for p53 is discussed in Fig.4.8). 
Secondly, gRNAs targeting the same gene could induce opposite 
enrichment/depletion phenotypes, thereby confounding a statistical based analysis 
of hits. This is technically possible considering gRNA indel-inducing abilities might not 
necessarily result in nonsense-mediated decay, but could result in truncated proteins 
with different functions. However this is unlikely, based on previously published 
screen papers and data from the Kaji lab, that this would happen for many genes, and 
actually, data suggests in most cases that functional gRNAs that manage to induce 
indels generally lead to consistent phenotypes (Tzelepis et al., 2016; Evers et al., 
2016). Thirdly, the KO phenotype responsible for the enrichment or depletion of 
gRNAs is too mild to be statistically significant at the coverage used for this screen. 
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At 48 hours post-induction of the BAM factors, all cells in the culture become post-
mitotic, preventing a stronger difference between enrichment and depletion 
phenotypes being generated by the proliferation of successfully converting mutants. 
Based on the expected coverage, each gRNA species will have been transduced within 
2250 MEFs and be represented in 450 iNs. A gRNA that decreases the conversion 
efficiency by 50% would instead be only carried in 225 iNs. However, these numbers 
are only averages; in reality the actual numbers of iNs with a certain gRNA will depend 
on experimental variation and the stochastic nature of the iN conversion, both 
factors that will introduce high background noise. Moreover, as cells die off due to 
the transduction and conversion stress, the bottleneck-effect will introduce artificial 
enrichment/depletion biases that will be specific for each replicate. It’s possible that 
the phenotypes generated by the gRNAs are not strong enough to stand out over the 
technical variations in each experiment.  
 
4.2.4 Neuron and fibroblast samples are significantly variable  
To understand how variable the replicates of each sample are, we used gRNA read 
counts to perform Principal Component Analysis – results are shown in Fig.4.6.  
The most striking feature is the separation of the neuron samples across both 
principal components, clearly indicating a high variability among all three of them. 
Fibroblast samples cluster closer, though there seems to be one of the three that is 
clearly separated from the others on PC1. Plasmid replicates instead cluster tightly 
close together. It’s also important to notice how the fibroblast and plasmid clusters 
are very close together, and possibly explains why there’s no differentially enriched 
gene when comparing those two samples. 
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Fig. 4.6 – PCA of normalized sgRNA counts. gRNA normalised counts were used to 
generate a PCA plot to understand the samples similarities. PC1 shows a very significant 
separation between all three neuron replicates, and a smaller, but significant difference 
between one of the fibroblast replicates and the other two. PC2 separates again hugely the 
neuron replicates, and mildly the same fibroblast replicate again. Plasmid replicates cluster 
tightly together in both PCs. 
 
The high variability between replicates will have made it difficult for any enrichment 
or depletion in gRNA to become statistically significant and offers one explanation as 
to why no gene was found to be enriched or depleted with a low enough FDR, at least 
when considering neuron samples. The variability is likely to be derived from the 
reprogramming process, which will select some gRNAs and exclude others regardless 
of gRNA function when cells die off due to the transduction and conversion stress. 
The BAM factors are also introduced lentivirally, which will result in heterogeneous 
levels of each of the factors within the neurons. This could be contributing for 
instance to some subset of neurons overcoming essential gene depletion thanks to 
higher expression levels of BAM.  
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Another thing to consider is that MEFs were transduced with the library lentiviral 
pool at MOI3, meaning that on average cells receive 3 different gRNAs. This was 
necessary because using an MOI0.3, which would have allowed to have only 1 gRNA 
per cell, would require transducing only 30% of the cells and thus would have 
required 3 times the number of cells to achieve the same library coverage.  
This means that if one gRNA lead to an increase in iN conversion efficiency by 
disrupting a inhibitory gene, it would simultaneously enrich the other two gRNAs 
inserted within the same cell. Likewise, if one gRNA lead to a decrease in iNs by 
targeting an essential gene for the conversion, it would lead to an artificial depletion 
of the two gRNAs transduced in the same cell. However, since the chances of the 
same 2 gRNAs being co-transduced with that gRNA are extremely low, this should not 
be a major concern in terms of generating false positives or false negatives but it 
might contribute to increase background noise in gRNA read counts and, since it will 
be specific for each replicate, will lead to increased variability.  
 
4.2.5 gRNAs within cells are not exposed to high selective pressure  
The next thing I wanted to address was the representation of gRNAs within each 
comparison to understand the distribution of the enrichment and depletion of 
gRNAs. We used MA plots to show the fold enrichment over the read counts of each 
gRNA for the neuron vs plasmid comparison, neuron vs fibroblast comparison, and 
fibroblast vs plasmid comparison. Plots are shown in Fig.4.7.  
The three comparisons have relatively similar distributions, with the first plot 
showing a slight trend towards a linear relationship between fold change and average 
gRNA count (the cluster of gRNAs is slightly oriented towards a diagonal line). Two 
observations can be made, that very few gRNAs show greater than two-fold 
enrichment (> 1 log2 [fold change]) and that gRNAs with high log2(fold change) have 
very low read count. gRNAs with low read counts are bound to have higher technical 






Fig. 4.7 – MA plots for each comparison. Plots are comparing log2(fold change) between 
the normalised replicate averages of each sample against the log2 of the average sgRNA 
count within the samples. (a) Neuron vs plasmid comparison. (b) Neuron vs fibroblast 
comparison. (c) Fibroblast vs plasmid comparison.  
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To explain this, it is helpful to consider the “life-span” of gRNAs during the conversion. 
The only criterion for selective pressure against gRNAs in this screen is whether their 
presence will allow a cell to convert into a neuron or not. A gRNA targeting a potential 
roadblock will increases the chances of MEFs becoming neurons, so should be 
enriched in the neuronal population. However, because neurons are post-mitotic, the 
copy number difference compared to a neutral gRNA which does not affect the 
conversion would not get amplified by cell proliferation – a phenomenon that other 
screens instead rely on, for instance screens looking at genes involved in cell 
survival/growth, or reprogramming to a proliferative cell type like iPSCs (Koike-Yusa 
et al., 2014; Shalem et al., 2014; Zhou et al., 2014; Tzelepis et al., 2016; Kaemena, 
Beniazza et al., submitted for publication). 
Conversely, a gRNA targeting a potential essential gene for the conversion will 
prevent a cell from becoming a neuron, and is supposed to be underrepresented in 
the neuronal population. However, as the rest of the cells also stop proliferating, 
there is not a lot of chance for it to be out-grown. 
The strength of the phenotype of each gRNA relies on its efficiency to induce indels 
at single copy. The biological result of the KO – abolishing iN conversion, would need 
to be particularly strong (e.g. result in all cells that receive the gRNA to not convert 
into neurons) to be picked up as a significant decrease in gRNA read counts in the 
neuron population.  
 
To try and understand better individual gRNA behaviour, reported in Fig.4.8 are the 
normalised read counts for all 5 gRNAs targeting Ascl1 and p53. Looking at Ascl1 (top 
table) we can notice straight away how gRNA counts are a lot closer in plasmid 
replicates compared to fibroblasts and neurons. gRNA #1 actually does show lower 
read counts in neuron samples compared to plasmid replicates – but the difference 
between neurons and plasmid means is actually a 0.7 fold decrease, which is quite 
minor. All the other gRNAs show very little to no decrease in read counts, consistent 
with inefficient KO of exogenous Ascl1.  
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Looking at p53 instead, it’s interesting to focus on plasmid and fibroblast replicates. 
When p53 gRNAs are transduced at MOI5, we observe significant proliferation of cells 
within the first 48h. Looking at the read counts from the screen, a net enrichment in 
the fibroblast samples can only be identified for gRNAs #3 and #4, but again, the fold-
change is well below 1. This could be due to the fact that cell proliferation that is 
restricted to the first 48h is not enough to allow gRNA read count inflation. It could 
also be due to too low coverage: too few cells receive p53 gRNAs and their 
proliferation is not enough to be picked up from the noise.  
 
 
Fig. 4.8 – Normalized read counts for Ascl1 and p53 gRNAs. Plasmid replicates are in 
grey, fibroblast replicates in blue, neuron replicates in red. Upper table: Ascl1 gRNAs read 
counts for all three replicates of each sample. Lower table: p53 gRNAs read counts for all 
three replicates of each sample. 
 
Overall this data suggests that the screen conditions were not powerful enough to 
pick up on phenotypes. This is likely because of the high variation within replicates, 
and because phenotypes are not strong enough to induce a big fold-change. 
 
4.2.6 Selecting 22 gRNAs to test individually from the screen results 
Because there were no significantly enriched or depleted genes, I decided to look at 
the behaviour of each gRNA and select a few to test individually and at high MOI. I 
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used FDR as a selection criterion, regardless of whether it was calculated against 
enrichment or depletion. The assumption was that the gRNAs that managed to obtain 
a low FDR had better chances of being the result of a real phenotype. 
Fig. 4.9 summarises the selection process. I selected, from the neuron over fibroblast 
comparison, the gRNAs with low FDR (for either enrichment or depletion). I then did 
the same for the neuron over plasmid comparison, and then overlapped the two lists. 
This way, I identified 10 gRNAs from 10 different genes, listed in the box on the right 
(Fig.4.9a). Moreover, I also used gRNAs with FDR <0.05 from the neuron over 
fibroblast comparison to select a set of genes that had 2 or more gRNAs within this 




Fig. 4.9 – Selection of gRNAs to test individually from the screen results. (a) gRNAs 
from the iN vs plasmid comparison with FDR <0.3 (regardless of enrichment or depletion 
direction) were intersected with gRNAs from the iN vs Fibroblast comparison with FDR <0.05. 
The 10 gRNAs resulting from the overlap are listed in the box on the right. Graph generated 
with Venny (Oliveros, 2007). (b) Genes from the box were selected from the IN vs Fibroblast 
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comparison if they had 2 or more gRNAs with FDR <0.05 targeting them. The 2 gRNAs 
identified were tested individually. Os9 appeared in both lists, gRNAs #2 and #3 were tested.  
 
gRNAs were cloned into the pLV-U6-gRNA-BFP vector as previously described, 
packaged into lentiviruses and transduced into converting Cas9-MEFs at MOI5. 
Converting cells at day 3 were transduced with hSyn1-dsRed to allow quantification 
of neurons at day 15 via flow cytometry. The results of testing the above gRNAs are 
shown in Fig. 4.10. Virtually all gRNAs failed to show a clear phenotype, as the fold 
enrichment compared to the non-targeting Zeomycin control is around 1. The 
notable exception is gRNA #2 targeting Sf3a1, which results in a 50% decrease in 
conversion efficiency.  
To verify that this phenotype was due to Sf3a1 KO and not off-target effects of the 
gRNA, I tested two more guides from the same gene (Fig. 4.10b). All three gRNAs 




Fig. 4.10 – Individual testing of the selected gRNAs from the screen. (a) Fold 
enrichment over Zeomycin non-targeting gRNA of % iNs at day 15 upon transduction of 
Pecam1 gRNA or gRNAs against genes listed in Fig.4.9 (n=2). (b) Fold enrichment over 
Zeomycin non-targeting gRNA of % iNs at day 15 upon transduction of Pecam1 gRNA or Sf3a1 
gRNAs #1,2 and 3 (n=3). Error bars indicate standard deviation. 
 
4.2.7 Sf3a1 KO decreases iN conversion efficiency 
Sf3a1 is a protein part of the spliceosome complex, specifically of the small nuclear 
ribonucleoprotein particle U2. It was first identified in 1995 as the mammalian 
homologue of the yeast essential splicing factor Prp21p and the Drosophila 
alternative splice regulator “suppressor-of-white-apricot” (Krämer et al., 1995). In 
human cells, it interacts with U1-SL4 to allow spliceosome assembly on pre-mRNA 
(Sharma et al., 2014) and it’s required for HeLa cell survival, as its depletion leads to 
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severe defects in gene expression and consequent cell death (Tanackovic & Krämer, 
2005). SNPs in its coding sequence have also been associated with several types of 
cancer, including pancreatic, colorectal (Chen et al., 2015; Tian et al., 2015).  
It is known to be involved in modulating the strength of the innate immune response 
by regulating the production of alternative inhibitory splice forms of proteins 
involved in Toll-like receptor signalling in macrophages (De Arras & Alper, 2013; 
O’Connor et al., 2015). 
In neurons, it interacts with P2X6, a nuclear receptor protein suggested to recruit 
SF3A1 and impair its splicing abilities in aging mice (Díaz-Hernández et al., 2015).  
It has also been implicated to have a role in cell identity conversions: depletion of 
Sf3a1 decreased the efficiency of reprogramming fibroblasts to cardiomyocytes, as 
well as decreasing the total number of cells (Zhou et al., 2018). 
 
In the MEF to iN conversion, it is expressed quite broadly in all cell types except 
myoblast-like cells at day 5 and 22 (Fig.4.11). Reported in Fig.4.11b are the 
normalised read counts for plasmid samples and neuron samples, together with log 
fold change and FDR. gRNA #2, the one that I originally selected based on FDR, is 
actually overrepresented in iNs by 2-fold (1 log2 fold change). Based on the gRNA’s 
behaviour when tested individually, we can safely say that this is clearly an artefact 
of the screen conditions, and one example of how the screen noise is too high for 
even low FDRs to be reliable. The other two gRNAs’ read counts show virtually no 
change. This is confirmation that the screen results are unreliable and overall the 
screening process did not work. 
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Fig. 4.11 – Sf3a1 expression and screen results. (a) Sf3a1 expression pattern across the 
iN conversion (Treutlein et al., 2016). Pan neuronal markers Map2 and Tubb3, and 
housekeeping genes Gapdh and Tbp are shown as reference. (b) Normalised read counts 
from Sf3a1 gRNAs #1,2 and 3 in the plasmid replicates and neuron replicates. LFC: Log fold 
change. FDR: False discovery rate.  
 
I made use of the CRISPR/Cas9 genome-wide screen performed by Dr. Kaemena in 
our lab (Kaemena, Beniazza et al., submitted for publication) to check the behaviour 
of Sf3a1 gRNAs in the context of MEF to iPSC (induced pluripotent stem cell) 
reprogramming. Briefly, similarly to the screen discussed here, a genome-wide gRNA 
library was transduced into MEFs that were then reprogrammed into iPSCs. iPSCs 
were sorted at the end of reprogramming and the representation of gRNAs was 
verified through NGS. Fig.4.12a below shows the results of their screen. Compared 
to the plasmid library control, all 5 gRNAs against Sf3a1 are severely depleted in 
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iPSCs. This could be due to Sf3a1 being required for cell survival, or proliferation or 
being essential for the reprogramming process itself. Though the amount of 
information is limited, it serves as another piece of information that identifies Sf3a1 
as necessary for cell growth and possibly cell identity changes.  
 
I then wanted to verify whether Sf3a1 was having an effect on MEFs in the neuronal 
conversion context. I transduced Cas9-MEFs with either non-targeting gRNA 
Zeomycin or the three Sf3a1 gRNAs individually, at MOI5, and cultured them in 
conversion medium for 15 days. I tracked the whole well cell numbers across this 
two-week period to check the effects of Sf3a1 KO on these cells. Results are shown 
in Fig.4.12b. Though cell numbers overall decrease from day 6 to day 15, as cells stop 
proliferation and start dying off, Sf3a1 KO cell numbers by day 6 are already more 
than 2-fold lower than control. This difference is maintained at day 10 and day 15. 
Sf3a1 KO is clearly having an impact on proliferation, though this data is not enough 




Fig. 4.12 – Sf3a1 KO decreases cell numbers. (a) Normalised read counts from the iPSC 
reprogramming CRISPR/Cas9 screen performed in the lab (Kaemena, Beniazza et al., 
submitted for publication). All 5 Sf3a1 gRNAs are shown. In yellow, read counts from the 
plasmid library, in green read counts from each of the 3 replicates of iPS. All 5 gRNAs show 
severe depletion in the iPS samples, indicating they are required for survival or proliferation 
of the cells. (b) Cas9-MEFs were transduced with gRNAs against Zeomycin or Sf3a1 at MOI5 
and then cultured in conversion medium for 15 days. Reported are whole well cell numbers 
for day 6, 10 and 15. Sf3a1 KO results in a drastic reduction (more than 2-fold) in cell numbers 
from day 6 already that is maintained through day 15 (n=2). Error bars indicate standard 
deviation. 
 
Sf3a1 seems to be having a double role in the iN conversion: KO of Sf3a1 is decreasing 
total cell numbers, as well as decreasing the percentage of cells that manage to 
convert into neurons. Further investigation would be required to understand how 
these phenotypes are brought about. Considering its role in aging neurons, it would 
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be interesting to investigate its associations with senescence pathways. Moreover, 
considering its role in modulating alternative splicing in macrophages, it would be 
interesting to test whether overexpression of Sf3a1 in the MEF to iN conversion might 
influence the conversion efficiency through the stabilisation of certain mRNA 
isoforms. A more thorough discussion of the relevance of this gene in iNs is described 
in chapter 6.  
 
4.3 Discussion 
4.3.1 Screening tools and conditions could not be verified and likely contributed to 
the failure of the screen 
Figures 4.8 and 4.11 showing read counts for Ascl1, p53 and Sf3a1 gRNAs within the 
screen results clearly indicate that the screen conditions were not suitable for 
detection of these phenotypes. There are a few technical issues that might have 
contributed to this. 
Firstly, the lack of a proper set-up for a pilot screen made it difficult to optimise the 
screening conditions. Specifically, I was not able to find an appropriate control gene 
that, upon knock-out, would give a known and predictable phenotype that I could try 
to pick-up on using the expected screen coverage. A recent publication showed how 
Kmt2b is required for efficient conversion of MEFs into iNs and how Kmt2b knock-out 
MEFs show deficiencies in their conversion ability (Barbagiovanni et al., 2018). I’ve 
verified this phenotype in my system (discussed in the next chapter). For the purpose 
of a future screen, it could be used as control gene to verify the coverage 
requirements for detection of a depletion phenotype.  
Secondly, it’s worth mentioning that the MEFs used in this study express an SpCas9 
sequence that contains a single nuclear localization signal (NLS). It has been shown 
how a double NLS improves the protein nuclear localization in mammalian cells and 
improves its editing efficiency (Cong et al., 2013), so this factor could have made the 
system less efficient than other reported screens and made it harder to pick-up 
phenotypes from sub-optimal conditions like poor gRNA efficiency. Nonetheless, I’ve 
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shown how this Cas9 can induce efficient KO when cells are transduced with gRNA at 
MOI5, as shown by Ascl1 KO in Fig.4.2a and by Sf3a1 KO experiments in figures 4.10-
12.  I’ve also shown how this Cas9 can induce efficient KO when provided with a single 
gRNA copy lentivirally (Fig.4.2b), suggesting that lentiviral gRNA expression and  
gRNA efficiency  can compensate for the absence of a second NLS.  
Another consideration to keep in mind is gRNA competition. As mentioned before, 
each gRNA within the screen context will on average be present as a single expression 
construct within the transduced cells, and will have to compete with two other gRNA 
species also integrated as single constructs for Cas9 loading. I have not addressed 
whether in this competition environment Cas9 expression levels become a limiting 
factor in its editing efficiency, and whether this is made worse by its sub-optimal 
nuclear localization. 
Moreover, it has been shown how Cas9 targeting of heterochromatin regions is less 
efficient (Knight et al., 2015; Singh et al., 2015). Considering the library’s bias towards 
neuronal genes that are mostly in a repressed closed state in MEFs, as assessed by 
ATACseq and FAIREseq (Wapinski et al., 2013; Treutlein et al., 2016; Wapinski et al., 
2017), it is possible that Cas9 editing at those loci was less efficient. Many of the loci 
would have become open at 48h and then at day 5 post-induction of the TFs 
(Wapinski et al., 2017), so they could have been potentially targeted then. 
Nonetheless, Cas9 expression level changes during the reprogramming process have 
not been addressed. Though the Rosa26 locus should be constitutively expressed, 
the chromatin conformational changes associated with the reprogramming process 
might lead to temporary or permanent silencing. There is also the possibility that, 
even If a locus became accessible at day 2 or day 5 for Cas9 to edit, the cell would 
have already made its decision to convert into a neuron, and/or the protein of the 
gene knocked-out would still be around for long enough to allow conversion.  
Overall, these considerations on the screening tools and starting conditions 
potentially explain the low power of the system to pick up verified phenotypes like 
Sf3a1.   
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4.3.2 Selective pressure improves screen data analysis 
Cell proliferation plays an important role in the enrichment or depletion of gRNAs 
within the populations. Previous CRISPR/Cas9 KO screening have used ESCs or cancer 
lines that grow indefinitely, and screened for phenotypes looking at cell fitness or 
resistance to a specific drug (Tzelepis et al., 2016; Koike-Yusa et al., 2014; Shalem et 
al., 2014; Wang et al., 2014). In this context, a gRNA targeting an essential gene will 
become depleted quite efficiently, as the cells harbouring neutral gRNAs (or gRNAs 
enhancing cell growth) will be propagated by repeated cell divisions, and thus the 
depletion will be easier to distinguish from background. Moreover, these type of cell 
lines can specifically be used to artificially boost gRNA depletion or enrichment by 
allowing the cells to grow for extended periods of time to give milder phenotypes 
enough cell doublings to become statistically relevant. One study kept proliferating 
cells in culture for 3 weeks and performed serial passaging to induce a strong 
selective pressure on gRNA representation (Doench et al., 2016). In contrast, the 
experimental setup of the iN conversion is extremely limiting in this regard. Firstly, 
because the target cell population, the neurons, is post-mitotic, and stops dividing 
between day 3 and day 5 when the major wave of cell fate change is occurring. This 
means that a gRNA targeting a roadblock gene will be overrepresented in the iN 
population, but won’t be expanded by the cell growth as it happened in the screen 
papers reported. Similarly, a gRNA targeting an essential gene will be depleted, but 
because the remaining of the cells won’t out-grow the cells harbouring it, its 
depletion will struggle to become statistically relevant. This becomes more evident 
when we consider a second aspect, i.e. that overall all of the cells stop proliferating 
around 48h post-induction of the TFs. Even without the transduced BAM conditions, 
MEFs in vitro senesce quickly and arrest proliferation through contact inhibition 
mechanisms. The neuronal medium moreover lacks serum, another factor limiting 
MEF growth.    
A clear example of the limitations of this system comes from the results of the p53 
gRNAs read counts within the non-neuronal population as compared to the library 
read counts. These gRNAs have been validated as functional and do induce significant 
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proliferation within previous screens in the lab (Kaemena, Beniazza et al., submitted) 
and in this thesis as well, although under optimal conditions such as MOI5 and no 
competing gRNAs (Fig.3.2). Nonetheless, in these experimental conditions, p53 
gRNAs are not enriched even within the population of cells that has the potential to 
proliferate. This indicates that either p53 KO is not enough to overcome the non-
proliferating conditions that the cells are put in (i.e. BAM overexpression might be 
blocking proliferation more than p53 KO could enhance), or that the KO is inefficiently 
happening, or that there are too few cells that receive the gRNA and manage to 
proliferate, but the coverage of the screen is not enough to pick up on their growth. 
Considering this set-up, and having identified potential controls to be used in pilot-
settings, a smaller scale screening strategy would allow for higher gRNA coverage and 
increase the chances of identifying significantly depleted or enriched genes. For 
instance, using the same number of cells, the gRNA number could be reduced to 2000 
(1/3rd of this library), to increase the gRNA coverage in iNs from 450 to 1350. It would 
also allow the use of a library transduction at MOI=0.3, so that each cell would only 
have 1 gRNA species. This would limit gRNA competition for Cas9, possibly increasing 
its editing efficiency, and would limit the potential background noise coming from 
neutral gRNAs being carried-over together with functional gRNAs. To clarify this with 
an example: the gRNAs that were transduced in the same cells as gRNAs targeting 
Sf3a1 would have gotten depleted artificially as cells died off. Because these gRNAs 
likely were different in each cell, this process will have increased depletion 
background noise.  
 
4.3.3 Sf3a1’s role in cell identity conversions and alternative splicing 
As reported by the analysis of Sf3a1 KO, this gene seems to be important for both cell 
fitness, since it decreases total cell numbers, and iN conversion efficiency, since it 
decreases the percentage of iNs obtained. This role doesn’t seem to be specific for 
the MEF to iN system, as it has been already reported to be required for survival of 
human HeLa cells (Tanackovic & Krämer, 2005), survival of MEFs and induced 
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cardiomyocytes, as well as the efficiency of surviving MEFs to be converted into 
cardiomyocytes (Zhou et al., 2018). Fig. 4.12 highlights its potential role in iPSC 
reprogramming, although it seems to be essential for mESC fitness in general, as 
revealed by the depletion of gRNAs targeting Sf3a1 in mESC fitness CRISPR-Cas9 loss-
of-function screen performed by the Yusa lab (Tzelepis et al., 2016). 
It also seems to be required for fitness in five different immortalised and cancer 
human cell lines (Hart et al., 2015).  
In the context of cell identity conversions, alternative RNA splicing has been 
associated with regulating pluripotency and differentiation. The MBNL proteins have 
been identified as negative regulators of pluripotency splicing profiles, and their 
knock-down leads to an upregulation of ESC-like alternative splicing events (Han et 
al., 2013). MBNL proteins regulate an alternative splicing event that generates an ES-
specific form of FOXP1. This isoform upregulates pluripotency-related genes and 
suppresses differentiation genes, and its knock-down drastically reduces the 
efficiency of MEF to iPSC conversion (Gabut et al., 2011). Alternative splicing has 
further been characterised in IPSCs: converting MEFs switch from a somatic to a 
pluripotent splicing profile, and the knock-down of two RNA-binding proteins U2AF1 
(also part of the U2 splicing complex) and SRSF3 decreases IPSC reprogramming 
efficiency (Ohta et al., 2013).  
Sf3a1 has not been extensively characterised, but one relevant study has highlighted 
its role in innate immune response in mice (O’Connor et al., 2015). The authors 
showed how Sf3a1 is required for robust immune response by inhibiting the 
production of alternatively spliced signalling adaptor MyD88, that would normally 
work within a negative feedback loop to dampen the immune activation. They also 
showed how Sf3a1 knock down in this system does not impact cell viability, but 
weakens the innate immune response of murine macrophages. This suggests that 
Sf3a1 works, at least within these cells, by preventing alternative splicing of negative 
regulators of immunity. 
Based on this information, it would be very interesting to characterise alternative 
splicing in the conversion of MEFs to induced neurons, with particular attention to 
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Sf3a1. Firstly, it would be worth investigating the difference between knock-out and 
knock-down, to check whether knock-down might allow enough SF3A1 protein levels 
to maintain cell proliferation, but impact conversion.  
Secondly, overexpressing Sf3a1 during the iN conversion could potentially stabilise 
certain protein isoforms required for neuronal identity and enhance the conversion 
efficiency. It would also be interesting to characterise the pre-mRNA species bound 
by Sf3a1 in MEFs and iNs using technologies like Cross-linking immunoprecipitation 
(CLIP) to identify alternatively spliced genes that would be otherwise be harder to 
distinguish using traditional RNAseq. 
 
4.3.4 Sf3a1 – clues to aging neurons 
SF3A1 has been identified as a binding partner of the purinergic receptor subunit 
P2X6 in mouse hippocampal neurons (Díaz-Hernández et al., 2015). As P2X6 localises 
to the nucleus, it recruits and partly sequesters SF3A1, impairing splicing events. As 
the expression and nuclear localisation of both genes is increased in aging mice, and 
P2X6 overexpression leads to a decrease in splicing events, it has been suggested that 
P2X6 might be partly responsible for defective splicing in aging neurons. Pre-mRNA 
splicing defects have long been associated in fact with aging and senescence 
(reviewed in Meshorer and Soreq, 2002). 
In the context of induced neurons, it would be interesting to investigate whether 
P2X6 expression levels are different between MEFs and adult mouse fibroblasts, or 
between human fibroblast of embryonic or neonatal origin versus adult and possibly 
aged patients. We can speculate how excessive levels of this protein might be 
impairing iN reprogramming efficiency by sequestering SF3A1. Conversely, P2X6 
knock-out might lead to an increased availability of SF3A1 that could potentially 
mimic its overexpression – consequences of which have been considered in the 
previous section. 
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Overall, the role of Sf3a1 in neurons has not been extensively addressed, hence it 
could hold potential as a starting point to better understand the relationship 
between mRNA splicing and neuronal fate.   
 
4.4 Summary 
This chapter discusses CRISPR/Cas9 screen itself, the analysis of the sequencing 
results and the validation of Sf3a1 as an essential gene for iN conversion. 
 
The first part focuses on pilot-testing the conditions for the screen, using Ascl1 KO 
and Tubb3 KO phenotypes to try and predict in small scale the behaviour of gRNA 
representation in iNs after the conversion. Unfortunately, both Ascl1 and Tubb3 
proved to be unsuitable controls to knock-out to perform a pilot testing.  
 
The second part focuses on the experimental screen conditions and the analysis of 
the sequencing results. MAGeCK, the algorithm used to rank gRNA representation 
and identify gene hits, reported that no gene was significantly (FDR <0.05) enriched 
or depleted when comparing neurons with fibroblasts, neurons with plasmid and 
fibroblasts with plasmid. This is probably due to the intrinsic high variability between 
neuronal and, to a smaller extent, non-neuronal samples, as well as the coverage not 
high enough to pick up on minor phenotypes due to the absence of selective pressure 
against neutral gRNAs or biological amplification of gRNAs that produce a phenotype. 
A few gRNAs were selected based on their individual FDR and individually tested at 
MOI5. One gRNA against sf3a1 resulted in 50% decrease in neuronal conversion 
efficiency when tested individually. Two more gRNAs against Sf3a1 confirmed this 
phenotype.  
 
The third part focuses on validating and contextualising the Sf3a1 KO phenotype. 
Sf3a1 is part of the pre-mRNA spliceosome complex, and it is known to be involved 
in cell survival. It has been shown to have a role in fibroblast to cardiomyocyte 
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conversion. In the context of iNs, it is expressed in neurons and fibroblast-like cells 
and, upon KO, reduces the conversion efficiency to neurons by about 50%. It also 
significantly decreases the cell numbers of MEFs alone, though further 
characterisation would need to address whether cells are dying or proliferating at a 
slower pace. 
 
The next and final results chapter takes a parallel approach to screening and focuses 
























Chapter 5 Investigating individual candidate genes as potential 
regulators of the iN conversion 
5.1 Introduction 
In addition to the screening, I aimed to test the KO of several candidate genes in order 
to identify important regulators of the iN conversion. Considering the differences 
between neuronal differentiation and iN conversion (for instance that during MEF to 
iN conversion cells do not go through a neural stem cell state (Treutlein et al., 2016)), 
I decided to select candidate genes exclusively based on iNs papers, reasoning that 
those would be more likely to result in relevant hits. I used two different approaches 
to select the candidate genes: first, I looked for genes reported to be targets of Ascl1 
or to have a role as facilitators of the conversion. Ascl1 is the pioneer master TF of 
the conversion and is able to reprogram fibroblasts to neurons alone, although at a 
lower efficiency and yielding immature neurons (Wapinski et al., 2013; Vierbuchen 
et al., 2010). I hypothesised that knocking out its targets could potentially impair 
Ascl1 function and hinder the conversion. 
Second, I selected candidate genes from the 1203 genes included in the library based 
on their expression within the first 5 days of the conversion. I selected the genes that 
were consistently differentially expressed between day 2 induced cells (cells that had 
high Ascl1 activation levels, see Table 3.1 for more detailed explanation) and MEFs, 
day 5 neurons and day 2 induced cells, and day 5 neurons vs non neuronal cells. This 
served the secondary purpose of identifying potential internal library controls: if the 
KO of any of these genes resulted in a clear phenotype (increase or decrease in 
neuronal conversion efficiency), I could use this information to examine the read 
counts of the gRNAs targeting that gene within the screening sequencing results and 
assess the screen’s ability to pick up known phenotypes. 
In total, I tested 20 individual genes. The knock-out of one of these, Stxbp1, resulted 
in a reduction of neuronal conversion efficiency, which lead me to investigate 
Stxbp1’s role in the iN system. 
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5.1.1 Aims of this chapter 
The first half of this chapter aims to investigate the possible role of 20 individual 
genes in the iN conversion. The second half focuses on characterizing the function of 
Stxbp1 – the knock-out of which decreases iN conversion efficiency by about 50%. 
 
5.1.2 Notes 
1) The genes analysed in this chapter were labelled for convenience with 
numbers ranging from 1 to 19 – and they are reported with this labelling in 








Ascl1 target based on 
ChIPseq 
2 Hes6 Transcription factor 
Ascl1 target based on 
ChIPseq 
3 Lmo2 Transcription factor 
Increases efficiency of Myt1l 
+ Zfp238 reprogramming 
4 Mfng Glycosyltransferase 
Ascl1 target based on 
ChIPseq 
5 NeuroD4 Transcription factor 
Ascl1 target based on 
ChIPseq 
6 Olig2 Transcription factor 
Increases efficiency of Ascl1-
only reprogramming 
7 Brn4 (Pou3f4) Transcription factor 
Increases efficiency of Ascl1-
only reprogramming 
8 Rfx1 Transcription factor 
Increases efficiency of Myt1l 
+ Zfp238 reprogramming 
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9 TcfL5 Transcription factor 
Increases efficiency of Myt1l 
+ Zfp238 reprogramming 
10 Zfp238 (Zbtb18) Transcription factor 
Ascl1 target, makes iNs 
when expressed with Myt1l 
11 Zic1 Transcription factor 
Increases efficiency of Ascl1-
only reprogramming 














16 Fam171b Uncharacterised Upregulated 
17 Gja1 Gap junction protein Downregulated 
18 Stxbp1 
Syntaxin binding 





coiled coil protein 
Upregulated 
Table 5.1 – Gene number codes and descriptions. Information on the genes’ role in the 
conversion is taken from Vierbuchen et al., 2010 and Wapinski et al., 2013. 
 
2) As for chapter 4, results of gene KO in conversion experiments assessed by 
flow cytometry are reported as the fold-enrichment of the percentages of 
hSyn1-dsRed+ve cells over samples transduced with the Zeomycin control 
gRNA. The second control, reported together with the rest of the samples in 
the graph, is the intronic gRNA for Pecam1. 
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5.2  Results 
5.2.1 Selecting genes to individually test based on their function and gene 
expression 
The first 11 genes I selected were chosen based on their implication in the iN 
conversion from previously published work (Vierbuchen et al., 2010; Wapinski et al., 
2013, 2017). Fig5.1 summarizes their expression patterns and levels relative to the 
neuronal markers Tubb3 and Map2, and the housekeeping genes Gapdh and Tbp.  
Zic1, Brn4 (Pou3f4) and Olig2 were selected because, when overexpressed, they 
increase the conversion efficiency of Ascl1-only reprogramming (highlighted in green 
hues in Fig5.1b). 
Dl11, Hes6, Mfng and NeuroD4 were selected because they are targets of Ascl1 based 
on ChIP-seq analysis and upregulated during the first phases of iN conversion 
(highlighted in red hues in Fig5.1b). 
Zfp238 is a direct target of Ascl1 and is able to reprogram MEFs to iNs in the absence 
of Ascl1 when combined with Myt1l. Its KO leads to a significant decrease in Ascl1-
only conversion efficiency. Adding Lmo2, Rfx1 or Tclf5 to the Zfp238+Myt1l 
reprogramming cocktail greatly increases their conversion efficiency (highlighted in 
blue hues in Fig5.1b). 
These 11 genes could potentially be facilitators of the conversion and their KO might 
lead to a decrease in neuronal conversion efficiency.  
 
As shown in the heatmap, the majority of the genes’ expression increases in neuronal 
cells as the conversion progresses, with the exception of Zic1 (showing detectable 
expression only  in day 22 fibroblasts (based on this dataset) and NeuroD4 and Olig2, 
that show consistently low expression across the conversion. The raw expression 
levels, as shown in Fig.5.1b, are quite variable. Only Hes6, Mfng and Zfp238 show 
significant levels at day 2, day 5 and day 22 cells above the housekeeper Tbp and 




Fig. 5.1 – Expression patterns and levels of the first 11 candidate genes. (a) Heatmap 
showing the expression patterns of the 11 genes across the different cell populations 
analysed by Treutlein and colleagues (Treutlein et al., 2016). The neuronal markers Tubb3 
and Map2, and the housekeeping genes Gapdh and Tbp are included as reference. (b) 
Expression levels – from the same dataset – of the 11 genes. Highlighted in green hues are 
conversion facilitators Zic1, Brn4 and Olig2. Highlighted in red hues are Ascl1 targets Dl11, 
Hes6, Mfng and NeuroD4. Highlighted in blue hues are Zfp238 and Lmo2, Rfx1 and TcfL5, 
which increase conversion efficiency when co-expressed with Zfp238 and Myt1l.  
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Further 8 genes were selected from the screening library itself, based on expression 
levels. This meant that I could also potentially use any validated phenotype as an 
internal control for the screen. I focused on the initial steps of conversion – up to day 
5, reasoning that a gene likely to have a big impact on the conversion would show 
strong upregulation or downregulation in the early phases of the establishment of 
iNs. I used the comparisons between day 2 induced cells vs MEFs, day 5 iNs vs day 2 
induced cells, and day 5 iNs vs day 5 Tau-eGFP-ve cells (more details about this 
categorisation of cell populations are found in Table 3.1).  
2700081O15Rik, Dcaf5, Fam171b, Stxbp1 and Vmac were chosen because they are 
consistently upregulated (>2 fold-change) in all three comparisons. 
Anxa3, Cnn2 and Gja1 were chosen because they are consistently downregulated 
(<0.3 fold-change) in all three comparisons.   
Expression patterns and levels of these 8 genes are shown in Fig.5.2a,c and Fig.5.2b,d 
respectively.  
Of the upregulated genes, only Fam171b and Stxbp1 maintain high expression in day 
22 iNs, though Fam171b is also expressed in day 22 myoblasts. 
All three downregulated genes show very little expression in day 22 iNs and show 




Fig. 5.2 – Expression patterns and levels of the remaining 8 candidate genes. (a, b) 
Heatmap showing the expression patterns of the 8  genes across the different cell 
populations analysed by Treutlein and colleagues (Treutlein et al., 2016). The neuronal 
markers Tubb3 and Map2, and the housekeeping genes Gapdh and Tbp are included as 
reference. (c) Expression levels – from the same dataset – of the 5 upregulated genes. (d) 
Expression levels – from the same dataset – of the 3 downregulated genes.  
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I additionally tested one more gene: Kmt2b. This gene was shown in October 2018 to 
be required for the conversion of MEFs into iNs (Barbagiovanni et al., 2018). In the 
paper, they use genetically engineered MEFs from a mouse line where exon 2 of 
Kmt2b is flanked by LoxP sites and KO is achieved by expression of Cre recombinase 
upon tamoxifen-driven induction. They use PSA-NCAM to quantify iNs by flow 
cytometry, and Tubb3 to quantify iNs by immunofluorescence, and they report a 33% 
and 66% reduction in iNs upon Kmt2b KO as assessed by Tubb3+ve or PSA-NCAM +ve 
cells respectively.  
By testing the effects of Kmt2b KO in the iN conversion myself I wanted to validate 
the efficiency of my system in reproducing published phenotypes while using 
different genetic tools for KO and iN selection.  
 
3 gRNAs per each of these 20 genes were chosen from the same genome-wide library 
used in Chapters 3 and 4 (Tzelepis et al., 2016) and cloned within the pLV-U6-gRNA 
backbone for lentiviral delivery.  
 
5.2.2 Kmt2b KO reduces the percentage of iNs generated 
Each gRNA was tested individually in a conversion experiment by transducing 
converting MEFs at day -1 with lentiviral particles at MOI5 together with the BAM 
factors. At day 3 converting cells were transduced with hSyn1-dsRed to allow 
quantification of iNs via flow cytometry.  
Fig.5.3 summarises the results of testing these 20 genes. Panel (a) shows the results 
of Kmt2b KO with three different gRNAs. The KO induces a mild reduction (about 30% 
on average) in the % of dsRED+ve cells by day 15 of the conversion for all three gRNAs 
tested. This is confirmation that the system I developed using CRISPR/Cas9 to induce 
KO and hSyn1-dsRed to mark iNs can reproduce published phenotypes.  
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5.2.3 Stxbp1 shows a 50% reduction in iN conversion 
Results of knocking-out the other 19 genes are shown in Fig.5.3b-c. With the 
exception of gene #18, all the other genes tested fail to show any significant change 
in dsRED % upon KO, with most gRNAs yielding a fold-enrichment over the control 
sample (Zeomycin gRNA) between 1 and 1.2. It has to be mentioned that, not having 
verified each gRNA’s ability to induce indels and lead to KO, it is possible that some 
of these genes failed to be deleted, and thus these results could be false negatives. 
Thus we can’t claim that KO of any of these genes does not affect the conversion. 
It is surprising that the KO of Zfp238 did not decrease the percentage of dsRED+ve 
iNs. 3 major factors are different between the work by Wapinski and colleagues 
(Wapinski et al., 2017) and the experimental set-up here: the use of Zfp238 KO MEFS 
vs gRNAs, the use of Ascl1-only reprogramming vs BAM reprogramming cocktail, and 
the quantification of cells using TUBB3/MAP2 staining vs hSyn1-dsRed flow 
cytometry. Assuming gRNAs are correctly inducing KO, it’s possible that Zfp238 is not 
required in the presence of Brn2 and Myt1l. It’s also possible hSyn1-dsRed is marking 
a broader subset of iNs that, if analysed by staining, would show failure to upregulate 
Tubb3 and Map2 in the absence of Zfp238. 
 
The KO of Stxbp1 (gene 18 based on the labelling in Table 5.1) instead shows a 
remarkable phenotype, resulting in an average 50% decrease in dsRED +ve cells at 




Fig. 5.3 – Kmt2b and 19 candidate genes KO results assessed by hSyn1-dsRed 
expression via flow cytometry. (a) Fold enrichment over Zeomycin non-targeting gRNA of 
% iNs at day 15 upon transduction of Pecam1 gRNA or Kmt2b gRNAs (n=3). (b) Fold 
enrichment over Zeomycin non-targeting gRNA of % iNs at day 15 upon transduction of 
Pecam1 gRNA or gRNAs against genes 1-11 in Table 5.1 (n=2). (c) Fold enrichment over 
Zeomycin non-targeting gRNA of % iNs at day 15 upon transduction of Pecam1 gRNA or 
gRNAs against genes 12-19 in Table 5.1 (n=2). KO of Gene #18 – Stxbp1 – shows a 50% 
decrease in the % of iNs. Error bars indicate standard deviation. ***p<0.005, **p<0.01, 
*p<0.05 based on an unpaired two-tailed Student's t test. 
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Fig.5.4a shows the validation of each of Stxbp1 3 gRNAs in 3 biological replicates. 
Each guide shows a consistent effect – within itself and among the other 2 two guides. 
Considering all three guides are giving the same phenotype, it is safe to assume the 
effect is coming from Stxbp1 KO and not off-target effects of the gRNAs, which would 
be unlikely to result in the same phenotype from 3 different guides.  
Nonetheless, to confirm Stxbp1 KO at DNA sequence level, I selected gRNA #3, the 
one giving the strongest phenotype, and assessed the presence of indels using TIDE 
(Brinkman et al., 2014). This software allows the deconvolution of Cas9-edited 
pooled sequences and calculates the percentage of indels generated by a given gRNA. 
I transduced MEFs with gRNA #3 at MOI5, then extracted the genome after 72h 
(when Cas9 editing will have fully occurred (Tzelepis et al., 2016; Koike-Yusa et al., 
2014)) and PCR-amplified a 500bp region containing the gRNA target sequence from 
edited MEFs (wt sequence amplified from unedited MEFs was used as a reference in 
the TIDE algorithm).  This region was then sent for Sanger sequencing and the 
resulting chromatograms were inputted into the TIDE web tool 
(https://tide.deskgen.com/ - Accessed on 20/10/18).  
The results are shown in Fig.5.4b. gRNA #3 is correctly editing exon 1 of Stxbp1 with 
an indel efficiency of 69.4%.  
 
 
Fig. 5.4 – Stxbp1 KO results. (a) % of dsRED+ve cells at day 15 of the conversion. Shown is 
the fold enrichment over a control (Zeomycin) non-targeting gRNA. All 3 gRNAs tested for 
Stxbp1 show a circa 50% reduction in iNs compared to the Pecam1 (Pe1) control gRNA (n=3). 
Error bars indicate standard deviation. ***p<0.005, **p<0.01, *p<0.05 based on an unpaired 
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two-tailed Student's t test. (b) Indel efficiency of Stxbp1 gRNA #3 was assessed by TIDE. X axis 
indicates the numbers of deleted or inserted nucleotides.  
 
5.2.4 Stxbp1 screen results  
Although the phenotype of Stxbp1 KO was confirmed for 3 independent gRNAs, and 
gRNA indel efficiency was confirmed, the screen set-up failed to pick-up Stxbp1 as 
having an effect on iN conversion. Table 5.2 below shows the read counts of all 3 
individually tested Stxbp1 gRNAs in the plasmid and iN samples in the screen. The 
read counts show high variability among replicates in the neuron samples, and the 
resulting means actually show a mild increase in representation of the gRNAs in 
neuronal samples compared to plasmid. This is further proof that the screen setup 
was inadequate for detection of even a 50% depletion phenotype, and it’s probably 
due to the low coverage and the high variability of the system. 
 
gRNA Plasmid counts iN counts Plasmid 
mean 
iN  
mean LFC FDR 
Stxbp1_1 1191.3/1210.9/1186.7 1426.7/2176.4/1567 1191.3 1567 0.39515 0.99797 
Stxbp1_2 130.44/142.97/153.29 177.9/218.3/124.78 142.97 177.9 0.31338 0.99797 
Stxbp1_3 807.62/865.01/838.01 957.31/1439/906.92 838.01 957.31 0.19181 0.99797 
Table 5.2 – gRNA counts from screen results. gRNA read counts from three replicates of 
plasmid and iNs samples are shown for all 3 gRNAs against Stxp1 that were individually 
tested. LFC: Log fold change; FDR: False discovery rate. LFC is calculated from iN mean over 
Plasmid mean. The LFC actually shows a minor overrepresentation of the gRNAs in iNs, but 
the FDR for all 3 of them is >0.95.  
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 5.2.5 Stxbp1 regulates neurotransmitter released and its knock-out leads to 
neuronal death 
Stxbp1, also known as Munc18-1, is a syntaxin-binding protein required for 
neurotransmitter release by neurons. It was first discovered as a protein binding the 
N-terminus of Syntaxin1A in pre-synaptic vesicle fusion protein complexes. (Hata, 
Slaughter & Südhof, 1993). It is expressed almost exclusively in the brain in rodents 
and humans (Garcia et al., 2003; Kalidas et al., 2000), and it is localised preferably 
within axons in membranes proximity, thanks to its association with Syntaxin1 and 
other binding partners within the vesicle fusion complexes (Garcia et al., 1995; 
Toonen & Verhage, 2007).  
 It works by binding Syntaxin1 in closed conformation, allowing the assembly and 
stabilisation of the SNARE complex (Dulubova et al., 2007; Toonen & Verhage, 2007). 
Missense mutations and deletion-derived haploinsufficiency of Stxbp1 were first 
associated with epileptic encephalopathies in 2008 (Saitsu et al., 2008). Stxbp1 has 
since then become one of the genes most associated with epileptic encephalopathies 
in new-borns and children, and linked to movement and behavioural disorders 
(Khaikin & Mercimek-Mahmutoglu, 2016). 
 
Null mice derived from deletion of both Stxbp1 alleles result in viable embryos and 
develop normally assembled brains with fully differentiated neurons that produce 
spontaneous action potentials. These neurons though are then unable to respond to 
synaptic stimuli because the lack of Stxbp1 makes them incapable of 
neurotransmitter release. The neurons undergo apoptosis after E12, and pups die at 
birth (Verhage et al., 2000). The same developmentally healthy but eventually 
apoptotic phenotype was observed in human neurons in vitro:  loss of function Stxbp1 
mutations in hESC-derived neurons were sufficient to induce neuronal death, but did 
not impact ESC to neuron specification (Patzke et al., 2015).  
 
Based on Stxbp1’s role in neuronal survival, and my observations upon Stxbp1 KO, I 
wanted to verify whether Stxbp1 was having the same role in iNs.  
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RNAseq (Treutlein et al., 2016) shows it is selectively expressed at progressively 
higher levels in converting and maturing iNs (Fig. 5.5a). The reduction in iN numbers 
upon KO was confirmed by TUBB3 staining, as shown by whole well images and 
quantifications of iNs in Fig.5.5b-c, and shows again as a 50% conversion efficiency 





Fig. 5.5 – Stxbp1 expression across the conversion and KO effect by IF. (a) Gene 
expression of Stxbp1 through conversion – data from (Treutlein et al., 2016). Neuronal 
markers Tubb3 and Map2, and housekeeping genes Gapdh and Tbp are shown as reference. 
(b) Whole well images of day 15 transdifferentiating cells upon transduction of neutral 
(Pecam1) gRNA or Stxbp1 gRNAs #2 and #3. IF performed against TUBB3 shows visually a 
severe decrease in iNs that does not impact the overall cell numbers – based on DAPI stain. 
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(c) Quantification of b. Stxbp1 KO results in about 50% depletion in TUBB3+ve cells, 
consistent with 50% depletion of dsRED+ve cells as reported by flow cytometry (n=2). Error 
bars indicate standard deviation.  ***p<0.005, **p<0.01, *p<0.05 based on an unpaired two-
tailed Student's t test. 
 
To verify whether this reduction was coming from decreased neuronal specification 
or post-specification neuronal death, I monitored the % of iNs – as assessed by 
dsRED+ve cells with flow cytometry – from day 6, the earliest time-point of dsRED 
signal detection.  
As shown in Fig.5.6a, at day 6 the percentage of dsRED +ve cells is the same in the 
control sample (using Pecam1 gRNA) and the samples that received Stxbp1 gRNAs #2 
or #3, indicating that Stxbp1 KO is not having an impact on induction of neuronal fate, 
consistent with reported phenotypes of in vivo neuronal differentiation of Stxbp1 null 
mice.  
By day 10, Stxbp1 KO samples show a significant decrease in dsRED +ve cells 
compared to control, already close to the 50% decrease reached at day 15. This 
suggests that neuronal cells start to die off soon after conversion, indicating the 
fundamental role of Stxbp1 in early iN survival and consistent with the reported 
findings that Stxbp1 KO neurons die off when synaptic activity would normally 
emerge.  
To confirm that cell death is specific to neuronal cells only, cell counts for whole wells 
at day 6, 10 and 15 (Fig.5.6b) show that the overall number of cells is not being 
affected by the KO. This is consistent with the selective expression of Stxbp1 in 
neurons, as cells lacking its expression are not likely to require it for survival, and 
consistent with null mice showing brain-specific defects, as well as mutations in 









Fig. 5.6 – Effects of Stxbp1 KO on iNs and overall cell numbers across the early 
stages of conversion. (a) Fold enrichment of iNs (assessed as hSyn1-dsRed+ve cells by flow 
cytometry) over the control (Zeomycin) gRNA of cells transduced with the intronic gRNA 
against Zeomycin, or Stxbp1 gRNAs #2 and #3. The number of iNs is similar – and more 
variable – at day 6, but then stabilises and shows as early as day 10 a marked decrease upon 
Stxbp1 KO. (n=3). (b) The same gRNAs show no effect on overall cell growth, as the total 
number of cells at day 6, 10 and 15 is unvaried upon Stxbp1 KO compared to the non-
targeting gRNA (Zeomycin) (n=2). Error bars indicate standard deviation. 
 
5.2.6 Stxbp1 overexpression does not induce an increase in converted iNs  
Once I verified that the phenotype of Stxbp1 KO was consistent with the gene’s 
reported role in neurons, I looked at how overexpressing it might affect neuronal 
physiology. 
Overexpression of Stxbp1 in Drosophila leads to inhibition of neurotransmitter 
release, possibly due to Stxbp1 sequestering Syntaxin1 and impairing SNARE complex 
formation and vesicle release  (Schulze et al., 1994; Wu et al., 1998). 
Stxbp1 has also been found to be upregulated in patients affected by schizophrenia 
(Behan et al., 2009).  
Stxbp1 has two isoforms. Isoform A is longer and expressed selectively in the brain 
and retina. Isoform B is predominantly expressed in the cerebellum and retina, but 
can be found at low levels ubiquitously in rats and humans (Swanson, Steel & Valle, 
1998).  
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In order to generate a mouse model for schizophrenia, isoform A was selectively 
overexpressed in glutamatergic and GABAergic neurons. This indeed led to 
schizophrenic-like cellular, molecular and behavioural changes, consistent with data 
from human patients indicating that neuroexocytosis defects related to Stxbp1 could 
be key regulators of schizophrenia (Urigüen et al., 2013). 
 
In the iN system, Stxbp1 is upregulated early after Ascl1 induction (levels are 
increased at day 2 already), at the same time as cells are exiting the cell cycle and 
switching to neuronal programming. I decided to test the effects of overexpressing 
Stxbp1 on the conversion. I hypothesised that the increased presence of Stxbp1 might 
influence the membrane properties of cells, or influence their vesicle release, and 
possibly push partially-reprogrammed cells to fully upregulate neuronal markers. I 
also hypothesised that overexpression of Stxbp1 might influence the vesicle 
trafficking properties and hence firing properties of early neurons, which in turn 
could influence the behaviour/identity of their neighbouring cells.  
 
To test these hypotheses, I cloned the cDNAs of both isoforms of Stxbp1 into the tetO 
lentiviral backbone used for the expression of the Wernig factors. 
I decided to test both isoforms. The cDNAs were PCR-amplified from whole cDNA 
extracted from adult mouse brain. Primers contain EcoRI restriction sites to allow 
ligation into the FUW-TetO backbone.  
The PCR products were processed with gel electrophoresis and correctly showed a 
single band at the expected length of 1.6kb.  
After purification, PCR products were digested and ligated within the pre-digested 
(EcoRI) tetO lentiviral backbone. The orientation of the insert was verified with 
restriction enzyme digestion, and the sequence of each isoform was confirmed via 
Sanger sequencing.  
The overexpression construct was transduced into transdifferentiating MEFs 
together with the Wernig factors via lentiviruses. As an overexpression control, a 
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vector expressing BFP (Blue fluorescent protein) under the control of the tetO 
promoter (cloned within the same FUW-TetO backbone) was used.   
 
Converting MEFs were transduced at day -1 with tetO-BFP or tetO-Stxbp1A/B at MOI5 
together with the BAM factors. Dox was added at day 0 to induce TF expression. At 
day 3, cells were transduced with the hSyn1-dsRed construct to allow quantification 
of iNs. 
Fig.5.7 shows the results of overexpressing both Stxbp1 isoforms on day 15 iNs. Panel 
a shows the result of Stxbp1 overexpression within the full BAM reprogramming 
cocktail. Panel b shows the result of overexpressing Stxbp1 in Ascl1-only 
reprogramming – the idea being that Stxbp1 OE might push more cells towards 
neuronal programming in the less efficient system.  
As assessed by dsRED+ cells percentage, neither isoform impacts the neuronal yield 
of the conversion as compared to the BFP control sample. 
This suggests that overexpression of Stxbp1 in MEFs is not sufficient to push cells 
changing fate towards a neuronal lineage.  
 
 
Fig. 5.7 – Overexpression of Stxbp1 does not influence iN conversion efficiency. (a) 
% of dsRED+ve cells at day 15 of the conversion upon overexpression of BFP, Stxbp1 isoform 
A or Stxbp1 isoform B. (b) % of hSyn1-dsRed+ve cells at day 15 of the conversion in the 




It is reasonable to hypothesise that Stxbp1 overexpression might be impacting 
membrane properties, neurotransmitter release and firing abilities of the iNs. Visual 
inspection did not show any clear difference in neuronal morphology or clustering 
between control and Stxbp1 OE, not even in Ascl1-only reprogramming, but a more 
thorough investigation of the neurons’ properties might reveal important 
differences. It would be for instance very interesting to test whether and how Stxbp1 
is impacting the different neuronal subtypes within the culture.  
 
5.3 Discussion 
5.3.1 Zfp238 KO unexpectedly did not decrease iN conversion efficiency   
As shown in Fig. 5.3, the knock-out of Zfp238 with 3 different gRNAs in BAM-
transduced Cas9-MEFs did not lead to a reduction in the number of dsRED+ve iNs 
compared to the control gRNA as assessed by flow cytometry. Of course, there is a 
possibility that all 3 gRNAs are inefficient at inducing indels, thus resulting in a 
functional ZFP238 protein that will not impact the conversion efficiency. The knock-
out phenotype reported by Wapinski and colleagues though is quite striking: when 
reprogramming MEFs into iNs with Ascl1 alone, they show an 8-fold decrease in the 
number of iNs generated from Zfp238 KO MEFs as assessed by TUBB3 and MAP2 
staining (Wapinski et al., 2017). It seems unlikely that, shall that phenotype also verify 
in BAM-transduced MEFs, neither one of the 3 gRNAs were able to induce even a mild 
decrease in iN conversion efficiency. 
An alternative explanation is that, considering the huge differences in efficiency 
between Ascl1-only and BAM-mediated iN reprogramming (Vierbuchen et al., 2010; 
Wapinski et al., 2013), the knock-out of Zfp238 would severely decrease the 
efficiency of the former but not the latter. Brn2 and Myt1l are known to work by 
stabilizing and maintaining neuronal fate induced mostly by Ascl1 (as well as, 
especially Myt1l, improving the maturation of the iNs), and it’s possible that their 
presence would be able to compensate for the absence of Zfp238 in directing the 
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neuronal network. As mentioned, Zfp238 and Myt1l can generate iNs in the absence 
of Ascl1 (Wapinski et al., 2013, 2017), indicating that the induction of neuronal 
programming can be achieved through compensatory mechanisms that upregulate 
the same shared network. 
To verify this hypothesis, I could replicate the same experiment by transducing Cas9-
MEFs with the Zfp238 gRNAs and Ascl1-only lentiviruses, then assess the neuronal 
yield using hSyn1-dsRed. It would be useful to also assess neuronal conversion 
efficiency in parallel, for both Ascl1-only and BAM reprogramming, using 
TUBB3/MAP2 staining, to verify whether this phenotype discrepancy is coming from 
the different neuronal reporters used for quantification. As mentioned in the 
discussion of chapter 3 regarding Tau and Tubb3 differences, it’s possible that hSyn1-
dsRed is detecting pro-neuronal cells in Zfp238 KO conditions that do not upregulate 
full neuronal markers like Tubb3 and Map2 and would thus not be picked up by 
staining.  
 
5.3.2 Stxbp1 knock-out iNs as an in vitro model for neurodevelopmental disorders.  
The results shown in Fig.5.5-6 confirm what is known about Stxpb1’s role in in vivo 
neurons: its expression is specific for neuronal cells, and its presence is required for 
neuronal survival.  
I have not addressed in this thesis whether the iNs are going through apoptosis 
following the same pathway as their in vivo counterparts, but it is a reasonable 
assumption based on what is known about their gene expression and physiological 
similarities.  
Models of Stxbp1 haploinsufficiency in mice have shown enhanced aggressiveness 
and impaired fear-mediated learning, both of which can be ameliorated by artificially 
potentiating excitatory synaptic transmission (Miyamoto et al., 2017). But 
haploinsufficiency is not the only possible cause for the neurological diseases 
associated with Stxbp1 mutations: missense mutations can give rise to cellular 
aggregates of Stxbp1 that impair its ability to form neuroexocytosis complexes 
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(Martin et al., 2014). Recently, mutant aggregative forms of Stxbp1 have been shown 
to aggregate wt forms of the protein as well in a prion-like manner, and induce the 
formation of a-synuclein aggregates and Lewy body-like structures in cultured rat 
hippocampal neurons (Chai et al., 2016). This study showed how Stxbp1 acts as a 
molecular chaperone for a-synuclein, how its haploinsufficiency leads to an increased 
a-synuclein aggregation phenotype, and potentially linked for the first time two 
apparently distinct neurodevelopmental and neurodegenerative disorders. 
The versatility of the iN system makes it an ideal platform to study patient-derived, 
subtype specific neuronal defects arising from specific mutations. The work in this 
thesis on Stxbp1 KO confirms it can faithfully reproduce in vivo phenotypes and lead 
to iN death. The integration of Cas9-expressing cells within the conversion system 
would potentially allow the introduction of multiple mutations in subtype specific 
cells with relative ease and efficiency, and possibly expand on the newly-discovered 
interactions between aggregating disease-associated proteins of neurological 
diseases.  
 
5.3.3 Stxbp1 overexpression – a candidate in vitro model for schizophrenia?   
Regulation of Stxbp1 expression levels seems to be critical for correct neuronal 
synaptic function. On the opposite end of haploinsufficiency, Stxbp1 upregulation has 
been identified in human patients suffering from schizophrenia (Behan et al., 2009) 
and Stxbp1a overexpression in mouse glutamatergic and GABAergic neurons induced 
in the animals schizophrenia-like behaviours (Urigüen et al., 2013). Interestingly, this 
model also showed a decrease of D1 receptors of the dopamine signalling pathway 
and downregulation of the DA membrane transporter, as well as tyrosine hydroxylase 
overexpression in the cortex and striatum. 
In this chapter I’ve tested how the overexpression of Stxbp1 could affect the 
conversion efficiency of MEFs into iNs, using both the BAM combination and Ascl1 
alone. As assessed by hSyn1-dsRed quantification, the conversion efficiency is neither 
decreased nor increased upon Stxbp1 overexpression. This is consistent with the 
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knock-out phenotype at day 5, suggesting that in the iN system Stxbp1 levels do not 
impact the neuronal fate induction machinery. Expression levels of Stxbp1 in iNs are 
comparable between day 5 and day 22, suggesting that the required amounts for 
proper neuronal function are expressed early on in neuronal specification. 
Considering what is known about Stxbp1 overexpression though, it is possible that 
the iNs overexpressing it would have differences in their neuroexocytosis properties. 
In such an environment, it would be interesting to test whether it might skew the 
relative abundance of neuronal subtypes, or impact the behaviour of some types 
more than others – for instance, it would be worth investigating whether 
overexpressing Stxbp1 in induced dopaminergic neurons makes them more active, or 
increases their dopamine release, or impacts their receptor expression. 
 
5.4 Summary 
This chapter aimed to examine the role of 20 genes in the MEF to iN system using the 
CRISPR/Cas9-mediated KO to assess gene function, and hSyn1-dsRed expression to 
quantify neurons, both tools established in Chapter 3.  
 
The first important result is that Kmt2b KO in this system leads to a decrease in the 
conversion efficiency as assessed by dsRED+ve iNs via flow cytometry. This confirms 
previously published results from Km2tb null and heterozygous mouse cells, showing 
that Kmt2b KO leads to a reduction in iNs as assessed by TUBB3 and PSA-NCAM 
expression. This further validation confirms that the platform discussed in this thesis 
is reliable and allows the investigation of genetic phenotypes in a complex system 
such as iNs quickly and easily, bypassing the need for KO mouse lines and allowing 
quantification of iNs with a simple and specific reporter.  
 
The second important result is the discovery that Stxbp1 KO decreases the yield of iN 
by 50%. This is not achieved by impairing the cell identity switch, but likely through 
neuronal apoptosis following neurotransmitter accumulation due to impaired vesicle 
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release. This is further proof of how iNs reproduce characteristics and behaviours of 
in vivo neurons despite their origin and heterogeneous cell environment, and 
strengthens the fibroblast to neuron conversion platform as a system to model 

























Chapter 6 Conclusion 
In the 9 years since the establishment of the first induced neurons from mouse 
fibroblasts, a lot has been learned about their biology, their similarities and 
differences with in vivo neurons, their abilities to mature and form networks of 
synchronized firing. Different combinations of transcription factors, differentiation 
media, small molecule inducers and cells of origin can give rise to a huge variety of 
neuronal subtypes (reviewed in Colasante et al., 2019). Though lots of efforts have 
gone into increasing the efficiency of the conversion and the neuronal purity of the 
end culture, the genetic and molecular mechanisms driving the reprogramming 
processes are still not well understood. RNAseq, ATACseq and ChIPseq analyses have 
contributed to broaden our knowledge of the gene regulatory network that 
suppresses fibroblast identity and promotes the specification of neuronal fate 
(Wapinski et al., 2013, 2017; Treutlein et al., 2016; Mall et al., 2017), but how that 
network differs between cell sources and neuronal subtypes, or If and how it can be 
manipulated to optimise the different systems still remains to be addressed.  
The iN system also represents an interesting model to study cell identity conversions 
between somatic cell states, particularly because it does not pass through a stem-cell 
intermediate (Vierbuchen et al., 2010; Treutlein et al., 2016), and thus does not 
mimic differentiation mechanisms of cell specification. It would thus represent a 
suitable platform to investigate processes such as genome re-organisation and 
chromatin remodelling that have been broadly associated and implicated in fate 
specifications and conversions. 
 
One major remaining caveat in this system is the heterogenicity of the cultures. 
Although purity, even within specific neuronal subtypes, has been significantly 
enhanced in the last few years, the intrinsic origin of the cells, i.e. the non-neural 
environment that iNs are subjected to – be it fibroblast and myoblast-like cells, or 
blood lineages, exposes the cells to very non-physiological conditions that are bound 
to affect their properties. In fact, most publications that focus on neuronal 
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maturation and functionality, for which electrophysiology is the gold standard, rely 
on iN sorting followed by co-culture with ex-vivo astrocytes or cortical neurons 
(Vierbuchen et al., 2010; Caiazzo et al., 2011; Pfisterer et al., 2011; Pereira et al., 
2014; Ruetz et al., 2017; reviewed in Colasante et al., 2019) . In this regard, astrocyte-
derived iNs, both in vitro and especially in vivo, represent perhaps a better source for 
maturation of iNs, as they also provide a more nurturing environment.  The 
advantage of in vivo iN reprogramming is that the neurons can directly integrate with 
the local circuitry and respond to endogenous physiological stimuli.  
 
The system established in this thesis represents a strong platform to perform loss-of-
function studies of specific target genes in iNs in a quick and easy way. Constitutive 
Cas9 expression allows the temporal control of gene knock-out, achieved efficiently 
by gRNA lentiviral transduction. This means that KO could be directly induced within 
neurons, bypassing the need to engineer murine animal models to study the genetic 
and molecular pathology of neurological diseases.  
Subtype-specific promoters could be used to drive gRNA expression and allow KO 
within selective populations. This could be used as a strategy to understand, even 
within a heterogeneous context, how selected genes act in selected subtypes. 
The availability of mouse lines that constitutively and ubiquitously express Cas9 
would also allow the investigation of knock-out phenotypes in in vivo converted iNs 
by lentiviral delivery of gRNAs in target brain regions. 
The hSyn1 promoter activity documented in this thesis could bypass the need to 
engineer mouse models by crossing them with the Tau-eGFP line to make use of that 
reporter to mark iNs. At the same time, it bypasses the need of using antibodies to 
sort neurons based on the expression of specific extracellular antigens like PSA-
NCAM. Considering neuronal yield, the loss of cells associated with staining 
procedures for flow cytometry, and the promiscuity of certain antibodies, this 
represents a significant advantage. 
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Although the screening performed was unsuccessful, the tools and knowledge 
developed would be useful in optimising the conditions and potentially perform a 
more targeted, stringent and higher-coverage screen. Kmt2b, Sf3a1 and Stxbp1 KO 
phenotypes verified in this thesis would serve as controls in setting-up an efficient 
platform with higher chances of success.   
The work performed on Stxbp1 confirmed the validity of iNs as modelling platform 
for their in vivo counterpart and their suitability to mimic disease phenotypes.  
The discovery of Sf3a1 as an essential regulator of cell fitness in this context, as well 
as modulator of the iN conversion efficiency, highlights the role of the relatively 
unexplored area of RNA processing in cell identity conversions. 
Overall, this work has established a solid platform for characterising induced neurons 
and has given examples of how it can reveal basic biology pathways as well as 
reproduce disease phenotypes. A new and improved screen plan could reveal insights 
into the genetic machinery that controls iN specification and improve its suitability 
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Appendix 1 Library gene list 
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Bbs4 
Bbs7 
BC005764 
Bcar1 
Bcl2l11 
Bcl7a 
Bcl7b 
Bcorl1 
Bend4 
Bend6 
Bex2 
Bgn 
Bicd1 
Birc5 
Blvrb 
Bmp4 
Bmp7 
Bscl2 
Btbd2 
Btbd7 
Cabin1 
Cadm1 
Calm1 
Calm2 
Calm3 
Calm4 
Calm5 
Calml3 
Calml4 
Camk2b 
Camk4 
Capg 
Casc3 
Casp12 
Casp6 
Casp7 
Casp8 
Cav1 
Cby1 
Ccdc181 
Ccdc28b 
Ccdc80 
Ccdc97 
Ccm2 
Ccna2 
Ccne2 
Ccng2 
Ccp110 
Cd151 
Cd200 
Cd24a 
Cd59a 
Cd9 
Cd99l2 
Cdc23 
Cdc25b 
Cdc34 
Cdh11 
Cdipt 
Cdk16 
Cdk20 
Cdkn1c 
Cdkn2d 
Cdon 
Celf4 
Cenpt 
Cenpw 
Cep170b 
Cep19 
Cep44 
Cers4 
Cers5 
Cgnl1 
Chac2 
Chchd10 
Chchd6 
Chd7 
Chek2 
Chic1 
Chpt1 
Chrna4 
Ciapin1 
Cib3 
Cic 
Cisd3 
Cited2 
Ckb 
Cks1b 
Clasp2 
Clcn3 
Cltb 
Cmas 
Cndp2 
Cnih2 
Cnn2 
Cnot10 
Cnr1 
Cnrip1 
Cntn1 
Coil 
Col11a1 
Col1a1 
Col1a2 
Col3a1 
Col5a2 
Copz2 
Coq2 
Coq3 
Coro7 
Cotl1 
Cox19 
Cox8b 
Cplx2 
Cpsf1 
Cpt1c 
Creb1 
Creb3 
Creb3l1 
Creb3l2 
Creb3l3 
Creb3l4 
Creb5 
Crebbp 
Crebl2 
Crebrf 
Crebzf 
Creld2 
Crlf1 
Crtac1 
Crtap 
Csdc2 
Csf1 
Csgalnact2 
Csnk1d 
Cthrc1 
Ctnna1 
Ctps2 
Ctsk 
Ctsz 
Cx3cl1 
Cxcl12 
Cxxc5 
Cyba 
Cyp51 
Cyr61 
D10Bwg1379e 
D230025D16Rik 
Daam1 
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Dab1 
Dalrd3 
Dap 
Dbf4 
Dbn1 
Dbpht2 
Dcaf5 
Dcn 
Dcx 
Ddah1 
Ddit3 
Ddr2 
Ddx25 
Ddx39 
Ddx41 
Ddx55 
Ddx56 
Deaf1 
Decr2 
Dennd5b 
Dffa 
Dgkz 
Dhcr7 
Dis3l2 
Dkc1 
Dlc1 
Dlx3 
Dnajb2 
Dnal1 
Dner 
Dnm1 
Dnm2 
Dock1 
Dock4 
Dohh 
Dos 
Dot1l 
Dpp3 
Dpp9 
Dpy19l1 
Dpysl4 
Dpysl5 
Dscam 
Dse 
Dsel 
Dtd1 
Dtx3 
Dusp14 
Dusp8 
Dync1i1 
Ebf2 
Ebp 
Ece1 
Ecel1 
Ecscr 
Edem2 
Edem3 
Edil3 
Eepd1 
Efemp2 
Eif2s3y 
Eif4ebp1 
Elavl2 
Elf2 
Elovl1 
Elovl6 
Elp3 
Emb 
Emc10 
Emc9 
Emd 
Eml5 
Emp1 
Enah 
Endod1 
Eno1 
Eno2 
Epha5 
Exd2 
Exoc6 
Exosc7 
Extl2 
F2r 
Fads1 
Fam114a1 
Fam117a 
Fam122a 
Fam126a 
Fam134b 
Fam155a 
Fam169a 
Fam171b 
Fam174a 
Fam184a 
Fam196a 
Fam19a5 
Fam21 
Fam213b 
Fam214b 
Fam217b 
Fam57b 
Fam60a 
Fam69a 
Fam69b 
Fam73a 
Fas 
Fbn1 
Fbxl16 
Fbxl2 
Fbxl5 
Fbxo30 
Fbxo32 
Fbxo42 
Fbxo44 
Fbxo46 
Fcgrt 
Fdft1 
Fdps 
Fech 
Fez1 
Fgf7 
Fhl2 
Fibin 
Fkbp9 
Flad1 
Flna 
Flot1 
Flrt1 
Flrt2 
Flrt3 
Fn1 
Fn3k 
Fosb 
Fosl2 
Foxn2 
Foxp2 
Frk 
Fry 
Fsd1l 
Fstl1 
G6pc3 
Gaa 
Gabarapl1 
Gabpa 
Gabrb3 
Gadd45a 
Gadd45g 
Gale 
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Galnt9 
Ganab 
Gas1 
Gas6 
Gca 
Gclc 
Gdap1 
Gfra1 
Gga3 
Ghr 
Gins4 
Gja1 
Glce 
Gli3 
Glipr1 
Glrb 
Gm561 
Gmds 
Gmpr 
Gnai1 
Gnao1 
Gnb4 
Gng11 
Gng2 
Gon4l 
Got1 
Gpc3 
Gpc4 
Gpc6 
Gpd2 
Gpm6b 
Gpnmb 
Gpr125 
Gpr137 
Gpr137c 
Gpr180 
Gpr22 
Gpr64 
Gpr85 
Gprasp1 
Grb2 
Grhpr 
Gria2 
Gria3 
Grin1 
Gse1 
Gsn 
Gsta4 
Gtf2i 
Gtpbp8 
Gulp1 
Gusb 
H2-K1 
Hadh 
Haghl 
Hap1 
Haus3 
Hdac6 
Hdac9 
Hddc3 
Heatr3 
Heca 
Helz 
Hepacam2 
Hes6 
Hexb 
Hist1h1c 
Hist1h2ba 
Hist1h2bb 
Hist1h2bj 
Hist2h2bb 
Hist3h2a 
Hk2 
Hmcn1 
Hmga1 
Hmga2 
Hmgcl 
Hmgxb4 
Homer2 
Hoxa7 
Hoxd13 
Hras1 
Hsd17b7 
Hspbp1 
Htr3a 
I830012O16Rik 
Id3 
Idi1 
Ier2 
Ier3 
Iffo1 
Ifi35 
Ifit3 
Ifitm2 
Ifitm3 
Ift88 
Igf2 
Igfbp7 
Ikbip 
Ikbkap 
Ikbkg 
Il11ra1 
Il13ra1 
Ilkap 
Impdh2 
Ina 
Inhba 
Ints3 
Ip6k1 
Ip6k2 
Ipo13 
Irf7 
Itm2a 
Jag1 
Kat2a 
Katnb1 
Kctd17 
Kdelc1 
Kdelc2 
Kdelr3 
Kdm1b 
Kif1a 
Kif21a 
Kif26b 
Kif5a 
Kif5c 
Klf10 
Klf4 
Klhdc10 
Klhl21 
Klhl5 
Krt33b 
Lamb1 
Lamc1 
Lasp1 
Lats2 
Ldhb 
Lgals3bp 
Lgals8 
Lhfp 
Lhfpl2 
Lhfpl4 
Lhx3 
Lin7a 
Lipa 
Lman2l 
Lmbr1 
Lmbrd2 
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Lmtk2 
Lonrf2 
Lox 
Loxl1 
Lpar6 
Lpcat4 
Lpin2 
Lrrc17 
Lrrc4c 
Lrrtm4 
Lsm10 
Ltbp1 
Lum 
Mad2l1bp 
Maf 
Mafg 
Magee1 
Magi1 
Maml2 
Maoa 
Map1b 
Map2k7 
Mapk10 
Mapk8ip1 
Mapk9 
Mapre3 
Mapt 
March1 
Marf1 
Mblac2 
Mbnl3 
Mccc2 
Mcm4 
Mcm6 
Mcm7 
Mcts2 
Mcu 
Mdk 
Mecr 
Med22 
Mef2c 
Meis2 
Men1 
Mettl14 
Mettl17 
Mfap3 
Mfap4 
Mfge8 
Mfn1 
Mfng 
Mgp 
Mgrn1 
Mgst1 
Mkl2 
Mkx 
Mlec 
Mllt11 
Mmp14 
Mn1 
Moap1 
Morn2 
Morn4 
Mpp1 
Mpped2 
Mrpl3 
Mrps10 
Msantd4 
Msrb2 
Msto1 
Msx1 
Mtap 
Mtfp1 
Mthfs 
Mtmr7 
Mum1l1 
Mvk 
Mxra8 
Myh9 
Myo10 
Myod1 
Myof 
Myt1l 
Nagk 
Nalcn 
Nap1l2 
Nap1l3 
Napb 
Napg 
Ncdn 
Ndrg4 
Ndufaf6 
Nefl 
Negr1 
Neu1 
Nexn 
Nfat5 
Nfatc1 
Nfatc2 
Nfatc2ip 
Nfatc3 
Nfatc4 
Nfkb1 
Nfkb2 
Nfkbia 
Nfkbib 
Nfkbid 
Nfkbie 
Nfkbil1 
Nfkbiz 
Nfrkb 
Nid1 
Nid2 
Nin 
Nipsnap1 
Nit1 
Nkain1 
Nlgn2 
Nme7 
Nmnat2 
Nnmt 
Nomo1 
Nprl2 
Nr2c2ap 
Nrg1 
Nrk 
Nrn1 
Nsdhl 
Nsmf 
Nt5dc2 
Nubpl 
Nucb1 
Nudt10 
Nudt22 
Nup54 
Nup85 
Nup98 
Nupr1 
Nxn 
Oat 
Ocrl 
Odf2l 
Ogfod1 
Ogfrl1 
Olfm1 
Olfml2b 
Orai3 
Os9 
Osbpl1a 
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Osbpl2 
Osgin2 
Oxr1 
Pacsin2 
Pak3 
Palm 
Palmd 
Pam 
Pard6a 
Parp8 
Pbx3 
Pcdh18 
Pcdhb17 
Pcdhb7 
Pck2 
Pclo 
Pcolce 
Pcp4l1 
Pcsk2 
Pcyt2 
Pdcd2 
Pdcd2l 
Pddc1 
Pde1c 
Pde2a 
Pde6d 
Pdgfrl 
Pdia4 
Pdlim1 
Pdpn 
Pdxk 
Peg3 
Penk 
Perp 
Pfas 
Pfkfb2 
Pfkm 
Pgam2 
Pgap1 
Pgd 
Pgm2l1 
Phgdh 
Phldb2 
Phtf1 
Phtf2 
Phyhipl 
Pigq 
Pigu 
Pik3r3 
Pim2 
Pkd2 
Pknox2 
Pla2g4a 
Plagl1 
Plcb4 
Plekha1 
Plekhj1 
Plin2 
Plk2 
Plxna3 
Pmepa1 
Pmp22 
Pmvk 
Pnck 
Pnma2 
Pnmal1 
Pnmal2 
Polr3e 
Pom121 
Postn 
Pou3f2 
Pou4f1 
Ppa1 
Ppap2b 
Ppfia2 
Ppic 
Ppie 
Ppil1 
Ppm1d 
Ppme1 
Ppp1r16b 
Ppp1r9a 
Ppp3ca 
Ppp3cb 
Ppp3cc 
Ppp3r1 
Ppp3r2 
Pptc7 
Pqlc3 
Prepl 
Prim2 
Prkcb 
Prkcdbp 
Prkcz 
Prmt10 
Prmt7 
Prorsd1 
Prpf40b 
Prps1 
Prune 
Prune2 
Psat1 
Psmb10 
Psmd13 
Psmd9 
Psmf1 
Ptchd1 
Ptgds 
Ptgr1 
Ptpn5 
Ptrf 
Pus7 
Pwwp2b 
Pxdn 
Pygb 
Qpct 
R3hcc1 
Rab36 
Rab39b 
Rab3c 
Rab5c 
Rabgap1l 
Rabggta 
Rabl5 
Ralgds 
Ralgps2 
Ramp3 
Ranbp6 
Ranbp9 
Rasal2 
Rassf1 
Rassf4 
Rbbp8 
Rbfox1 
Rbm12 
Rbms1 
Rbmx2 
Rbpj 
Rcc2 
Rcn1 
Rcn3 
Rdh11 
Reep2 
Reep3 
Reps1 
Rfc4 
Rgmb 
Rgs16 
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Rgs17 
Rhog 
Rhoj 
Rimklb 
Rims2 
Ripk1 
Rit2 
Rnf121 
Rnf122 
Rnf145 
Rnf157 
Rnf167 
Rnf170 
Rnf182 
Rnf19a 
Rnf34 
Rnft1 
Rpp14 
Rpp25l 
Rpp30 
Rpp38 
Rprd1a 
Rprm 
Rps15a 
Rrm2 
Rsph3a 
Rsph3b 
Rspry1 
Rtca 
Rtn1 
Rtp4 
Rufy3 
Rundc3b 
Runx1 
Ruvbl1 
Ruvbl2 
Rwdd2a 
S100a1 
S100a16 
S100a6 
S100pbp 
S1pr2 
Samd12 
Sapcd1 
Sbk1 
Scaf8 
Scamp5 
Scg3 
Scg5 
Schip1 
Scpep1 
Scrn3 
Sdc3 
Sdc4 
Sdr39u1 
Sema5a 
Sema6a 
Sepp1 
Sept5 
Serinc5 
Serpine2 
Serpini1 
Sestd1 
Setd6 
Sf3a1 
Sfrp2 
Sgce 
Sgk1 
Sgms1 
Sgpp2 
Sgsm3 
Sh2d3c 
Sh3d19 
Sh3gl2 
Shank1 
Shc1 
Shisa2 
Shisa9 
Shmt2 
Siah2 
Sigmar1 
Sirt1 
Sirt3 
Sirt5 
Six4 
Slc22a17 
Slc25a10 
Slc25a14 
Slc25a19 
Slc25a20 
Slc25a27 
Slc25a44 
Slc27a4 
Slc29a1 
Slc2a13 
Slc2a6 
Slc31a2 
Slc33a1 
Slc39a1 
Slc39a7 
Slit2 
Slitrk5 
Smad1 
Smarca1 
Smc4 
Smim18 
Smoc1 
Smox 
Smyd5 
Snap23 
Snap29 
Snapc2 
Snapc5 
Snrnp40 
Snurf 
Snx10 
Snx24 
Sorbs3 
Sos2 
Sparc 
Spata5 
Spata7 
Spats2l 
Spcs3 
Spock1 
Spop 
Spred2 
Spryd3 
Spryd4 
Sqle 
Srgap3 
Srpk3 
Srrm4 
Srrt 
Srsf12 
Ssh2 
Sspn 
St18 
St3gal4 
St3gal5 
St8sia2 
St8sia4 
Stk19 
Stmn2 
Stoml1 
Stxbp1 
Stxbp5 
Sulf1 
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Sulf2 
Sult2b1 
Sumf2 
Susd4 
Svil 
Syn1 
Syn3 
Syngr3 
Synpo 
Syp 
Syt4 
Tacc1 
Taf1 
Taf9b 
Tagap 
Tagap1 
Tagln 
Tagln2 
Taok2 
Tapbp 
Tars2 
Taz 
Tbc1d8 
Tbc1d9b 
Tceanc2 
Tcf3 
Tcn2 
Tdrkh 
Tecpr1 
Tfap2b 
Tfcp2l1 
Tfpi 
Tgds 
Tgfb1i1 
Tgfbr2 
Tgfbr3 
Tiam1 
Timp3 
Tk2 
Tle4 
Tm4sf1 
Tmcc3 
Tmed5 
Tmeff1 
Tmem101 
Tmem119 
Tmem150a 
Tmem176a 
Tmem180 
Tmem246 
Tmem38a 
Tmem39a 
Tmem41a 
Tmem47 
Tmem55b 
Tmem69 
Tmem80 
Tmem8b 
Tmod2 
Tmpo 
Tnfaip8 
Tnnt2 
Tnnt3 
Tnpo2 
Tom1l2 
Tomm40l 
Tor1aip1 
Tpgs1 
Tppp3 
Tpra1 
Tprn 
Tpst2 
Tram1l1 
Trim25 
Trim3 
Trmt10b 
Trmt1l 
Trnp1 
Tro 
Trp53 
Trp53inp1 
Tsc2 
Tsfm 
Tspan12 
Tspan13 
Tspan14 
Tspan7 
Tspyl4 
Tspyl5 
Tssc4 
Ttc28 
Ttc37 
Ttl 
Ttyh2 
Tuba4a 
Tubb3 
Tubb4a 
Tubb6 
Tubg1 
Tusc2 
Txndc5 
Tyms 
Uap1l1 
Ube2d1 
Ube2l6 
Ube2o 
Ube2q1 
Ube2ql1 
Ubxn8 
Uchl1 
Umps 
Unc119b 
Unc80 
Usp28 
Usp32 
Usp34 
Usp37 
Usp46 
Utrn 
Vamp2 
Vamp8 
Vash2 
Vasp 
Vcam1 
Vgll3 
Vim 
Vmac 
Vps13a 
Vps45 
Vstm2a 
Wbp1 
Wdr12 
Wdr18 
Wdr35 
Wdr47 
Wdr6 
Wdr91 
Wdr92 
Wdyhv1 
Wipi2 
Wisp1 
Wnt5a 
Wwtr1 
Xaf1 
Ypel1 
Zbtb1 
Zbtb18 
Zbtb6 
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Zbtb7a 
Zc3h10 
Zc3h12c 
Zcchc12 
Zcchc18 
Zfand2b 
Zfp259 
Zfp266 
Zfp30 
Zfp35 
Zfp36 
Zfp36l2 
Zfp423 
Zfp444 
Zfp449 
Zfp503 
Zfp512 
Zfp715 
Zfp763 
Zfp781 
Zfp81 
Zfp830 
Zfp874a 
Zfp933 
Zfp938 
Zfp952 
Zfyve27 
Zkscan16 
Zkscan6 
Zmiz2 
Zmym1 
Zmym3 
Znrf3 
Zswim1 
 
